

arthritis and rheumatism

Official Journal of the American Rheumatism Association Section of the Arthritis Foundation

VOLUME 28

JANUARY

NO. 1

ARA Presidential Address: 1984-2034: The Next Half-Century for American Rheumatology <i>James R. Klinenberg</i>	1
Characterization of T Cells Bearing HLA-DR Antigens in Rheumatoid Arthritis <i>Seth H. Pincus, Daniel O. Clegg, and John R. Ward</i>	8
Reproducibility of Multiple-Observer Scoring of Radiologic Abnormalities in the Hands and Wrists of Patients with Rheumatoid Arthritis <i>John T. Sharp, Gilbert B. Bluhm, Andrew Brook, Anne C. Brower, Mary Corbett, John L. Decker, Harry K. Genant, J. Philip Gofton, Neal Goodman, Arvi Larsen, Martin D. Lidsky, Pekka Pussila, Aaron S. Weinstein, Barbara N. Weissman, and Donald Y. Young</i>	16
Quantitative Histologic Studies on the Pathogenesis of Periarticular Osteoporosis in Rheumatoid Arthritis <i>Shinichi Shimizu, Shunichi Shiozawa, Kazuko Shiozawa, Shigeaki Imura, and Takuo Fujita</i>	25
Therapeutic Value of Graded Aerobic Exercise Training in Rheumatoid Arthritis <i>Thomas M. Harkcom, Richard M. Lampman, Barbara Figley Banwell, and C. William Castor</i>	32
Spondylitic Disease Without Radiologic Evidence of Sacroiliitis in Relatives of HLA-B27 Positive Ankylosing Spondylitis Patients <i>Muhammad A. Khan, Sjef M. van der Linden, Irving Kushner, Hans A. Valkenburg, and Arnold Cats</i>	40
Surface Antigen Specificity of Cold-Reactive IgM Antilymphocyte Antibodies in Systemic Lupus Erythematosus <i>Akira Yamada, Melody Shaw, and John B. Winfield</i>	44
Effects of L-Canavanine on T Cells May Explain the Induction of Systemic Lupus Erythematosus by Alfalfa <i>Jorge Alcocer-Varela, Antonio Iglesias, Luis Llorente, and Donato Alarcón-Segovia</i>	52
Lupus Pregnancy. II. Unusual Pattern of Hypocomplementemia and Thrombocytopenia in the Pregnant Patient <i>Michael D. Lockshin, Peter C. Harpel, Maurice L. Druzin, Carl G. Becker, Renate F. Klein, Rosemarie M. Watson, Keith B. Elkon, and Elizabeth Reinitz</i>	58
The Lupus Anticoagulant: A Disease Marker in Antinuclear Antibody Negative Lupus that is Cross-Reactive with Autoantibodies to Double-Stranded DNA <i>C. Bernard Colaco and Keith B. Elkon</i>	67
<i>Salmonella</i> Bacteremia in Systemic Lupus Erythematosus: Eight-Year Experience at a Municipal Hospital <i>Steven Abramson, Sara B. Kramer, Allen Radin, and Robert Holzman</i>	75
The Incidence of Systemic Lupus Erythematosus in Baltimore, Maryland, 1970-1977 <i>Marc C. Hochberg</i>	80
Evolution of Primary Raynaud's Phenomenon (Raynaud's Disease) to Connective Tissue Disease <i>David D. Gerbracht, Virginia D. Steen, Gayle L. Ziegler, Thomas A. Medsger, Jr., and Gerald P. Rodnan</i>	87
Brief Reports	
Beneficial Effect of Intravenous Cyclophosphamide and Oral Prednisone on D-Penicillamine-Associated Bronchiolitis Obliterans <i>Martinus A. F. J. van de Laar, Cees J. J. Westermann, Sjoerd Sc. Wagenaar, and Huibert J. Dinant</i> ..	93
Isolation of Echovirus Type 11 from Synovial Fluid in Acute Monocytic Arthritis <i>Greg Kujala and James H. Newman</i>	98
Systemic Lupus Erythematosus and Common Variable Panhypogammaglobulinemia: A Patient with Absence of Circulating B Cells <i>Rose Goldstein, Carlos Izaguirre, C. Douglas Smith, Egils Mierins, and Jacob Karsh</i>	100
Ibuprofen May Induce Meningitis in (NZB x NZW)F ₁ Mice <i>Shlomo Berliner, Abraham Weinberger, Yehuda Shoenfeld, Uri Sandbank, Bilha Hazaz, Henry Joshua, Menachem Rosen, and Jack Pinkhas</i>	104

arthritis and rheumatism

Official Journal of the American Rheumatism Association Section of the Arthritis Foundation

VOLUME 28

JANUARY

NO. 1

ARA Presidential Address: 1984-2034: The Next Half-Century for American Rheumatology <i>James R. Klinenberg</i>	1
Characterization of T Cells Bearing HLA-DR Antigens in Rheumatoid Arthritis <i>Seth H. Pincus, Daniel O. Clegg, and John R. Ward</i>	8
Reproducibility of Multiple-Observer Scoring of Radiologic Abnormalities in the Hands and Wrists of Patients with Rheumatoid Arthritis <i>John T. Sharp, Gilbert B. Bluhm, Andrew Brook, Anne C. Brower, Mary Corbett, John L. Decker, Harry K. Genant, J. Philip Gofton, Neal Goodman, Arvi Larsen, Martin D. Lidsky, Pekka Pussila, Aaron S. Weinstein, Barbara N. Weissman, and Donald Y. Young</i>	16
Quantitative Histologic Studies on the Pathogenesis of Periarticular Osteoporosis in Rheumatoid Arthritis <i>Shinichi Shimizu, Shunichi Shiozawa, Kazuko Shiozawa, Shigeaki Imura, and Takuo Fujita</i>	25
Therapeutic Value of Graded Aerobic Exercise Training in Rheumatoid Arthritis <i>Thomas M. Harkcom, Richard M. Lampman, Barbara Figley Banwell, and C. William Castor</i>	32
Spondylitic Disease Without Radiologic Evidence of Sacroiliitis in Relatives of HLA-B27 Positive Ankylosing Spondylitis Patients <i>Muhammad A. Khan, Sjef M. van der Linden, Irving Kushner, Hans A. Valkenburg, and Arnold Cats</i>	40
Surface Antigen Specificity of Cold-Reactive IgM Antilymphocyte Antibodies in Systemic Lupus Erythematosus <i>Akira Yamada, Melody Shaw, and John B. Winfield</i>	44
Effects of L-Canavanine on T Cells May Explain the Induction of Systemic Lupus Erythematosus by Alfalfa <i>Jorge Alcocer-Varela, Antonio Iglesias, Luis Llorente, and Donato Alarcón-Segovia</i>	52
Lupus Pregnancy. II. Unusual Pattern of Hypocomplementemia and Thrombocytopenia in the Pregnant Patient <i>Michael D. Lockshin, Peter C. Harpel, Maurice L. Druzin, Carl G. Becker, Renate F. Klein, Rosemarie M. Watson, Keith B. Elkon, and Elizabeth Reinitz</i>	58
The Lupus Anticoagulant: A Disease Marker in Antinuclear Antibody Negative Lupus that is Cross-Reactive with Autoantibodies to Double-Stranded DNA <i>C. Bernard Colaco and Keith B. Elkon</i>	67
<i>Salmonella</i> Bacteremia in Systemic Lupus Erythematosus: Eight-Year Experience at a Municipal Hospital <i>Steven Abramson, Sara B. Kramer, Allen Radin, and Robert Holzman</i>	75
The Incidence of Systemic Lupus Erythematosus in Baltimore, Maryland, 1970-1977 <i>Marc C. Hochberg</i>	80
Evolution of Primary Raynaud's Phenomenon (Raynaud's Disease) to Connective Tissue Disease <i>David D. Gerbracht, Virginia D. Steen, Gayle L. Ziegler, Thomas A. Medsger, Jr., and Gerald P. Rodnan</i>	87
Brief Reports	
Beneficial Effect of Intravenous Cyclophosphamide and Oral Prednisone on D-Penicillamine-Associated Bronchiolitis Obliterans <i>Martinus A. F. J. van de Laar, Cees J. J. Westermann, Sjoerd Sc. Wagenaar, and Huibert J. Dinant</i> ..	93
Isolation of Echovirus Type 11 from Synovial Fluid in Acute Monocytic Arthritis <i>Greg Kujala and James H. Newman</i>	98
Systemic Lupus Erythematosus and Common Variable Panhypogammaglobulinemia: A Patient with Absence of Circulating B Cells <i>Rose Goldstein, Carlos Izaguirre, C. Douglas Smith, Egils Mierins, and Jacob Karsh</i>	100
Ibuprofen May Induce Meningitis in (NZB x NZW) _{F1} Mice <i>Shlomo Berliner, Abraham Weinberger, Yehuda Shoenfeld, Uri Sandbank, Bilha Hazaz, Henry Joshua, Menachem Rosen, and Jack Pinkhas</i>	104

Evaluation of an Educational Program for Primary Care Practitioners, on the Management of Osteoarthritis	
<i>Jeoffrey K. Stross and Giles G. Bole</i>	108
In Vitro Synthesis of Low Molecular Weight IgM in Rheumatoid Arthritis	
<i>D. Neil Jones, Lin Y. Koh, James V. Bertouch, and Peter J. Roberts-Thomson</i>	112
Letters	
Pulmonary Hypertension and Chronic Cutaneous Lupus Erythematosus: Association with the Lupus Anticoagulant	
<i>Ronald A. Asherson, Stephen H. Morgan, Nigel Harris, Azzudin E. Gharavi, Graham R. V. Hughes, and Ann B. Millar</i>	118
Chondrocytes That Accumulate Proteoglycans and Inorganic Pyrophosphate in the Pathogenesis of Chondrocalcinosis	
<i>Koichiro Ishikawa</i>	118
Synovial Fluid Lymphocyte Subpopulations in the Polyarthritis of Immunoblastic Lymphadenopathy	
<i>Robert G. Gray</i>	120

VOLUME 28

FEBRUARY

NO. 2

Current Comment: Sex Steroids and the Rheumatic Diseases	
<i>Robert G. Lahita</i>	121
Plasma Follicle-Stimulating Hormone, Luteinizing Hormone, and Sex Hormones in Patients with Gout	
<i>Enrico Marinello, Giuseppe Riario-Sforza, and Roberto Marcolongo</i>	127
Clinical Characteristics of Fibrositis. II. A "Blinded," Controlled Study Using Standard Psychological Tests	
<i>Sharon Clark, Stephen M. Campbell, Mary E. Forehand, Elizabeth A. Tindall, and Robert M. Bennett</i>	132
Juvenile Primary Fibromyalgia Syndrome: A Clinical Study of Thirty-Three Patients and Matched Normal Controls	
<i>Muhammad B. Yunus and Alfonse T. Masi</i>	138
HLA Gene Frequencies in Children and Adults with Systemic Onset Juvenile Rheumatoid Arthritis	
<i>Marc L. Miller, Stephen Aaron, Jean Jackson, Patricia Fraser, Lloyd Cairns, Susan Hoch, Yves Borel, Martin Larson, and David N. Glass</i>	146
Immunogenetic Studies of Juvenile Dermatomyositis. III. Study of Antibody to Organ-Specific and Nuclear Antigens	
<i>Lauren M. Pachman, Jan M. Friedman, Mona L. Maryjowski-Sweeney, Olga Jonnason, Ruta M. Radvany, Gordon C. Sharp, Mike A. Cobb, Norma D. Battles, William E. Crowe, Chester W. Fink, Virgil Hanson, Joseph E. Levinson, Charles H. Spencer, and Donita B. Sullivan</i>	151
The Diagnostic Value of Antihistone Antibodies in Drug-Induced Lupus Erythematosus	
<i>Alan Epstein and Peter Barland</i>	158
The Binding of Antihistone Antibodies to <i>Crithidia Luciliae</i> Kinetoplasts is Growth Cycle-Dependent	
<i>Jau-Shyong Deng, Richard D. Sontheimer, Mary F. Lipscomb, and James N. Gilliam</i>	163
Abnormal Calcium and Magnesium Stores in Erythrocytes and Granulocytes from Patients with Inflammatory Connective Tissue Diseases: Relationship to Inflammatory Activity and Effect of Corticosteroid Therapy	
<i>Roger Hällgren, Karin Svenson, Erland Johansson, and Ulf Lindh</i>	169
Immunohistochemical Studies of Interleukin-2 and γ -Interferon in Rheumatoid Arthritis	
<i>Gunnar Husby and Ralph C. Williams, Jr.</i>	174
Circulating Natural Killer Cells in Sjögren's Syndrome	
<i>Yukinobu Ichikawa, Miyoko Yoshida, Masatoshi Takaya, Mitsuaki Uchiyama, Hiroaki Shimizu, and Shigeru Arimori</i>	182
Soluble Mediators from Mononuclear Cells Increase the Synthesis of Glycosaminoglycan by Dermal Fibroblast Cultures Derived from Normal Subjects and Progressive Systemic Sclerosis Patients	
<i>Theresa L. Whiteside, Jennifer G. Worrall, Robert K. Prince, Robert B. Buckingham, and Gerald P. Rodnan</i>	188
Arthroscopy in Septic Arthritis: Lidocaine- and Iodine-Containing Contrast Media are Bacteriostatic	
<i>M. A. Dory and M. J. Wautelet</i>	198
Diagnosis-Related Group Regulations: Implications for the Practicing Rheumatologist	
<i>Morris Weinberger, Marilyn K. Potts, and Kenneth D. Brandt</i>	204

Brief Reports

Changes in Nongonococcal Septic Arthritis: Drug Abuse and Methicillin-Resistant <i>Staphylococcus Aureus</i> <i>Glorietta Z. Ang-Fonte, Michael B. Rozboril, and George R. Thompson</i>	210
Postgastrectomy Blind Loop Syndrome and the Arthritis-Dermatitis Syndrome <i>Alice V. Klinkhoff, Howard B. Stein, Otto L. A. Schlappner, and William B. Boyko</i>	214
Bone Crisis of Gaucher's Disease Due to Bone Ischemia: A Case Report <i>Anne Davidson, Victor Kalff, and Peter F. J. Ryan</i>	218
Ability to Activate Complement is Not Required for the Detection of Immune Complexes by the Fluid-Phase C1q Binding Assay <i>Guy P. Fiocco, John S. Davis, IV, and Joseph J. Burge</i>	222
Nucleolar Localization of the PM-Scl Antigen <i>Ira N. Targoff and Morris Reichlin</i>	226
Multicentric Reticulohistiocytosis: A Cause of Dysphagia with Response to Corticosteroids <i>Peter J. Zeale, David Miner, Stephen Honig, Marian Waxman, and Harry Bartfield</i>	231

Letters

A Followup Study of Children Exposed to Gold Compounds In Utero <i>Ulrik Tarp and Hans Graudal</i>	235
HLA-Bw35 and Gold Toxicity in Rheumatoid Arthritis <i>Graciela S. Alarcón, William J. Koopman, Ronald T. Acton, and Bruce O. Barger</i>	236
Renal Malakoplakia and Systemic Lupus Erythematosus <i>John Varga</i>	237
Correction of Data on Salicylate and Indomethacin Concentrations in Cartilage <i>Marshall J. Palmoski and Kenneth D. Brandt</i>	237
Pregnancy and Systemic Sclerosis <i>Mario Giordano, Gabriele Valentini, Salvatore Lupoli, and Andrea Giordano</i>	237
Reply <i>Stanley P. Ballou and Irving Kushner</i>	238
Coexistent Rheumatoid Arthritis and Gout <i>Arthur M. Virshup</i>	238
Epidemiology of Juvenile Arthritis in Rochester, Minnesota <i>Eric S. Schned</i>	239
Reply <i>Clement J. Michet</i>	239
Serum C1q Levels in Rheumatoid Arthritis <i>N. Parhami, C. L. Rosano, and C. Hurwitz</i>	240

ARA Announcements.....	A15
------------------------	-----

VOLUME 28

MARCH

NO. 3

Autoantibody Specificities of Immune Complexes Sequestered in Articular Cartilage of Patients with Rheumatoid Arthritis and Osteoarthritis <i>Hugo E. Jasin</i>	241
Prognostic Factors in Polymyositis/Dermatomyositis: A Computer-Assisted Analysis of Ninety-Two Cases <i>Jochanan Benbassat, Dov Gefel, Keren Larholt, Shaul Sukenik, Vladimir Morgenstern, and Avinoam Zlotnick</i>	249
Evidence for Intravascular Coagulation in Systemic Onset, But Not Polyarticular, Juvenile Rheumatoid Arthritis <i>J. Paul Scott, Patricia Gerber, Mona C. Maryjowski, and Lauren M. Pachman</i>	256
Subset Specificity of Antilymphocyte Antibodies in Systemic Lupus Erythematosus: Preferential Reactivity with Cells Bearing the T4 and Autologous Erythrocyte Receptor Phenotypes <i>Akira Yamada, Philip L. Cohen, and John B. Winfield</i>	262
Neonatal Lupus Erythematosus Occurring in One Fraternal Twin: Serologic and Immunogenetic Studies <i>Jeffrey P. Callen, Joseph F. Fowler, Kevin B. Kulick, Gregory Stelzer, and Stephen Z. Smith</i>	271
Effects of Long-Term Procainamide Therapy on Immunoglobulin Synthesis <i>Chia-Li Yu and Morris Ziff</i>	276

Patterns of Antihistone Antibody Specificity in Systemic Rheumatic Disease. I. Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Primary Sicca Syndrome, and Rheumatoid Arthritis with Vasculitis	
Robert M. Bernstein, Roderick N. Hobbs, Donald J. Lea, Donald J. Ward, and Graham R. V. Hughes	285
Quantitation of the Sm Nuclear Antigen in Tissues and Activated Lymphocytes	
Cinda M. Boyer, Robert A. Eisenberg, and Philip L. Cohen	294
Assessing Physician/Patient Perceptions in Rheumatoid Arthritis: A Vital Component in Patient Education	
Ilene J. Silvers, Melbourne F. Hovell, Michael H. Weisman, and Mary Rose Mueller	300
Double-Blind, Multicenter Controlled Trial Comparing Topical Dimethyl Sulfoxide and Normal Saline for Treatment of Hand Ulcers in Patients with Systemic Sclerosis	
H. James Williams, Daniel E. Furst, Stephen L. Dahl, Virginia D. Steen, Carolly Marks, Elaine J. Alpert, Avery M. Henderson, Cecil O. Samuelson, Jr., James N. Dreyfus, Arthur Weinstein, Edmund J. MacLaughlin, Graciela S. Alarcón, Stanley B. Kaplan, Maria Guttadauria, Michael E. Luggen, James C. Reading, Marlene J. Egger, and John R. Ward	308
Substrain Heterogeneity in Prostaglandin E ₂ Synthesis of Human Dermal Fibroblasts: Differences in Prostaglandin E ₂ Synthetic Capacity of Substrains are Not Stimulus-Restricted	
Joseph H. Korn	315
Kinetics of Extraction of Proteoglycans from Human Cartilage	
Lawrence A. Pottenger, June E. Webb, and Nancy B. Lyon	323
Radiologic Vignette: Tarsal Coalition	
David J. Sartoris and Donald L. Resnick	331
Brief Reports	
A Subset of Rheumatoid Arthritis Patients with a Pattern of Epstein-Barr Virus Antibodies Similar to That Found in Primary and Secondary Immunodeficiency Diseases	
Jacques H. M. Cohen, Thomas L. Vischer, Jocelyn Carquin, and François Blanchard	339
Thrombotic Thrombocytopenic Purpura Developing During Pregnancy in a C2-Deficient Patient with a History of Systemic Lupus Erythematosus	
R. Dixit, Arthur M. Krieg, and J. P. Atkinson	341
Cardiac Involvement in Behçet's Disease	
Carolyn A. Bowles, Audrey M. Nelson, Stephen C. Hammill, and J. Desmond O'Duffy	345
Defective Immune Adherence Receptors (CR1) on Erythrocytes in Autoimmune Diseases: An Association with HLA-Cw3	
Yukio Matsumura, Shigeko Inokuma, Tetsuo Hayakawa, and Tomonari Kasaki	349
Response of the Acute-Phase Reactants, C-Reactive Protein and Serum Amyloid A Protein, to Antibiotic Treatment of Whipple's Disease	
John I. Reed, Jean D. Sipe, Jeffrey R. Wohlgethan, Wilhelm G. Doos, and Juan J. Canoso	352
Letters	
In Vitro IgM and IgG Rheumatoid Factor Production and Response to Remittive Agents in Rheumatoid Arthritis	
Graciela S. Alarcón, William J. Koopman, and Ralph E. Schrohenloher	356
Comment on Article by van der Linden et al	
Andrei Calin	357
Reply	
Sjef M. van der Linden, Arnold Cats, and Hans Valkenburg	358
The CREST Acronym and Some Related Problems	
Mario Giordano	359
Digital Angiography for the Diagnosis of Dural Sinus Thrombosis in Behçet's Disease	
P. Brissaud, L. Laroche, A. de Gramont, and M. Krulik	359
ARA Announcements	A28, A29

VOLUME 28

APRIL

NO. 4

Evaluation of Factors Associated with Glucocorticoid-Induced Osteopenia in Patients with Rheumatic Diseases

Thomas R. Dykman, Oscar S. Gluck, William A. Murphy, Theodore J. Hahn, and Bevra H. Hahn 361

The Effect of Glucocorticoids on Bone Mass in Rheumatoid Arthritis Patients: Influence of Menopausal State <i>Orla Skibsted Als, Anders Gotfredsen, and Claus Christiansen</i>	369
Evaluation of D-Penicillamine in Juvenile Chronic Arthritis: A Double-Blind, Multicenter Study <i>A. M. Prieur, C. Piussan, P. Manigne, P. Bordigoni, and C. Griscelli</i>	376
Serum C-Reactive Protein in Polymyalgia Rheumatica: A Prospective Serial Study <i>R. K. Mallya, C. R. K. Hind, H. Berry, and M. B. Pepys</i>	383
Atrophic Gastritis in Sjögren's Syndrome: Morphologic, Biochemical, and Immunologic Findings <i>C. P. J. Maury, T. Törnroth, and A-M. Teppo</i>	388
Phagocytosis and Intracellular Killing by Polymorphonuclear Cells from Patients with Rheumatoid Arthritis and Felty's Syndrome <i>Ferdinand C. Breedveld, Maria T. van den Barselaar, Peter C. J. Leijh, Arnold Cats, and Ralph van Furth</i>	395
Human Rheumatoid Arthritic Cartilage and its Neutral Proteoglycan-Degrading Proteases: The Effects of Antirheumatic Drugs <i>Johanne Martel-Pelletier, Jean-Marie Cloutier, David S. Howell, and Jean-Pierre Pelletier</i>	405
Cartilage Nucleoside Triphosphate Pyrophosphohydrolase. II. Role in Extracellular Pyrophosphate Generation and Nucleotide Metabolism <i>Lawrence M. Ryan, Robert L. Wortmann, Barbara Karas, and Daniel J. McCarty, Jr.</i>	413
Cartilage Response to Mechanical Force in High-Density Chondrocyte Cultures <i>G. P. J. van Kampen, J. P. Veldhuijzen, R. Kuijer, R. J. van de Stadt, and C. A. Schipper</i>	419
A Longitudinal Study of High and Low Avidity Antibodies to Double-Stranded DNA in Systemic Lupus Erythematosus <i>Hugh McGrath, Jr. and Joseph J. Biundo, Jr.</i>	425
Spontaneous In Vitro Production of Anti-DNA and Anti-RNA by Systemic Lupus Erythematosus and Normal Peripheral Blood Mononuclear Cells <i>Michael R. Liebling, Curtice Wong, and Jean Radosevich</i>	431
Intraarticular Volume and Clearance in Human Synovial Effusions <i>Wayne J. Wallis, Peter A. Simkin, Wil B. Nelp, and David M. Foster</i>	441
Government Affairs: FDA Arthritis Advisory Committee Meeting <i>Harold E. Paulus</i>	450
Brief Reports	
Myocarditis in Adult Still's Disease <i>Ilan Bank, Charles C. Marboe, Rita F. Redberg, and Jerry Jacobs</i>	452
A Persistent Adenovirus Type 1 Infection in Synovial Tissue from an Immunodeficient Patient with Chronic, Rheumatoid-Like Polyarthritis <i>Kevin J. Fraser, Barry J. Clarris, Kenneth D. Muirden, J. Robert E. Fraser, and Ian Jack</i>	455
Raynaud's Phenomenon of a Single Digit Following Local Intradermal Bleomycin Sulfate Injection <i>Edwin A. Smith, Frank E. Harper, and E. Carwile LeRoy</i>	459
Concurrent Systemic Lupus Erythematosus and Common Variable Hypogammaglobulinemia <i>Anthony Stein, Alan Winkelstein, and Amrit Agarwal</i>	462
Bowel Involvement in Systemic Lupus Erythematosus: Crohn's Disease or Lupus Vasculitis? <i>Dafna D. Gladman, Theodore Ross, Beverley Richardson, and Savita Kulkarni</i>	466
Special Article: Rheumatology Training at Internal Medicine and Family Practice Residency Programs <i>Don L. Goldenberg, Raphael J. DeHoratius, Stephen R. Kaplan, John Mason, Robert Meenan, Susan G. Perlman, and John B. Winfield</i>	471
Letters	
Comment on Article by Faure et al <i>Barry Lee Myones, Earl D. Silverman, and John J. Miller, III</i>	477
Popliteal Cyst Presenting as an Anterior Tibial Mass <i>A. Thevenon, P. Hardouin, and B. Duquesnoy</i>	477
Comment on Article by Brenner et al <i>Stephen Aaron</i>	478
Tender Point Count <i>Frederick Wolfe</i>	479
Angiotensin Converting Enzyme Inhibitors and Rheumatoid Arthritis <i>Allen Traficante, Michael A. Catalano, and George E. Ehrlich</i>	480
Book Review	480
ARA Announcements	A37

49th Annual Meeting American Rheumatism Association	S1
20th Annual Meeting Arthritis Health Professions Association	S132

Antibodies to Human T Cell Leukemia Virus are Absent in Patients with Systemic Lupus Erythematosus <i>Takao Koike, Masaru Kagami, Katsuhiko Takabayashi, Naoki Maruyama, Hisao Tomioka, and Sho Yoshida</i>	481
When Does Rheumatoid Disease Start? <i>K. Aho, T. Palosuo, V. Raunio, P. Puska, A. Aromaa, and J. T. Salonen</i>	485
Nifedipine and Esophageal Dysfunction in Progressive Systemic Sclerosis: A Controlled Manometric Study <i>André Kahan, Bruno Bour, Daniel Couturier, Bernard Amor, and Charles J. Menkes</i>	490
Relationship Between Nailfold Capillary Abnormalities and Organ Involvement in Systemic Sclerosis <i>Michael Lovy, Daryl MacCarter, and James C. Steigerwald</i>	496
Selective Inhibition of Excessive Scleroderma Fibroblast Collagen Production by Lymphokines From Normal Human Mononuclear Cells <i>Sergio A. Jimenez, William M. McArthur, Reza I. Bashey, and Joel Rosenbloom</i>	502
Synovial Fluid Crystals in Osteoarthritis <i>Paul A. Gibilisco, H. Ralph Schumacher, Jr., Joseph L. Hollander, and Keith A. Soper</i>	511
Blastomycosis Presenting as Monarticular Arthritis: The Role of Synovial Fluid Cytology <i>Alfred L. George, Jr., J. Taylor Hays, and Barney S. Graham</i>	516
Induction of Chronic Polyarthritis in Rabbits by Hyperimmunization with <i>Escherichia Coli</i> . I. Pathologic and Serologic Features in Two Breeds of Rabbits <i>Shigehisa Aoki, Koji Ikuta, Tsunemasa Nonogaki, and Yoshitake Ito</i>	522
Etiopathogenesis of the Rheumatoid Arthritis-Like Disease in MRL/l Mice. I. The Histomorphologic Basis of Joint Destruction <i>Frank X. O'Sullivan, Hans-Georg Fassbender, Steffen Gay, and William J. Koopman</i>	529
The Autologous Mixed Lymphocyte Reaction is Decreased in Freund's Adjuvant-Injected Rats of Arthritis-Susceptible and -Insusceptible Strains <i>William E. Crowe, Jack R. Battisto, and R. N. Smith</i>	537
Comparative Measurement Efficiency and Sensitivity of Five Health Status Instruments for Arthritis Research <i>Matthew H. Liang, Martin G. Larson, Karen E. Cullen, and Julie A. Schwartz</i>	542
Proteoglycan Depletion, Rather than Fibrillation, Determines the Effects of Salicylate and Indomethacin on Osteoarthritic Cartilage <i>Marshall J. Palmoski and Kenneth D. Brandt</i>	548
Role of Synovial Membrane Inflammation in Cartilage Matrix Breakdown in the Pond-Nuki Dog Model of Osteoarthritis <i>Jean-Pierre Pelletier, Johanne Martel-Pelletier, Latifa Ghandur-Mnaymneh, David S. Howell, and J. Frederick Woessner, Jr.</i>	554
The Specificity of Antibodies to the F(ab') ₂ Fragment of Human IgG <i>Ralph Heimer, Lawrence D. Wolfe, and John L. Abruzzo</i>	562
Special Article: Winners of the 1984 Slide Competition <i>Sidney Block and the Audiovisual Aids Subcommittee of the ARA Education Committee</i>	569
Brief Reports	
Systemic Lupus Erythematosus in a Premature Infant <i>Nancy P. Cummings, Jeffrey Hansen, and J. Roger Hollister</i>	573
Meningococcemia Presenting as Septic Arthritis, Pericarditis, and Tenosynovitis <i>Michael S. Rosen, Allen R. Myers, and Burton Dickey</i>	576
Relationship of Autoantibody Expression and HLA Phenotype in Japanese Patients with Connective Tissue Diseases <i>Masahiko Nishikai and Susumu Sekiguchi</i>	579
Aortic Regurgitation in Giant Cell Arteritis <i>Alice V. Klinkhoff, Graham D. Reid, and Michael Moscovich</i>	582

Wrist Drop in Progressive Systemic Sclerosis (Scleroderma): Complete Rupture of the Extensor Tendon Mechanism <i>Lewis H. Rosenbaum, William M. Swartz, Gerald P. Rodnan, and Thomas A. Medsger, Jr.</i>	586
Combination Immunosuppressive Treatment of Steroid-Resistant Dermatomyositis/Polymyositis <i>Daniel J. Wallace, Allan L. Metzger, and Kathy K. White</i>	590
Letters	
Diagnosis of Sjögren's Syndrome <i>Troy E. Daniels and John P. Whitcher</i>	593
Aortic Arch Syndrome Associated with Anticardiolipin Antibodies and the Lupus Anticoagulant: Comment on Ferrante Paper <i>Ronald A. Asherson, E. Nigel Harris, Azzudin E. Gharavi, Helen E. Englert, and Graham R. V. Hughes</i>	594
Nephrotic Syndrome Induced by Tiopronin: Association with the HLA-DR3 Antigen <i>Carlo Salvarani, PierLuigi Macchioni, Fulvia Rossi, Ido Iori, and Giordano Filippi</i>	595
Idiopathic Thrombocytopenic Purpura with High-Titer, Speckled Pattern Antinuclear Antibodies: Possible Marker for Systemic Lupus Erythematosus <i>H. Daniel Perez, Ernest Katler, and Stephen Embury</i>	596
Autoantibodies During Captopril Treatment <i>Cees G. M. Kallenberg</i>	597
Systemic Lupus Erythematosus and Down's Syndrome <i>C. Michael Franklin and Dennis Torretti</i>	598
Low Plasma Renin Activity in Lupus-Prone Mice: A Metabolic Abnormality in MRL/Mp-lpr/lpr Mice? <i>Ulrich H. Rudofsky, Robert L. Dilworth, Albert M. Magro, and John B. Roths</i>	599
Botticelli and Arthritis <i>Donato Alarcón-Segovia</i>	600
ARA Announcements	A25

VOLUME 28

JUNE

NO. 6

The Immunoreactivity, Ligand, and Cell Binding Characteristics of Rheumatoid Synovial Fluid Fibronectin <i>Steven Carsons, Beverly B. Lavietes, Herbert S. Diamond, and Sandra G. Kinney</i>	601
Reduced Joint Count Indices in the Evaluation of Rheumatoid Arthritis <i>M. J. Egger, D. A. Huth, J. R. Ward, J. C. Reading, and H. J. Williams</i>	613
A Comparison of the Specificity of the 1971 and 1982 American Rheumatism Association Criteria for the Classification of Systemic Lupus Erythematosus <i>Constance M. Passas, Robert L. Wong, Margaret Peterson, Marcia A. Testa, and Naomi F. Rothfield</i>	620
Relationship Between Circulating Interferon and Anti-Interferon Antibodies and Impaired Natural Killer Cell Activity in Systemic Lupus Erythematosus <i>Wilmer L. Sibbitt, Jr., Dwayne L. Gibbs, Carol Kenny, Arthur D. Bankhurst, Robert P. Searles, and Kenneth D. Ley</i>	624
Cricopharyngeal Obstruction in Inflammatory Myopathy (Polymyositis/Dermatomyositis): Report of Three Cases and Review of the Literature <i>Lawrence J. Kagen, Raymond B. Hochman, and Elliot W. Strong</i>	630
Decreased Coronary Reserve in Primary Scleroderma Myocardial Disease <i>André Kahan, Alain Nitenberg, Jean-M. Foul, Bernard Amor, Charles-J. Menkes, Jean-Y. Devaux, Françoise Blanchet, Jeannine Perennec, Geneviève Lutfalla, and Jean-C. Roucayrol</i>	637
Collagen Synthesis Regulation by the Aminoprepeptide of Procollagen I in Normal and Scleroderma Fibroblasts <i>Jerome S. Perlish, Rupert Timpl, and Raul Fleischmajer</i>	647
Coronary Arteritis in Mice Following the Systemic Injection of Group B <i>Lactobacillus Casei</i> Cell Walls in Aqueous Suspension <i>Thomas J. A. Lehman, Sharyn M. Walker, Vladimir Mahnovski, and Deborah McCurdy</i>	652
Cartilage Surface Charge: A Possible Determinant in Aging and Osteoarthritic Processes <i>Zahava Laver-Rudich and Michael Silbermann</i>	660
Effectiveness of Cyclosporin Therapy for Behçet's Disease <i>Robert B. Nussenblatt, Alan G. Palestine, Chi-Chao Chan, Manabu Mochizuki, and Kim Yancey</i> ..	671

Outcomes of Self-Help Education for Patients with Arthritis <i>Kate Lorig, Deborah Lubeck, R. Guy Kraines, Mitchell Seleznick, and Halsted R. Holman</i>	680
Utilization of Nonsteroidal Antiinflammatory Drugs <i>Carlene Baum, Dianne L. Kennedy, and Mary B. Forbes</i>	686
Application, to Japanese Patients, of the 1982 American Rheumatism Association Revised Criteria for the Classification of Systemic Lupus Erythematosus <i>Ryuichi Yokohari and Tokugoro Tsunematsu</i>	693
Brief Reports	
Juvenile Progressive Systemic Sclerosis: Clinical and Serologic Findings <i>María E. Suárez-Almazor, Luis J. Catoggio, José A. Maldonado-Cocco, Rubén Cuttica, and Osvaldo García-Morteo</i>	699
Protective Effect of Poliomyelitis on Psoriatic Arthritis <i>Steven R. Weiner, Lawrence W. Bassett, and Ronald P. Reichman</i>	703
Allopurinol Hypersensitivity in a Patient with Severe, Chronic, Tophaceous Gout <i>Ella Webster and Richard S. Panush</i>	707
Oral Gold Therapy in a Patient with Rheumatoid Arthritis and Preexisting Uremia <i>Winfried Graninger, Gerald Seidl, Josef Kovarik, Wulf Pinggera, and Josef S. Smolen</i>	710
In Appreciation of Nathan J. Zvaifler, MD <i>Jane Diamond and Irving H. Fox</i>	713
Introducing the New Editor: William J. Koopman, MD <i>Eng M. Tan</i>	714
Letters	
Evaluation of the 1982 American Rheumatism Association Revised Criteria for the Classification of Systemic Lupus Erythematosus <i>F. Davatchi, C. Chams, and M. Akbarian</i>	715
Autoantibodies in Argentine Patients with Systemic Sclerosis (Scleroderma) <i>Luis J. Catoggio, Santiago Rodríguez, Hugo Laborde, Pedro M. Catoggio, and Patricia González Salas</i>	715
Calcium Pyrophosphate Dihydrate Crystal Deposition in Rheumatoid Arthritis <i>Daniel J. McCarty</i>	717
Reply <i>Michael Doherty, Paul Dieppe, and Iain Watt</i>	718
Comment on Zea-Mendoza Report <i>John Varga and Maggie Flinn</i>	719
Book Review	720
ARA Announcements	A15

VOLUME 28

JULY

NO. 7

Comparison of Low-Dose Oral Pulse Methotrexate and Placebo in the Treatment of Rheumatoid Arthritis: A Controlled Clinical Trial <i>H. James Williams, Robert F. Willkens, Cecil O. Samuelson, Jr., Graciela S. Alarcón, Maria Guttadauria, Cheryl Yarboro, Richard P. Polisson, Steven R. Weiner, Michael E. Luggen, Lynn M. Billingsley, Stephen L. Dahl, Marlene J. Egger, James C. Reading, and John R. Ward</i>	721
Impaired Killer Cell Generation in the Autologous Mixed Leukocyte Reaction by Rheumatoid Arthritis Lymphocytes <i>Makoto Goto and Nathan J. Zvaifler</i>	731
IgG and IgM Rheumatoid Factor Synthesis in Rheumatoid Synovial Membrane Cell Cultures <i>Richard M. Wernick, Peter E. Lipsky, Eusebio Marban-Arcos, John J. Maliakkal, Dale Edelbaum, and Morris Ziff</i>	742
Sex Ratio and Sibship Size in Juvenile Rheumatoid Arthritis Kindreds <i>Stephen Aaron, Patricia A. Fraser, Jean M. Jackson, Martin Larson, and David N. Glass</i>	753
Pulmonary Involvement in Systemic Sclerosis (Scleroderma) <i>Virginia D. Steen, Gregory R. Owens, Gregory J. Fino, Gerald P. Rodnan, and Thomas A. Medsger, Jr.</i>	759
Angiographic Findings in Mixed Connective Tissue Disease: Correlation with Fingernail Capillary Photomicroscopy and Digital Photoplethysmography Findings <i>Jeffrey S. Peller, Gary T. Gabor, John M. Porter, and Robert M. Bennett</i>	768

Cellular Immunity to Collagen and Laminin in Scleroderma <i>J. Eugene Huffstutter, Frank A. DeLustro, and E. Carwile LeRoy</i>	775
Inspiratory Muscle Dysfunction and Unexplained Dyspnea in Systemic Lupus Erythematosus <i>Sergio Jacobelli, Rodrigo Moreno, Loreto Massardo, Santiago Rivero, and Carmen Lisboa</i>	781
Antineuronal Antibodies in Neuropsychiatric Systemic Lupus Erythematosus <i>Angela How, Peter B. Dent, Shuen-Kuei Liao, and Judah A. Denburg</i>	789
The Association Between Mi-2 Antibodies and Dermatomyositis <i>Ira N. Targoff and Morris Reichlin</i>	796
Phosphorylation of Proteoglycans: Identification of Phosphorylation Sites in Chondroitin Sulfate-Rich Region of Core Protein <i>Roger S. Anderson and Edith R. Schwartz</i>	804
Influence of the Severity and Duration of Murine Antigen-Induced Arthritis on Cartilage Proteoglycan Synthesis and Chondrocyte Death <i>Marijn W. M. Kruijsen, Wim B. van den Berg, and Levinus B. A. van de Putte</i>	813
Radiologic Vignette: Pressure Erosions: A Pattern of Bone Resorption in Rheumatoid Arthritis <i>Barbara Monsees and William A. Murphy</i>	820
Brief Reports	
Jaccoud's Arthropathy of the Knees in Systemic Lupus Erythematosus <i>Mercedes de la Sota, Osvaldo García-Morteo, and José A. Maldonado-Cocco</i>	825
Gm Allotypes in White Patients with Systemic Lupus Erythematosus <i>Peter H. Schur, Janardan P. Pandey, and Joseph A. Fedrick</i>	828
Total Body Irradiation and the Course of Polymyositis <i>Stephen H. Morgan, Robert M. Bernstein, Jaqueline Coppen, Keith E. Halnan, and Graham R. V. Hughes</i>	831
Letters	
A Possible Mechanism of Action of Thalidomide on Rheumatoid Arthritis <i>Yoshiki Miyachi</i>	836
Immunofluorescence and Fibromyalgia <i>Daniel J. Wallace</i>	836
Reply <i>Xavier J. Caro</i>	836
An Additional Test for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica <i>J. B. Paolaggi, D. Chaouat, and L. Auquier</i>	837
Miller-Fisher Syndrome (Guillain-Barré Syndrome with Ophthalmoplegia) During Treatment with Gold Salts in a Patient with Rheumatoid Arthritis <i>J. Roquer, J. Herraiz, J. Maymo, A. Olivé, and J. Carbonell</i>	838
Intranuclear Location of the Myositis-Specific Jo-1 Antigen: Hopping Histidyl-tRNA Synthetase? <i>Chi V. Dang</i>	839
Reply <i>Morris Reichlin and Frank C. Arnett, Jr.</i>	840
ARA Announcements	A51

VOLUME 28

AUGUST

NO. 8

Current Comment: T Lymphocyte Clones Illuminate Pathogenesis and Affect Therapy of Experimental Arthritis <i>Irun R. Cohen, Joseph Holoshitz, Willem van Eden, and Ayalla Frenkel</i>	841
Impact of Diagnosis-Related Group-Based Reimbursement for Treatment of Rheumatic Diseases in a Teaching Hospital <i>Robert M. Hartley, Matthew H. Liang, and Karen E. Cullen</i>	846
Release of Interleukin-1 From Human Synovial Tissue In Vitro <i>David D. Wood, Earl J. Ihrie, and David Hamerman</i>	853
Different Populations of Rheumatoid Adherent Cells Mediate Activation Versus Suppression of T Lymphocyte Proliferation <i>Lars Klareskog, Rikard Holmdahl, Kristofer Rubin, Åse Victorin, and Jan Åke Lindgren</i>	863

Suppression of Rheumatoid Factor Synthesis by Antiidiotypic Antibody in Rheumatoid Arthritis Patients with Cross-Reactive Idiotypes	
<i>Tsutomu Takeuchi, Osamu Hosono, Jun Koide, Mitsuo Homma, and Tohru Abe</i>	873
The Effect of D-Penicillamine on Pulmonary Findings in Systemic Sclerosis	
<i>Virginia D. Steen, Gregory R. Owens, Carol Redmond, Gerald P. Rodnan, and Thomas A. Medsger, Jr.</i>	882
Anticytoskeletal Autoantibodies in the Connective Tissue Diseases	
<i>Jean-Luc Senécal, Janet M. Oliver, and Naomi Rothfield</i>	889
The Leukergy Test in Rheumatic Diseases: New Implications for an Old Test	
<i>Shlomo Berliner, Moshe Abramovitz, Naam Kariv, Abraham Weinberger, Michael Yaron, Gad Lavie, Jacob Pinkhas, and Moshe Aronson</i>	899
The Value of Complement and Immune Complex Determinations in Monitoring Disease Activity in Patients with Systemic Lupus Erythematosus	
<i>R. M. Valentijn, H. van Overhagen, H. M. Hazevoet, J. Hermans, A. Cats, M. R. Daha, and L. A. van Es</i>	904
In Vitro Production and Scavenging of Hydrogen Peroxide by D-Penicillamine: Relationship to Copper Availability	
<i>Nigel D. Staite, Ronald P. Messner, and David C. Zoschke</i>	914
Salicylate-Induced Depletion of Endogenous Inorganic Sulfate: Potential Role in the Suppression of Sulfated Glycosaminoglycan Synthesis in Murine Articular Cartilage	
<i>Bernard J. de Vries, Wim B. van den Berg, and Levinus B. A. van de Putte</i>	922
Computed Tomography in the Diagnosis of Early Ankylosing Spondylitis	
<i>Adel G. Fam, Joel D. Rubenstein, Hyacinth Chin-Sang, and Frances Y. K. Leung</i>	930
Brief Reports	
Association of Epidemic Kawasaki Syndrome with the HLA-A2, B44, Cw5 Antigen Combination	
<i>Richard A. Kaslow, Anne Bailowitz, Feng Y. C. Lin, Patricia Koslowe, Toni Simonis, and Ebenezer Israel</i>	938
Sympathetic Synovial Effusions Associated with Septic Arthritis and Bursitis	
<i>Roger W. Strickland, Richard J. Raskin, and Richard C. Welton</i>	941
Polyarthritis as the Presenting Symptom of a Malignant Fibrous Histiocytoma of the Heart	
<i>Jan W. Berkelbach van der Sprenkel, Alphons J. M. Timmermans, Hans R. J. Elbers, Gé van Herpen, and Huibert J. Dinant</i>	944
Eosinophilic Fasciitis in a Two-Year-Old Child	
<i>Earl D. Silverman, Bruce T. Adornato, and John J. Miller, III</i>	948
Severe Reflex Neurovascular Dystrophy in Childhood	
<i>Perry J. Rush, Dan Wilmot, Norman Saunders, Dafna Gladman, and Abraham Shore</i>	952
Letters	
Adult-Onset Still's Disease: A Case with Onset During Pregnancy	
<i>M. Yebra Bango, J. M. García Paez, J. J. Solovera, M. F. Merino, and J. A. Girón González</i>	957
Apophyseal Joint Ankylosis of the Cervical Spine in Adult-Onset Rheumatoid Arthritis	
<i>Robert L. Wong, Anthony J. Wilson, Frances S. Ingenito, and Ann Parke</i>	958
Erosive Granulomatous Arthritis in Crohn's Disease	
<i>Antoine Toubert, Maxime Dougados, and Bernard Amor</i>	958
Joint Involvement in Psoriasis: Uncommon or Frequent?	
<i>Walter Grassi and Monica Cervini</i>	959
Preliminary Study of Testosterone Levels in Rats with Adjuvant Arthritis	
<i>A. Barbier, J. C. Breliere, and R. Roncucci</i>	959
ARA Announcements	A7,A8

VOLUME 28

SEPTEMBER

NO. 9

Different Defects of T Cell Regulation of Epstein-Barr Virus-Induced B Cell Activation in Rheumatoid Arthritis	
<i>Alice Kahan, André Kahan, Bernard Amor, and Charles J. Menkes</i>	961
A Rheumatoid Arthritis B Cell Subset Expresses a Phenotype Similar to That in Chronic Lymphocytic Leukemia	
<i>G. Plater-Zyberk, R. N. Maini, K. Lam, T. D. Kennedy, and G. Janossy</i>	971

Intraarticular Variation in Synovitis: Local Macroscopic and Microscopic Signs of Inflammatory Activity are Significantly Correlated <i>Staffan Lindblad and Eva Hedfors</i>	977
The Clinical Features of Elderly-Onset Rheumatoid Arthritis: A Comparison with Younger-Onset Disease of Similar Duration <i>Chad L. Deal, Robert F. Meenan, Don L. Goldenberg, Jennifer J. Anderson, Burton Sack, Robert S. Pastan, and Alan S. Cohen</i>	987
No Demonstrable Relationship Between IgM and IgG Antinuclear Antibody Levels and Acetylator Phenotype in Patients with Systemic Lupus Erythematosus <i>Joseph P. Portanova, Calvin J. Small, and Peter F. Kohler</i>	995
Detection of Cross-Reactive Anti-DNA Antibody Idiotypes in the Serum of Systemic Lupus Erythematosus Patients and of Their Relatives <i>D. A. Isenberg, Y. Shoenfeld, M. Walport, C. Mackworth-Young, C. Dudeney, A. Todd-Pokropek, S. Brill, A. Weinberger, and J. Pinkas</i>	999
Impaired B Cell Proliferation by <i>Staphylococcus Aureus</i> Cowan 1 in Patients with Systemic Lupus Erythematosus <i>Shigemasa Sawada, Satoshi Amaki, Masami Takei, Miki Karasaki, and Ichita Amaki</i>	1008
Synthesis, Secretion, and Deposition of Fibronectin in Cultured Human Synovium <i>Beverly B. Lavietes, Steven Carsons, Herbert S. Diamond, and Richard S. Laskin</i>	1016
Morphologic and Cytochemical Changes in Maturing and Osteoarthritic Articular Cartilage in the Temporomandibular Joint of Mice <i>Erella Livne, Klaus von der Mark, and Michael Silbermann</i>	1027
Crystal-Induced Endogenous Pyrogen Production: A Further Look at Gouty Inflammation <i>Stephen E. Malawista, Gordon W. Duff, Elisha Atkins, Herman S. Cheung, and Daniel J. McCarty</i>	1039
Rheumatic Fever-Associated B Cell Alloantigens as Identified by Monoclonal Antibodies <i>J. B. Zabriskie, D. Lavenchy, R. C. Williams, Jr., S. M. Eu, C. A. Yeadon, M. Fotino, and D. G. Braun</i>	1047
Synovial Amyloidosis in Patients Undergoing Long-Term Hemodialysis <i>Thomas Bardin, Daniel Kuntz, Johanna Zingraff, Marie-Catherine Voisin, Alain Zelmar, and Juliette Lansaman</i>	1052
Brief Reports	
Pure Red Cell Aplasia and Protein-Losing Enteropathy in a Patient with Systemic Lupus Erythematosus <i>Louis W. Heck, Graciela S. Alarcón, Gene V. Ball, Robert L. Phillips, Lanning B. Kline, Hernan Moreno, Basil I. Hirschowitz, Alan N. Baer, and Emmanuel N. Dessypris</i>	1059
The Syndrome of Anserina Bursitis: An Overlooked Diagnosis <i>Lars-Goran Larsson and John Baum</i>	1062
Observer Variability in the Interpretation of Lumbar Spine Radiographs <i>Richard A. Deyo, Lawrence M. McNiesh, and Robert O. Cone, III</i>	1066
Production of Immunoglobulin and Rheumatoid Factor by Lymphoid Cells in Rheumatoid Pericardium <i>David M. Spalding, Patricia Haber, Ralph E. Schrohenloher, and William J. Koopman</i>	1071
Letters	
Erosive Azotemic Osteoarthropathy: Possible Role of Amyloidosis <i>J. P. Huaux, H. Noël, J. Malghem, B. Maldague, J. P. Devogelaer, and C. Nagant de Deuxchaisnes</i>	1075
Anticentromere Antibody is Not Specific for Connective Tissue Disease with a Promising Prognosis <i>S. Ray Mitchell, Gale A. McCarty, and Paul Katz</i>	1076
Congenital Heart Block, Systemic Lupus Erythematosus, and Anti-Ro Antibodies <i>Ann Parke and Naomi F. Rothfield</i>	1077
Cyclosporine: A New Adjuvant Therapy for Giant Cell Arteritis? <i>D. Wendling, B. Hory, and D. Blanc</i>	1078
Reflex Sympathetic Dystrophy Associated with Malignancy <i>Elliot Goldberg, Roman Dobransky, and Roy Gill</i>	1079
ARA Announcements.....	A7

VOLUME 28

OCTOBER

NO. 10

ARA Kunkel Memorial Lecture: Murine Lupus: A Model for Human Autoimmunity <i>Frank J. Dixon</i>	1081
--	------

Elevated C3 Anaphylatoxin Levels in Synovial Fluids From Patients with Rheumatoid Arthritis <i>George Moxley and Shaun Ruddy</i>	1089
Low Synovial Clearance of Iodide Provides Evidence of Hypoperfusion in Chronic Rheumatoid Synovitis <i>Wayne J. Wallis, Peter A. Simkin, and Wil B. Nelp</i>	1096
Extracellular Matrix-Cytoskeletal Interactions in Rheumatoid Arthritis. I. Immunoelectron Microscopic Analysis of the Fibronexus at the Adhesive Surface of Normal Porcine Type B Synoviocytes In Vitro <i>Irwin I. Singer, Diana M. Kazasis, Douglas W. Kawka, Elizabeth A. Rupp, and Ellen K. Bayne</i>	1105
Ibuprofen Disposition in Obese Individuals <i>Darrell R. Abernethy and David J. Greenblatt</i>	1117
Determination of 16 Alpha-Hydroxyestrone by Radioimmunoassay in Systemic Lupus Erythematosus <i>Robert G. Lahita, Richard Bucala, H. Leon Bradlow, and Jack Fishman</i>	1122
A Quantitative Test for Xerostomia: The Saxon Test, an Oral Equivalent of the Schirmer Test <i>Peter F. Kohler and Margaret E. Winter</i>	1128
Modulatory Effect of Sera From Scleroderma Patients on Lymphocyte-Induced Angiogenesis <i>Slawomir Majewski, Ewa Skopinska-Rożewska, Stefania Jablonska, Igor Polakowski, Maria Pawinska, Maria Marczak, and Andrzej Szmurlo</i>	1133
Stress-Induced Proteins in Chondrocytes From Patients with Osteoarthritis <i>Toshikazu Kubo, Christine A. Towle, Henry J. Mankin, and Benjamin V. Treadwell</i>	1140
Two Histopathologic Types of Inflammatory Vascular Disease in MRL/Mp Autoimmune Mice: Model for Human Vasculitis in Connective Tissue Disease <i>Elaine L. Alexander, Carolyn Moyer, Gregory S. Travlos, John B. Roths, and Edwin D. Murphy</i> ...	1146
Referral of Musculoskeletal Disease Patients by Family and General Practitioners <i>David T. Felson, Robert F. Meenan, Susan J. Dayno, and Paul Gertman</i>	1156
Continuing Medical Education: Changing Behavior and Improving Outcomes <i>Jeffrey K. Stross, H. Ralph Schumacher, Michael H. Weisman, and David M. Spalding</i>	1163
Government Affairs: FDA Arthritis Advisory Committee Meeting: Postmarketing Surveillance of Nonsteroidal Antiinflammatory Drugs <i>Harold E. Paulus</i>	1168
Brief Reports	
Failure to Demonstrate (Cross-Reacting) Antibodies to Human T Lymphotropic Viruses in Patients with Rheumatic Diseases <i>J. Steven McDougal, M. Susan Kennedy, V. S. Kalyanaraman, and Frederic C. McDuffie</i>	1170
Chronic Arthritis Following Benign Rheumatoid Nodules of Childhood <i>Perry J. Rush, Bram H. Bernstein, Charles R. Smith, and Abraham Shore</i>	1175
Fasciitis and Polyarthritis During Antituberculous Therapy <i>John M. Seaman, Marian Goble, Lorie Madsen, and James C. Steigerwald</i>	1179
Myocardial Infarction with Central Retinal Artery Occlusion in a Patient with Antinuclear Antibody-Negative Systemic Lupus Erythematosus <i>Yoseph Shalev, Leslie Green, Ayala Pollack, and Zvi Bentwich</i>	1185
Evidence Against Close Linkage to HLA of the Gene for Familial Amyloid Polyneuropathy <i>Anne Sigsbee, Alan S. Cohen, Lynn Collins, Martin Larson, and David N. Glass</i>	1188
Letters	
The Mechanism of Cartilage Destruction in Rheumatoid Arthritis <i>D. Mitrovic</i>	1192
Reply to Letter by Dr. Mitrovic <i>Hans-Georg Fassbender</i>	1193
Reply to Letter by Dr. Mitrovic <i>Shunichi Shiozawa</i>	1193
Rheumatoid Arthritis Pannus: True or False? <i>T. D. V. Cooke</i>	1195
Reply <i>David E. Woolley, Michael Bromley, and John M. Evanson</i>	1197
The Mechanism of Action of L-Canavanine in Inducing Autoimmune Phenomena <i>Pamela E. Prete</i>	1198
Reply <i>Jorge Alcocer-Varela and Donato Alarcón-Segovia</i>	1200
ARA Announcements	A45

ARA Presidential Address: A Time for Change and a Time to Remain the Same <i>Eng M. Tan</i>	1201
Total Lymphoid Irradiation in Patients with Refractory Rheumatoid Arthritis <i>Hubert G. Nüsslein, Manfred Herbst, Bernhard J. Manger, Martin Gramatzki, Gerd R. Burmester, Harald Fritz, Rolf Sauer, and Joachim R. Kalden</i>	1205
Lack of Correlation Between Blood Gold Concentrations and Clinical Response in Patients with Definite or Classic Rheumatoid Arthritis Receiving Auranofin or Gold Sodium Thiomalate <i>Stephen L. Dahl, Miki L. Coleman, H. James Williams, Mary Altz-Smith, Donald R. Kay, Harold E. Paulus, Arthur Weinstein, and Stanley Kaplan</i>	1211
IgA Rheumatoid Factor Synthesis by Dissociated Synovial Cells: Characterization and Relationship to IgM Rheumatoid Factor Synthesis <i>William J. Koopman, Ralph E. Schrohenloher, Sylvia S. Crago, David M. Spalding, and Jiri Mestecky</i>	1219
Antiarthritic Drugs Containing Thiol Groups Scavenge Hypochlorite and Inhibit Its Formation by Myeloperoxidase From Human Leukocytes: A Therapeutic Mechanism of These Drugs in Rheumatoid Arthritis? <i>Roelck A. Cuperus, Anton O. Muijsers, and Ron Wever</i>	1228
Computed Tomography of the Hindfoot with Rheumatoid Arthritis <i>Steven E. Seltzer, Barbara N. Weissman, Ethan M. Braunstein, Douglass F. Adams, and William H. Thomas</i>	1234
Hormonal Modulation in Systemic Lupus Erythematosus: Preliminary Clinical and Hormonal Results with Cyproterone Acetate <i>Paul Jungers, Frédérique Kuttann, Frédéric Liote, Clara Pelissier, Nicole Athea, Marie-Christine Laurent, Joëlle Viriot, Maxime Dougados, and Jean-François Bach</i>	1243
Two Types of Inflammatory Vascular Disease in Sjögren's Syndrome: Differential Association with Seroreactivity to Rheumatoid Factor and Antibodies to Ro (SS-A) and with Hypocomplementemia <i>Rodolfo Molina, Thomas T. Provost, and Elaine L. Alexander</i>	1251
Noninvasive Evaluation of Cardiac Dysrhythmias, and Their Relationship with Multisystemic Symptoms, in Progressive Systemic Sclerosis Patients <i>Clodoveo Ferri, Luigi Bernini, Maria Grazia Bongiorno, Dianora Levorato, Giovanni Viegi, Prassede Bravi, Carlo Contini, Giampiero Pasero, and Stefano Bombardieri</i>	1259
Triamcinolone Hexacetonide Protects Against Fibrillation and Osteophyte Formation Following Chemically Induced Articular Cartilage Damage <i>James M. Williams and Kenneth D. Brandt</i>	1267
Suppression of Hyaluronic Acid Synthesis in Synovial Organ Cultures by Corticosteroid Suspensions <i>Stephen L. Myers</i>	1275
Adenosine Triphosphate Pyrophosphohydrolase and Neutral Inorganic Pyrophosphatase in Pathologic Joint Fluids: Elevated Pyrophosphohydrolase in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease <i>John W. Rachow and Lawrence M. Ryan</i>	1283
Effective Patient Education: A Quasi-Experiment Comparing an Individualized Strategy with a Routinized Strategy <i>Christopher D. Lorish, Julia Parker, and Sam Brown</i>	1289
Brief Reports	
Progressive Myalgias and Polyarthralgias in a Patient with Myoadenylate Deaminase Deficiency <i>Edward V. Lally, Joseph H. Friedman, and Stephen R. Kaplan</i>	1298
Post-Traumatic Chylous Joint Effusion <i>Randal E. White, Christopher M. Wise, and Carlos A. Agudelo</i>	1303
Relapse of Lupus Transverse Myelitis Mimicked by Vertebral Fractures and Spinal Cord Compression <i>Ann K. Henry and Carolyn M. Brunner</i>	1307
Tophaceous Gout of the Spine in a Patient with No Peripheral Tophi: Case Report and Review of the Literature <i>John Varga, Casimiro Giampaolo, and Don L. Goldenberg</i>	1312
Letters	
Comment on Report by Collier et al <i>Alan M. Solinger and Evelyn V. Hess</i>	1316
Probable Role of Interleukin-1 in the Pathogenesis of Scleroderma <i>Donato Alarcón-Segovia and Jorge Alcocer-Varela</i>	1316

Is Primary Chronic Uveitis Responsive to Treatment with Nonsteroidal Antiinflammatory Drugs?	
<i>G. P. Astorga and M. T. Cuchacovich</i>	1317
Poe's Finger: The Tell-Tale Digit	
<i>Elam Toone, George F. Moxley, and David M. Hudgins</i>	1317
Comment on Article by Husby and Williams	
<i>Richard J. Warrington, Rachel McKenna, William Oforu-Appiah, and John A. Wilkins</i>	1318
Regulation of Susceptibility to Bacterial Cell Wall-Induced Arthritis in Rats	
<i>Ronald L. Wilder and Janice B. Allen</i>	1318
Prevalence of Monosodium Urate and Calcium Pyrophosphate Dihydrate Crystals in Postmortem Knee Synovial Fluid	
<i>Chr. Moens, D. Moens, and Ph. Moens</i>	1319
References From the Classical Rheumatologic Literature	
<i>G. Herrero-Beaumont and S. Castañeda</i>	1320
ARA Announcements	A16

VOLUME 28

DECEMBER

NO. 12

Ro (SS-A) Antibody and Antigen in a Patient with Congenital Complete Heart Block	
<i>John B. Harley, Jeffrey L. Kaine, Owen F. Fox, Morris Reichlin, and Barry Gruber</i>	1321
How Many Joints in the Hands and Wrists Should Be Included in a Score of Radiologic Abnormalities Used to Assess Rheumatoid Arthritis?	
<i>John T. Sharp, Donald Y. Young, Gilbert B. Bluhm, Andrew Brook, Anne C. Brower, Mary Corbett, John L. Decker, Harry K. Genant, J. Philip Gofton, Neal Goodman, Arvi Larsen, Martin D. Lidsky, Pekka Pussila, Aaron S. Weinstein, and Barbara N. Weissman</i>	1326
Cancer and Systemic Sclerosis: An Epidemiologic Study	
<i>Alan D. Roumm and Thomas A. Medsger, Jr.</i>	1336
Peripheral Inflammatory Vascular Disease in Sjögren's Syndrome: Association with Nervous System Complications	
<i>R. Molina, T. T. Provost, and E. L. Alexander</i>	1341
Temporal Shifts From Sm to Ribonucleoprotein Reactivity in Systemic Lupus Erythematosus	
<i>David E. Fisher, Westley H. Reeves, Rosanne Wisniewolski, Robert G. Lahita, and Nicholas Chiorazzi</i>	1348
Detection of Antibodies to Small Nuclear Ribonucleoproteins and Small Cytoplasmic Ribonucleoproteins Using Unlabeled Cell Extracts	
<i>Mark S. Forman, Mary Nakamura, Tsuneyo Mimori, Carmen Gelpi, and John A. Hardin</i>	1356
Seronegative Polyarthritis in Giant Cell Arteritis	
<i>William W. Ginsburg, Marc D. Cohen, Stephen B. Hall, Randall S. Vollertsen, and Gene G. Hunder</i> ..	1362
Quantification of Keratan Sulfate in Blood as a Marker of Cartilage Catabolism	
<i>Eugene J-M. A. Thonar, Mary Ellen Lenz, Gordon K. Klintworth, Bruce Caterson, Lauren M. Pachman, Paul Glickman, Robert Katz, John Huff, and Klaus E. Kuettner</i>	1367
Partial Characterization of Synovial Fluid Nucleotide Pyrophosphohydrolase	
<i>John W. Rachow and Lawrence M. Ryan</i>	1377
Effects of Gold Sodium Thiomalate on Functional Correlates of Human Monocyte Maturation	
<i>Bruce H. Littman and Robert E. Hall</i>	1384
Cartilage Degradation by Neutral Proteoglycanases in Experimental Osteoarthritis: Suppression by Steroids	
<i>Jean-Pierre Pelletier and Johanne Martel-Pelletier</i>	1393
Reactivation of Streptococcal Cell Wall-Induced Arthritis by Homologous and Heterologous Cell Wall Polymers	
<i>Ronald E. Esser, Stephen A. Stimpson, William J. Cromartie, and John H. Schwab</i>	1402
Brief Reports	
Basal Ganglia Calcifications in Central Nervous System Lupus Erythematosus	
<i>David M. Nordstrom, Sterling G. West, and Peter A. Andersen</i>	1412
Acute Neck Pain Due to Calcifications Surrounding the Odontoid Process: The Crowned Dens Syndrome	
<i>Jean-Pierre Bouvet, Jean-Marie le Parc, Bernard Michalski, Charif Benlahrache, and Louis Auquier</i>	1417
Isolated Candida Arthritis: Report of a Case and Definition of a Distinct Clinical Syndrome	
<i>David Katzenstein</i>	1421

Sporotrichal Arthritis Presenting as Granulomatous Myositis <i>Paul B. Halverson, Satish Lahiri, William C. Wojno, and A. R. Sulaiman</i>	1425
Ibuprofen Kinetics in Patients with Renal Insufficiency Who are Receiving Maintenance Hemodialysis <i>Hermann R. Ochs, David J. Greenblatt, and Birgitt Verburg-Ochs</i>	1430
Letters	
Psychogenic Rheumatism and Fibrositis <i>Michael D. Reynolds</i>	1435
Reply <i>Robert M. Bennett, Stephen Campbell, and Sharon Clark</i>	1436
Cyclosporine in the Treatment of Intractable Polymyositis <i>Henk Simon Goei The, Piet Jacobs, and Harry Houben</i>	1436
Multiclinic Study of DMSO for Systemic Sclerosis <i>Arthur L. Scherbel</i>	1437
Reply <i>H. James Williams, John R. Ward, and James C. Reading</i>	1438
Comment on Letter by Alarcón et al <i>Nancy J. Olsen, Morris Ziff, and Hugo E. Jasin</i>	1439
Reply <i>Graciela S. Alarcón, William J. Koopman, and Ralph E. Schrohenloher</i>	1439
Book Review	1440
Reviewers	1441
Contents Volume 28, 1985	1444
Indexes.....	1459
ARA Announcements.....	A10

AUTHOR INDEX

Arthritis and Rheumatism, Volume 28, Numbers 1 through 12, 1985

A

Aaron S, 146, 478, 753
Abe T, 873
Abernethy DR, 1117
Abramovitz M, 899
Abramson S, 75
Abruzzo JL, 562
Acton RT, 236
Adams DF, 1234
Adornato BT, 948
Agarwal A, 462
Agudelo CA, 1303
Aho K, 485
Akbarian M, 715
Alarcón GS, 236, 308, 356,
721, 1059, 1439
Alarcón-Segovia D, 52, 600,
1200, 1316
Alcocer-Varela J, 52, 1200,
1316
Alexander EL, 1146, 1251,
1341
Allen JB, 1318
Alpert EJ, 308
Als OS, 369
Altz-Smith M, 1211
Amaki I, 1008
Amaki S, 1008
Amor B, 490, 637, 958, 961
Andersen PA, 1412
Anderson JJ, 987
Anderson RS, 804
Ang-Fonte GZ, 210
Aoki S, 522
Arimori S, 182
Arnett FC Jr, 840
Aromaa A, 485
Aronson M, 899
Asherson RA, 118, 594
Astorga GP, 1317
Athea N, 1243
Atkins E, 1039
Atkinson JP, 341
Auquier L, 837, 1417

B

Bach J-F, 1243
Baer AN, 1059
Bailowitz A, 938
Ball GV, 1059
Ballou SP, 238
Bango MY, 957
Bank I, 452
Bankhurst AD, 624

Banwell BF, 32
Barbier A, 959
Bardin T, 1052
Barger BO, 236
Barland P, 158
Bartfield H, 231
Bashey RI, 502
Bassett LW, 703
Battisto JR, 537
Battles ND, 151
Baum C, 686
Baum J, 1062
Bayne EK, 1105
Becker CG, 58
Benbassat J, 249
Benlahrache C, 1417
Bennett RM, 132, 768, 1436
Bentwich Z, 1185
Berliner S, 104, 899
Bernini L, 1259
Bernstein BH, 1175
Bernstein RM, 285, 831
Berry H, 383
Bertouch JV, 112
Billingsley LM, 721
Biundo JJ Jr, 425
Blanc D, 1078
Blanchard F, 339
Blanchet F, 637
Block S, 569
Bluhm GB, 16, 1326
Bole GG, 108
Bombardieri S, 1259
Bongiorni MG, 1259
Bordigoni P, 376
Borel Y, 146
Bour B, 490
Bouvet J-P, 1417
Bowles CA, 345
Boyer CM, 294
Boyko WB, 214
Bradlow HL, 1122
Brandt KD, 204, 237, 548,
1267
Braun DG, 1047
Braunstein EM, 1234
Bravi P, 1259
Breedveld FC, 395
Brelriere JC, 959
Brill S, 999
Brissaud P, 359
Bromley M, 1197
Brook A, 16, 1326
Brower AC, 16, 1326
Brown S, 1289

Brunner CM, 1307
Bucala R, 1122
Buckingham RB, 188
Burge JJ, 222
Burmester GR, 1205

C

Cairns L, 146
Calin A, 357
Callen JP, 271
Campbell SM, 132, 1436
Canoso JJ, 352
Carbonell J, 838
Caro XJ, 836
Carquin J, 339
Carsons S, 601, 1016
Castaneda S, 1320
Castor CW, 32
Catalano MA, 480
Caterston B, 1367
Catoggio LJ, 699, 715
Catoggio PM, 715
Cats A, 40, 358, 395, 904
Cervini M, 959
Cham C, 715
Chan C-C, 671
Chaouat D, 837
Cheung HS, 1039
Chin-Sang H, 930
Chiorazzi N, 1348
Christian CL, 1440
Christiansen C, 369
Clark S, 132, 1436
Clarris BJ, 455
Clegg DO, 8
Cloutier J-M, 405
Cobb MA, 151
Cohen AS, 987, 1188
Cohen IR, 841
Cohen JHM, 339
Cohen MD, 1362
Cohen PL, 262, 294
Colaco CB, 67
Coleman ML, 1211
Collins L, 1188
Cone RO III, 1066
Contini C, 1259
Cooke TDV, 1195
Coppin J, 831
Corbett M, 16, 1326
Couturier D, 490
Crago SS, 1219
Cromartie WJ, 1402
Crowe WE, 151, 537
Cuchacovich MT, 1317

Cullen KE, 542, 846
Cummings NP, 573
Cuperus RA, 1228
Cuttica R, 699

D

Daha MR, 904
Dahl SL, 308, 721, 1211
Dang CV, 839
Daniels TE, 593
Davatchi F, 715
Davidson A, 218
Davis JS IV, 222
Dayno SJ, 1156
Deal CL, 987
Decker JL, 16, 1326
de Gramont A, 359
DeHoratius RJ, 471
de la Sota M, 825
DeLustro FA, 775
Denburg JA, 789
Deng J-S, 163
Dent PB, 789
Dessypris EN, 1059
Devaux J-Y, 637
Devogelaer JP, 1075
de Vries BJ, 922
Deyo RA, 1066
Diamond HS, 601, 1016
Diamond J, 713
Dickey B, 576
Dieppe P, 718
Dilworth RL, 599
Dinant HJ, 93, 944
Dixit R, 341
Dixon FJ, 1081
Dobrinsky R, 1079
Doherty M, 718
Doos WG, 352
Dory MA, 198
Dougados M, 958, 1243
Dreyfus JN, 308
Druzin ML, 58
Dudeney C, 999
Duff GW, 1039
Duquesnoy B, 477
Dykman TR, 361

E

Edelbaum D, 742
Egger MJ, 308, 613, 721
Ehrlich GE, 480
Eisenberg RA, 294
Elbers HRJ, 944

Elkon KB, 58, 67
 Embury S, 596
 Englert HE, 594
 Epstein A, 158
 Esser RE, 1402
 Evanson JM, 1197

F

Fam AG, 930
 Fassbender H-G, 529, 1193
 Fedrick JA, 828
 Felson DT, 1156
 Ferri C, 1259
 Filippi G, 595
 Fink CW, 151
 Fino GJ, 759
 Fiocco GP, 222
 Fisher DE, 1348
 Fishman J, 1122
 Fleischmajer R, 647
 Flinn M, 719
 Forbes MB, 686
 Forehand ME, 132
 Forman MS, 1356
 Foster DM, 441
 Fotino M, 1047
 Foults J-M, 637
 Fowler JF, 271
 Fox IH, 713
 Fox OF, 1321
 Franklin CM, 598
 Fraser JRE, 455
 Fraser KJ, 455
 Fraser P, 146, 753
 Frenkel A, 841
 Friedman JH, 1298
 Friedman JM, 151
 Fritz H, 1205
 Fu SM, 1047
 Fujita T, 25
 Furst DE, 308

G

Gabor GT, 768
 García-Morteo O, 699, 825
 Gay S, 529
 Gefel D, 249
 Gelpi C, 1356
 Genant HK, 16, 1326
 George AL Jr, 516
 Gerber P, 256
 Gerbracht DD, 87
 Gertman P, 1156
 Ghandur-Mnaymneh L, 554
 Gharavi AE, 118, 594
 Giampaolo C, 1312
 Gibbs DL, 624
 Gibilisco PA, 511
 Gill R, 1079
 Gilliam JN, 163

Ginsburg WW, 1362
 Giordano A, 237,
 Giordano M, 237, 359
 Gladman DD, 466, 952
 Glass DN, 146, 753, 1188
 Glickman P, 1367
 Gluck OS, 361
 Goble M, 1179
 Gofton JP, 16, 1326
 Goldberg E, 1079
 Goldenberg DL, 471, 987,
 1312
 Goldstein R, 100
 González JAG, 957
 Goodman N, 16, 1326
 Gottfredsen A, 369
 Goto M, 731
 Graham BS, 516
 Gramatzki M, 1205
 Graninger W, 710
 Grassi W, 959
 Graudal H, 235
 Gray RG, 120
 Green L, 1185
 Greenblatt DJ, 1117, 1430
 Griscelli C, 376
 Gruber B, 1321
 Guttadauria M, 308, 721

H

Haber P, 1071
 Hahn BH, 361
 Hahn TJ, 361
 Hall RE, 1384
 Hall SB, 1362
 Hällgren R, 169
 Halnan KE, 831
 Halverson PB, 1425
 Hamerman D, 853
 Hammill SC, 345
 Hansen J, 573
 Hanson V, 151
 Hardin JA, 1356
 Hardouin P, 477
 Harkcom TM, 32
 Harley JB, 1321
 Harpel PC, 58
 Harper FE, 459
 Harris EN, 118, 594
 Hartley RM, 846
 Hayakawa T, 349
 Hays JT, 516
 Hazaz B, 104
 Hazevoet HM, 904
 Heck LW, 1059
 Hedfors E, 977
 Heimer R, 562
 Henderson AM, 308
 Henry AK, 1307
 Herbst M, 1205
 Hermans J, 904

Herraiz J, 838
 Herrero-Beaumont G, 1320
 Hess EV, 1316
 Hind CRK, 383
 Hirschowitz BI, 1059
 Hobbs RN, 285
 Hoch S, 146
 Hochberg MC, 80
 Hochman RB, 630
 Hollander JL, 511
 Hollister JR, 573
 Holman HR, 680
 Holmdahl R, 863
 Holoshitz J, 841
 Holzman R, 75
 Homma M, 873
 Honig S, 231
 Hory B, 1078
 Hosono O, 873
 Houben H, 1436
 Hovell MF, 300
 How A, 789
 Howell DS, 405, 554
 Huaux JP, 1075
 Hudgins DM, 1317
 Huff J, 1367
 Huffstutter JE, 775
 Hughes GRV, 118, 285,
 594, 831
 Hunder GG, 1362
 Hurwitz C, 240
 Husby G, 174
 Huth DA, 613

I

Ichikawa Y, 182
 Iglesias A, 52
 Ihrie EJ, 853
 Ikuta K, 522
 Imura S, 25
 Ingenito FS, 958
 Inokuma S, 349
 Iori I, 595
 Isenberg DA, 999
 Ishikawa K, 118
 Israel E, 938
 Ito Y, 522
 Izaguirre C, 100

J

Jablonska S, 1133
 Jack I, 455
 Jackson JM, 146, 753
 Jacobelli S, 781
 Jacobs J, 452
 Jacobs P, 1436
 Janossy G, 971
 Jasin HE, 241, 1439
 Jimenez SA, 502
 Johansson E, 169

Jones DN, 112
 Jonnason O, 151
 Joshua H, 104
 Jungers P, 1243

K

Kagami M, 481
 Kagen LJ, 630
 Kahan A, 961
 Kahan A, 490, 637, 961
 Kaine JL, 1321
 Kalden JR, 1205
 Kalf V, 218
 Kallenberg CGM, 597
 Kalyanaraman VS, 1170
 Kaplan SB, 308, 1211
 Kaplan SR, 471, 1298
 Karas B, 413
 Karasaki M, 1008
 Kariv N, 899
 Karsh J, 100
 Kaslow RA, 938
 Katler E, 596
 Katz P, 1076
 Katz R, 1367
 Katzenstein D, 1421
 Kawka DW, 1105
 Kay DR, 1211
 Kazazis DM, 1105
 Kennedy DL, 686
 Kennedy MS, 1170
 Kennedy TD, 971
 Kenny C, 624
 Khan MA, 40
 Kinney SG, 601
 Kisaki T, 349
 Klareskog L, 863
 Klein RF, 58
 Kline LB, 1059
 Klinenberg JR, 1
 Klinkhoff AV, 214, 582
 Klintworth GK, 1367
 Koh LY, 112
 Kohler PF, 995, 1128
 Koide J, 873
 Koike T, 481
 Koopman WJ, 236, 356,
 529, 1071, 1219, 1439
 Korn JH, 315
 Koslowe P, 938
 Kovarik J, 710
 Kraines RG, 680
 Kramer SB, 75
 Krieg AM, 341
 Kruijsen MWM, 813
 Krulik M, 359
 Kubo T, 1140
 Kuettner KE, 1367
 Kuijter R, 419
 Kujala G, 98

Kulick KB, 271
Kulkarni S, 466
Kuntz D, 1052
Kushner I, 40, 238
Kuttann F, 1243

L

Laborde H, 715
Lahiri S, 1425
Lahita RG, 121, 1122, 1348
Lally EV, 1298
Lam K, 971
Lampman RM, 32
Lansaman J, 1052
Larholt K, 249
Laroche L, 359
Larsen A, 16, 1326
Larson MG, 146, 542, 753, 1188
Larsson L-G, 1062
Laskin RS, 1016
Laurent M-C, 1243
Lavenchy D, 1047
Laver-Rudich Z, 660
Lavie G, 899
Lavietes BB, 601, 1016
Lea DJ, 285
Lehman TJA, 652
Leijh PCJ, 395
Lenz ME, 1367
le Parc J-M, 1417
LeRoy EC, 459, 775
Leung FYK, 930
Levinson JE, 151
Levorato D, 1259
Ley KD, 624
Liang MH, 542, 846
Liao S-K, 789
Lidsky MD, 16, 1326
Liebling MR, 431
Lin FYC, 938
Lindblad S, 977
Lindgren JA, 863
Lindh U, 169
Liote F, 1243
Lipscomb MF, 163
Lipsky PE, 742
Lisboa C, 781
Littman BH, 1384
Livne E, 1027
Llorente L, 52
Lockshin MD, 58
Lorig K, 680
Lorish CD, 1289
Lovy M, 496
Lubeck D, 680
Luggen ME, 308, 721
Lupoli S, 237
Lutfalla G, 637
Lyon NB, 323

M

MacCarter D, 496
Macchioni P, 595
Mackworth-Young C, 999
MacLaughlin EJ, 308
Madsen L, 1179
Magro AM, 599
Mahnovski V, 652
Maini RN, 971
Majewski S, 1133
Malawista SE, 1039
Maldague B, 1075
Maldonado-Cocco JA, 699, 825
Malghem J, 1075
Maliakkal JJ, 742
Mallya RK, 383
Manger BJ, 1205
Manigne P, 376
Mankin HJ, 1140
Marban-Arcos E, 742
Marboe CC, 452
Marcolongo R, 127
Marczak M, 1133
Marinello E, 127
Marks C, 308
Martel-Pelletier J, 405, 554, 1393
Maruyama N, 481
Maryjowski MC, 256
Maryjowski-Sweeney MC, 151
Masi AT, 138
Mason J, 471
Massardo L, 781
Matsumura Y, 349
Maury CPJ, 388
Maymo J, 838
McArthur WM, 502
McCarty DJ Jr, 413, 717, 1039
McCarty GA, 1076
McCurdy D, 652
McDougal JS, 1170
McDuffie FC, 1170
McGrath H Jr, 425
McKenna R, 1318
McNiesh LM, 1066
Medsker TA Jr, 87, 586, 759, 882, 1336
Meenan RF, 471, 987, 1156
Menkes CJ, 490, 637, 961
Merino MF, 957
Messner RP, 914
Mestecky J, 1219
Metzger AL, 590
Michalski B, 1417
Michet CJ, 239
Mierins E, 100
Millar AB, 118

Miller JJ III, 477, 948
Miller ML, 146
Mimori T, 1356
Miner D, 231
Mitchell SR, 1076
Mitrovic D, 1192
Miyachi Y, 836
Mochizuki M, 671
Moens C, 1319
Moens D, 1319
Moens P, 1319
Molina R, 1251, 1341
Monsees B, 820
Moreno H, 1059
Moreno R, 781
Morgan SH, 118, 831
Morgenstern V, 249
Moscovich M, 582
Moxley G, 1089, 1317
Moyer C, 1146
Mueller MR, 300
Muijsers AO, 1228
Muirden KD, 455
Murphy ED, 1146
Murphy WA, 361, 820
Myers AR, 576
Myers SL, 1275
Myones BL, 477

N

Nagant de Deuxchaisnes C, 1075
Nakamura M, 1356
Nelp WB, 441, 1096
Nelson AM, 345
Newman JH, 98
Nishikai M, 579
Nitenberg A, 637
Noël H, 1075
Nonogaki T, 522
Nordstrom DM, 1412
Nussenblatt RB, 671
Nüsslein HG, 1205

O

Ochs HR, 1430
O'Duffy JD, 345
Ofosu-Appiah W, 1318
Olivé A, 838
Oliver JM, 889
Olsen NJ, 1439
O'Sullivan FX, 529
Owens GR, 759, 882

P

Pachman LM, 151, 256, 1367
Paez JMG, 957
Palestine AG, 671
Palmoski MJ, 237, 548

Palosuo T, 485
Pandey JP, 828
Panush RS, 707
Paolaggi JB, 837
Parhami N, 240
Parke A, 958, 1077
Parker J, 1289
Pasero G, 1259
Passas CM, 620
Pastan RS, 987
Paulus HE, 450, 1168, 1211
Pawinska M, 1133
Peebles CL, 720
Pelissier C, 1243
Peller JS, 768
Pelletier J-P, 405, 554, 1393
Pepys MB, 383
Perennec J, 637
Perez HD, 596
Perlsh JS, 647
Perlman SG, 471
Peterson M, 620
Phillips RL, 1059
Pincus SH, 8
Pinggera W, 710
Pinkas J, 999
Pinkhas J, 104, 899
Piussan C, 376
Plater-Zyberk C, 971
Polakowski I, 1133
Polisson RP, 721
Pollack A, 1185
Portanova JP, 995
Porter JM, 768
Pottenger LA, 323
Potts MK, 204
Prete PE, 1198
Prieur AM, 376
Prince RK, 188
Provost TT, 1251, 1341
Puska P, 485
Pussila P, 16, 1326

R

Rachow JW, 1283, 1377
Radin A, 75
Radosevich J, 431
Radvany RM, 151
Raskin RJ, 941
Raunio V, 485
Reading JC, 308, 613, 721, 1438
Redberg RF, 452
Redmond C, 882
Reed JL, 352
Reeves WH, 1348
Reichlin M, 226, 796, 840, 1321
Reichman RP, 703
Reid GD, 582
Reinitz E, 58

Resnick DL, 331
 Reynolds MD, 1435
 Riario-Sforza G, 127
 Richardson B, 466
 Rivero S, 781
 Roberts-Thomson PJ, 112
 Rodnan GP, 87, 188, 586, 759, 882
 Rodrigué S, 715
 Roncucci R, 959
 Roquer J, 838
 Rosano CL, 240
 Rosen M, 104
 Rosen MS, 576
 Rosenbaum LH, 586
 Rosenbloom J, 502
 Ross T, 466
 Rossi F, 595
 Rothfield NF, 620, 889, 1077
 Roths JB, 599, 1146
 Roucayrol J-C, 637
 Roumm AD, 1336
 Rozboril MB, 210
 Rubenstein JD, 930
 Rubin K, 863
 Ruddy S, 1089
 Rudofsky UH, 599
 Rupp EA, 1105
 Rush PJ, 952, 1175
 Ryan LM, 413, 1283, 1377
 Ryan PFJ, 218

S

Sack B, 987
 Salas PG, 715
 Salonen JT, 485
 Salvarani C, 595
 Samuelson CO Jr, 308, 721
 Sandbank U, 104
 Sartoris DJ, 331
 Sauer R, 1205
 Saunders N, 952
 Sawada S, 1008
 Scherbel AL, 1437
 Schipper CA, 419
 Schlappner OLA, 214
 Schned ES, 239
 Schrohenloher RE, 356, 1071, 1219, 1439
 Schumacher HR Jr, 511, 1163
 Schur PH, 828
 Schwab JH, 1402
 Schwartz ER, 804
 Schwartz JA, 542
 Scott JP, 256
 Seaman JM, 1179
 Searles RP, 624
 Seidl G, 710

Sekiguchi S, 579
 Seleznick M, 680
 Seltzer SE, 1234
 Senécal J-L, 889
 Shalev Y, 1185
 Sharp GC, 151
 Sharp JT, 16, 1326
 Shaw M, 44
 Shimizu H, 182
 Shimizu S, 25
 Shiozawa K, 25
 Shiozawa S, 25, 1193
 Shoenfeld Y, 104, 999
 Shore A, 952, 1175
 Sibbitt WL Jr, 624
 Sigsbee A, 1188
 Silbermann M, 660, 1027
 Silverman ED, 477, 948
 Silvers JJ, 300
 Simkin PA, 441, 1096
 Simonis T, 938
 Singer II, 1105
 Sipe JD, 352
 Skopinska-Rożewska E, 1133

Small CJ, 995
 Smith CD, 100
 Smith CR, 1175
 Smith EA, 459
 Smith RN, 537
 Smith SZ, 271
 Smolen JS, 710
 Solinger AM, 1316
 Solovera JJ, 957
 Sonthheimer RD, 163
 Soper KA, 511
 Spalding DM, 1071, 1163, 1219
 Spencer CH, 151
 Staite ND, 914
 Steen VD, 87, 308, 759, 882
 Steigerwald JC, 496, 1179
 Stein A, 462
 Stein HB, 214
 Stelzer G, 271
 Stimpson SA, 1402
 Strickland RW, 941
 Strong EW, 630
 Stross JK, 108, 1163
 Suárez-Almazor ME, 699
 Sukenik S, 249
 Sulaiman AR, 1425
 Sullivan DB, 151
 Svenson K, 169
 Swartz WM, 586
 Szmurlo A, 1133

T

Takabayashi K, 481
 Takaya M, 182

Takei M, 1008
 Takeuchi T, 873
 Tan EM, 714, 1201
 Targoff IN, 226, 796
 Tarp U, 235
 Teppo A-M, 388
 Testa MA, 620
 The HSG, 1436
 Thevenon A, 477
 Thomas WH, 1234
 Thompson GR, 210
 Thonar EJ-MA, 1367
 Timmermans AJM, 944
 Timpl R, 647
 Tindall EA, 132
 Todd-Pokropek A, 999
 Tomioka H, 481
 Toone E, 1317
 Törnroth T, 388
 Torretti D, 598
 Toubert A, 958
 Towle CA, 1140
 Traficante A, 480
 Travlos GS, 1146
 Treadwell BV, 1140
 Tsunematsu T, 693

U

Uchiyama M, 182

V

Valentijn RM, 904
 Valentini G, 237
 Valkenburg HA, 40, 358
 van de Laar MAFJ, 93
 van den Barselaar MT, 395
 van den Berg WB, 813, 922
 van de Putte LBA, 813, 922
 van der Linden SM, 40, 358
 van der Sprenkel JWB, 944
 van de Stadt RJ, 419
 van Eden W, 841
 van Es LA, 904
 van Furth R, 395
 van Herpen G, 944
 van Kampen GPJ, 419
 van Overhagen H, 904
 Varga J, 237, 719, 1312
 Veldhuijzen JP, 419
 Verburg-Ochs B, 1430
 Victorin Å, 863
 Viegi G, 1259
 Viriot J, 1243
 Virshup AM, 238
 Vischer TL, 339
 Voisin M-C, 1052
 Vollertsen RS, 1362
 von der Mark K, 1027

W

Wagenarr SS, 93
 Walker SM, 652
 Wallace DJ, 590, 836
 Wallis WJ, 441, 1096
 Walport M, 999
 Ward DJ, 285
 Ward JR, 8, 308, 613, 721, 1438
 Varrington RJ, 1318
 Watson RM, 58
 Watt I, 718
 Wautelet MJ, 198
 Waxman M, 231
 Webb JE, 323
 Webster E, 707
 Weinberger A, 104, 899, 999
 Weinberger M, 204
 Weiner SR, 703, 721
 Weinstein A, 308, 1211
 Weinstein AS, 16, 1326
 Weisman MH, 300, 480, 1163
 Weissman BN, 16, 1234, 1326
 Welton RC, 941
 Wendling D, 1078
 Wernick RM, 742
 West SG, 1412
 Westermann CJJ, 93
 Wever R, 1228
 Whitcher JP, 593
 White KK, 590
 White RE, 1303
 Whiteside TL, 188
 Wilder RL, 1318
 Wilkins JA, 1318
 Williams HJ, 308, 613, 721, 1211, 1438
 Williams JM, 1267
 Williams RC Jr, 174, 1047
 Willkens RF, 721
 Wilmot D, 952
 Wilson AJ, 958
 Winfield JB, 44, 262, 471
 Winkelstein A, 462
 Winter ME, 1128
 Wise CM, 1303
 Wisniewolski R, 1348
 Woessner JF Jr, 554
 Wohlgethan JR, 352
 Wojno WC, 1425
 Wolfe F, 479
 Wolfe LD, 562
 Wong C, 431
 Wong RL, 620, 958
 Wood DD, 853
 Woolley DE, 1197

Worrall JG, 188
Wortmann RL, 413

Y

Yamada A, 44, 262
Yancey K, 671

Yarboro C, 721
Yaron M, 899
Yeadon CA, 1047
Yokohari R, 693
Yoshida M, 182
Yoshida S, 481
Young DY, 16, 1326

Yu C-L, 276
Yunus MB, 138

Z

Zabriskie JB, 1047
Zeale PJ, 231

Zelmar A, 1052
Ziegler GL, 87
Ziff M, 276, 742, 1439
Zingraff J, 1052
Zlotnick A, 249
Zoschke DC, 914
Zvaifler NJ, 731

SUBJECT INDEX

Arthritis and Rheumatism, Volume 28, Numbers 1 through 12, 1985

A

- AA1 (other activation antigen) antibodies in SLE, 44
- Abdominal pain, in *Salmonella* bacteremia in SLE, 75
- Abortion
 - spontaneous, lupus anticoagulant and, 67
 - in thrombotic thrombocytopenic purpura in C2-deficient SLE, 341
- Abscesses, in hip joint, 199, 835 (erratum)
- Acetabula, cystic radiolucencies of in amyloidosis in hemodialysis, 1052
- Acetylator phenotype, IgM and IgG antinuclear antibodies and in SLE, 995
- Acid phosphatase, articular cartilage in aged ICR mice and, 1027
- Acquired hypogammaglobulinemia, adenovirus type 1 infection in RA-like polyarthritis and, 455
- Acroosteolysis, nailfold capillary abnormalities in systemic sclerosis and, 496
- Acrosclerosis, lymphocyte-induced angiogenesis and, 1133
- Activities of daily living
 - aerobic exercise in RA and, 32
 - patient education about in RA, 300
- Acute gouty arthritis, endogenous pyrogen (IL-1) in, 1039
- Acute monocytic arthritis, echovirus type 11 in, 98
- Acute neck pain due to calcifications, 1417
- Acute-phase inflammatory response, AMLR in adjuvant arthritis and, 537
- Acute-phase reactants, antibiotics in Whipple's disease and, 352
- Acute-phase response, endogenous pyrogen (IL-1), gouty inflammation and, 1039
- Acute polyarticular gout, endogenous pyrogen (IL-1) in, 1039
- Adenosine triphosphate pyrophosphohydrolase (ATPPPH)
 - cartilage nucleoside triphosphate pyrophosphohydrolase and, 413
 - in pathologic joint fluids, 1283
 - in synovial fluid, 1377
- Adenovirus type 1 infection, in rheumatoid-like polyarthritis with immunodeficiency, 455
- Adherent cells
 - procainamide and, 276
 - in RA, 863
- Adjuvant arthritis
 - autologous mixed lymphocyte reaction in, 537
 - T lymphocytes in, 841
 - testosterone in rats with, 959
- Adjuvant therapy, cyclosporine in giant cell arteritis, 1078
- Adult-onset juvenile rheumatoid arthritis, HLA type in, 146
- Adult-onset rheumatoid arthritis, apophyseal joint ankylosis of cervical spine in, 958
- Adult-onset Still's disease; *see also* Juvenile rheumatoid arthritis
 - HLA type in, 146
 - myocarditis in, 452
 - onset during pregnancy, 957
- Adverse reactions
 - to methotrexate in RA, 721
 - NSAID, 1168
- Aerobic exercises, in RA, 32
- Age of onset
 - elderly-onset and younger-onset RA, 987
 - sex ratio and sibship size in JRA and, 753
- Aging, cartilage surface charge in, 660
- Airways, cricopharyngeal obstruction in inflammatory myopathy and, 630
- A/J mice, coronary arteritis after *L. casei* injection, 652
- Aldolase, serum, in polymyositis/dermatomyositis, 249
- Alfalfa, L-canavanine in SLE and, 52
- Alkaline phosphatase, articular cartilage in aged ICR mice and, 1027
- Allied health professionals, patient education in RA and, 300
- Alloantigens, rheumatic fever-associated B cell, 1047
- Allopurinol hypersensitivity, in severe chronic, tophaceous gout, 707
- Allotypes, Gm, in SLE, 828
- 16 Alpha-hydroxyestrone in SLE, 1122
- α -interferon antibodies, in SLE, 624
- American Rheumatism Association
 - audiovisual aids subcommittee, 569
 - criteria for classification of SLE, 620
 - criteria for classification of SLE, revised, Japanese and, 693
 - evaluation of, 715
 - medical research education subcommittee, 471
 - presidential address, 1, 1201
 - slide competition, 1984, 569
- Amino acids
 - L-canavanine in SLE, 52
 - proteoglycan phosphorylation and, 810
- Amyloid
 - HLA in familial amyloid polyneuropathy, 1188
 - synovial, in end-stage renal failure, 1052
- Amyloid A protein, serum, antibiotics in Whipple's disease and, 352
- Amyloidosis
 - clinical features of, 1053
 - synovial, in hemodialysis, 1052
- Androgenic suppressive agents, sex steroids and, 121

- Anemia, methotrexate and, in RA, 721
- Aneurysms, coronary arteritis in mice after *L. casei* injection, 652
- Angiogenesis, lymphocyte-induced, scleroderma and, 1133
- Angiography
digital, dural sinus thrombosis, Behçet's disease and, 359
in mixed connective tissue disease, 768
- Angiotensin converting enzyme inhibitors, RA and, 480
- Animal studies; *see also* Canine; Guinea pig; Mouse; Murine; Pond-Nuki dog; Rabbit; Rat
cartilage response to force in chick chondrocytes, 419
erythrocytes and gold sodium thiomalate, 1384
- Anisocoria, transient, in SLE, 1059
- Ankle joint, 334
- Ankylosing spondylitis
clinical criteria for, 41
diagnosis of, 357
early, computed tomography in, 930
patterns of referrals of patients with, 1156
spondylitic disease in relatives of AS patients, 40
- Anserina bursitis, 1062
- Anti- α -interferon antibodies, in SLE, 624
- Anti- β_2 m, antibodies in SLE and, 44
- Antibiotics
acute-phase reactants, CRP and SAA in Whipple's disease, 352
Salmonella bacteremia in SLE and, 75
- Antibodies
AA1 (other activation antigens), 44
absence of, to human T cell leukemia virus in SLE, 481
 α -interferon, 624
anticardiolipin, 67, 118, 594
anticentromere, 87, 496, 715, 759, 1076
anticollagen, 1316
anti-dsDNA, 425
antihistone, 158, 163, 285
antiidiotypic, 873
anti-interferon, 624
antilymphocyte, 44, 262
antineuronal, 789
antinuclear, 273, 380, 597, 995, 1251, 1321
anti-skeletal muscle, 781
avidity, 425
 β_2 -microglobulin (β_2 m) in, 44
collagen II, in RA articular cartilage, 241
Epstein-Barr virus, 339
5E9, 44
4F2, 44
HLA-DR, 8, 44
to human T lymphotropic viruses in rheumatic diseases, 1170
IgG, 271, 285, 431
IgM, 285
IgM anti-DNA, 431
IgM antilymphocyte, 44
interferon, 624
interleukin-2 receptor, 44
- Antibodies (*cont'd*)
to intermediate filaments in connective tissue disease, 889
in juvenile dermatomyositis, 151
L243, 44
Leu-1, Leu-8, Leu-10, 44
Mi, 796
monoclonal, 44, 182, 276, 1047
monospecific, fibronexus and in RA, 1105
nDNA, 163
neuronal cell binding, 789
OKT4, OKT8 monoclonal, 276
organ-specific, in juvenile dermatomyositis, 151
pan-T, 44
precipitating, 796
Ro (SS-A), 1321
speckled high-titer, 596
SS-B, 388
T3, T4, T8, T11, 44
transferrin receptor, 44
used in immunoenzymatic staining in synovitis, 977
- Antibody specificity, to F(ab')₂ in human IgG, 562
- Anticardiolipin
aortic arch syndrome, lupus anticoagulant and, 594
lupus anticoagulant and, 67, 118
- Anticentromere antibodies
in connective tissue disease, 1076
in Raynaud's disease, 87, 1076
restrictive lung disease in CREST syndrome and, 759
in scleroderma, 715
in systemic sclerosis, 496
- Anticoagulant, lupus, aortic arch syndrome, anticardiolipin antibodies and, 594
- Anticollagen antibodies, HLA-DR antigens and, 1316
- Anticytoskeletal autoantibodies, in connective tissue disease, 889
- Anti-DNA
SLE and normal peripheral blood mononuclear cells and, 431
in SLE patients and relatives, 999
- Anti-double-stranded DNA antibody, in SLE, 425
- Anti-double-stranded DNA binding, cardiolipin and, 67
- Antigens
antibodies to Mi and, 796
anti-Ro, 58
factor VIII-related, 256
histocompatibility complex and, 8
histone, 163
HLA-DR, 1316
Ia, 174
murine antigen-induced arthritis, 813
nuclear, 151, 294
PM-Scl, 226
in rheumatoid synovial adherent cells, 869
Ro (SS-A), 1321
Sm, 294
surface, 262

- Antihistone antibodies
 binding of to *Crithidia luciliae*, 163
 in drug-induced lupus erythematosus, 158
 systemic rheumatic disease and, 285
- Anti-human leukocytic pyrogen, interleukin-1 and, 853
- Antiidiotypic antibodies, suppression of rheumatoid factor synthesis by in RA, 873
- Antiimmunoglobulin autoantibodies, RF synthesis in RA synovial membrane cells and, 742
- Anti-interferon antibodies, in SLE, 624
- Anti-keyhole limpet hemocyanin antibody production, RF synthesis, antiidiotypic antibody and, in RA, 873
- Anti-Leu-7, Anti-Leu-11 antibodies, natural killer cells and, in Sjögren's syndrome, 182
- Antilymphocyte antibodies
 IgM, 44
 in SLE, 44, 262
- Antimalarial drugs, hormone modulation and, in SLE, 1243
- Anti-Mi-1, Anti-Mi-2, complement fixation and, 796
- Anti-native DNA antibodies, acetylator phenotype in SLE and, 996
- Antineuronal antibodies
 in neuropsychiatric SLE, 789
 captopril and, 597
- Antinuclear antibodies
Crithidia luciliae kinetoplasts and, 163
 detection of, intermediate filaments, microfilaments and, 596
 IgG and IgM, acetylator phenotype and, in SLE, 995
 in neonatal LE, 273
 penicillamine in juvenile chronic arthritis and, 380
 pregnancy in SLE and, 58
 Ro (SS-A) in congenital complete heart block and, 1321
 speckled, idiopathic thrombocytopenic purpura, SLE and, 596
- Antinuclear antibody negative lupus, lupus anticoagulant and, 67
- Anti-RNA, SLE and normal peripheral blood mononuclear cells and, 431
- Anti-Ro antibodies
 congenital heart block, SLE and, 1077
 in neonatal LE, 271
- Anti-Ro antigen, pregnancy in SLE and, 58
- Anti-Ro (SS-A), in neonatal LE, 271
- Anti-Ro (SS-A) autoantibodies, in congenital complete heart block, 1321
- Anti-Scl-70 antibodies, in scleroderma, 715
- Anti-Sm to anti-RNP antibody shifts in SLE, 1348
- Anti-Sm in SLE, 294
- Anti-T cell effects of cyclosporine, in Behçet's disease, 671
- Anti-Tac antibodies
 HLA-DR+ T cells in RA and, 8
 in SLE, 44
- Antituberculosis therapy, fasciitis and polyarthritis during, 1179
- Aortic arch syndrome, anticardiolipin antibodies, lupus anticoagulant and, 594
- Aortic regurgitation, in giant cell arteritis, 582
- Apatite crystals, in OA, 511
- Aplasia, red cell, pure, in SLE, 1059
- Apophyseal joint ankylosis of cervical spine, in adult-onset RA, 958
- Arachidonic acid, substrain heterogeneity in PGE₂ synthesis and, 315
- Arches, in mixed connective tissue disease, 768, 1425
- Areflexia, in Miller-Fisher syndrome after gold in RA, 838
- Arterial intima, coronary arteritis after *L. casei* injection in mice, 652
- Arteries
 epicardial coronary, in scleroderma myocardial disease, 637
 in mixed connective tissue disease, 768
- Arteritis
 coronary, in mice, 652
 giant cell, polymyalgia rheumatica and, tests for, 837
 seronegative polyarthritis in, 1362
 temporal, 571
- Arthralgia, in polymyositis/dermatomyositis, 249
- Arthritis
 acute monocytic, 98
 adjuvant, 537, 841, 959
 bacterial cell wall-induced, 1318
 blastomycotic, 516
 Botticelli paintings and, 600
Candida, 1421
 chronic, 1175
 erosive granulomatous, 958
 experimental, 537, 841
 in giant cell arteritis, 1362
 gouty, 1089
 granulomatous, erosive, 958
 infectious, 941
 juvenile primary fibromyalgia syndrome and, 138
 juvenile rheumatoid; *see* Juvenile rheumatoid arthritis
 Lyme, 239
 monarticular, 516
 monocytic, acute, 98
 MRL/I, 529
 murine antigen-induced, 813
 nongonococcal, 210
 osteo-; *see* Osteoarthritis
 poly; *see* Polyarthritis
 in polymyositis/dermatomyositis, 249
 psoriatic, 703
 rheumatoid; *see* Rheumatoid arthritis
 self-help education for patients, 680
 septic, 198, 576, 941
 sporotrichal, 1425
 synovial fluid analysis, infrequent documentation by, 516
 traumatic, 1089

- Arthritis Knowledge Test, 1293
- Arthritis research, health status measurement and, 542
- Arthritis Self-Management Program (ASMP), 680
- Arthritis-dermatitis syndrome, postgastrectomy blind loop syndrome and, 214
- Arthrodesis, subtalar, computed tomography of hindfoot in RA and, 1234
- Arthrography, in septic arthritis, 198, 835 (erratum)
- Arthropathy, Jaccoud's, of knee in SLE, 825
- Articular involvement, penicillamine and in juvenile chronic arthritis, 378
- Articular surface, condylar, cartilage surface charge in aging and OA and, 660
- Arylsulfatase, articular cartilage in aged ICR mice and, 1027
- Ascites IgG, RF synthesis suppression in RA and, 873
- Ataxia, in Miller-Fisher syndrome after gold in RA, 838
- ATP metabolites, cartilage nucleoside triphosphate pyrophosphohydrolase and, 413
- Atrophic canine cartilage, salicylates, indomethacin and, in OA, 548
- Atrophic gastritis, in Sjögren's syndrome, 388
- Auranofin; *see also* Aurothioglucose; Chrysotherapy; Gold FDA and, 450
- with preexisting uremia, 710
- in RA, 1211
- Aurothioglucose; *see also* Auranofin; Chrysotherapy; Gold myeloperoxidase and, 1228
- Autoantibodies
- anticytoskeletal, 889
 - antiimmunoglobulin, RF in RA synovial membrane cells and, 742
 - anti-Ro (SS-A), 1321
 - captopril and, 597
 - in Japanese with connective tissue disease, 579
 - in juvenile dermatomyositis, 151
 - procainamide and, 276
 - RNP, 1348
 - in SLE peripheral blood mononuclear cells, 436
 - Sm, 1348
 - Sm antigen and, 294
 - in systemic sclerosis in Argentina, 715
- Autoantibody specificities, of immune complexes in RA and OA cartilage, 241
- Autoimmune disease
- AMLR in adjuvant arthritis and, 537
 - defective immune adherence receptors (CRI) in, 349
 - sex steroids and, 121
- Autoimmune hemolytic anemia, L-canavanine in alfalfa and, 52
- Autoimmune mice, MRL/Mp, inflammatory vascular disease in, 1146
- Autoimmune phenomena, L-canavanine and, 1198
- Autoimmune thyroiditis, in SLE, 1059
- Autoimmunity
- human, murine lupus model for, 1081
 - Autoimmunity (*cont'd*)
 - T1+ B cells in, 971
- Autoimmunology, T lymphocytes in, 841
- Autokines, regulatory, substrain heterogeneity in PGE₂ synthesis and, 315
- Autologous erythrocyte receptor phenotypes, in SLE, 262
- Autologous mixed leukocyte reaction, impaired killer cells and, in RA lymphocytes, 731
- Autologous mixed lymphocyte reaction, in adjuvant arthritis, 537
- Autologous T cells, Epstein-Barr virus-induced B cells in RA and, 961
- Avidity antibodies to dsDNA in SLE, 425
- Azotemic osteoarthropathy, erosive, amyloidosis and, 1075
- B**
- B₁ cell alloantigens
- in connective tissue diseases in Japanese, 579
 - rheumatic fever-associated, monoclonal antibodies and, 1047
- B cell mitogens, Sm and, 294
- B cell proliferation, *Staphylococcus aureus* Cowan 1 in SLE and, 1008
- B cell subsets, T1 antigen, chronic lymphocytic leukemia and, 971
- B cells
- antiidiotypic antibody in RA and, 879
 - circulating, in SLE and panhypogammaglobulinemia, 100
 - Epstein-Barr virus-induced, T cells and, in RA, 961
 - γ -interferon and, in RA, 174
 - procainamide and, 276
 - in SLE, 44
 - in SLE mice, 1083
 - synovial, IgA rheumatoid factor synthesis and, 1219
- B lymphocytes, rheumatic fever, monoclonal antibodies and, 1047
- Back pain, chronic inflammatory, in HLA-B27 positive ankylosing spondylitis relatives, 40
- Bacteria
- arthrography in septic arthritis and, 198, 835 (erratum)
 - phagocytosis, intracellular killing and, 395
 - streptococcal cell wall-induced arthritis and, 1402
- Bacterial cell wall-induced arthritis, in rats, 1318
- Balb/c mice, coronary arteritis after *L. casei* injection, 652
- Basal ganglia calcifications, in central nervous system lupus erythematosus, 1412
- Behavioral outcomes, of self-help patient education, 680
- Behçet's disease
- cardiac involvement in, 345
 - cyclosporine in, 671
 - diagnosis of dural sinus thrombosis in, 359
- Benign rheumatoid nodules of childhood, chronic arthritis following, 1175
- β_2 -microglobulin (β_2 -m), in SLE, 44

Biomechanics of, human femoral head OA articular cartilage, 521 (erratum)

Blastomycosis presenting as monarticular arthritis, 516

Bleomycin sulfate, intradermal, Raynaud's phenomenon of single digit after, 459

Blind loop syndrome, postgastrectomy, arthritis-dermatitis syndrome and, 214

Bone

- in Gaucher's disease, 218
- periarticular osteoporosis in RA and, 25

Bone fractures, prednisone and, 361

Bone growth, in childhood reflex neurovascular dystrophy, 952

Bone ischemia, Gaucher's disease and, 218

Bone loss, glucocorticoids in RA and, 369

Bone marrow suppression, total body irradiation in polymyositis and, 831

Bone mass, glucocorticoids and, in RA, 369

Bone resorption

- periarticular osteoporosis in RA and, 25
- pressure erosions in RA and, 820

Bone scans, hypertrophic pulmonary osteoarthropathy, 571

Bony erosions, of hindfoot, in RA, 1234

Book Reviews

- Antinuclear Antibodies* (McCarty GA et al), 720
- Differential Diagnosis in Rheumatology* (Calin), 480
- Rheumatoid Arthritis* (Utsinger et al), 1440

Bowel involvement, in SLE, 466

Brain, sex steroids, immunity and, 121

Brain cross-reactive lymphocytotoxins, in neuropsychiatric SLE, 789

Breast cancer, onset of systemic sclerosis and, 1336

Breath odor, topical DMSO and normal saline in systemic sclerosis and, 308

Bronchiolitis obliterans, penicillamine, cyclophosphamide, oral prednisone and, 93

Bursitis

- anserina, 1062
- sympathetic synovial effusions in, 941

C

C3Heb/FeJ mice, 652

C3H/HeJ mice, 652

C57BL/6 mice, coronary arteritis after *L casei* injection in, 652

Calcifications

- acute neck pain due to, 1417
- basal ganglia, in central nervous system LE, 1412
- soft tissue, in juvenile dermatomyositis, 151

Calcinosis, IgG antibodies in, 889

Calcium

- articular cartilage in aged ICR mice and, 1027
- in inflammatory connective tissue disease, 169
- nifedipine and esophageal dysfunction in PSS, 490

Calcium pyrophosphate dihydrate (CPPD)

- crystal deposition, in RA, 717
- crystals
- disease, elevated pyrophosphohydrolase in, 1283
- in knee synovial fluid, 1319
- in OA, 511

Cancer, systemic sclerosis and, 1336

Candida arthritis, isolated, 1421

Canine studies

- hyaluronic acid synthesis by corticosteroid suspensions, 1275
- salicylates and indomethacin in OA canine cartilage, 548

Captopril, autoantibodies and, 597

Carbohydrates, phosphopeptides, phosphorylation of proteoglycans and, 804

Carbon monoxide diffusion capacity, in scleroderma, 759, 882

Carcinoma polyarthritis, and malignant fibrous histiocytoma of heart, 944

Cardiac disease, procainamide and, 276

Cardiac involvement

- in Behçet's disease, 345
- Ig and rheumatoid factor in rheumatoid pericardium, 1071
- Ro (SS-A) in congenital complete heart block, 1321
- in scleroderma, 1259

Cardiolipin, anti-dsDNA binding, lupus anticoagulant and, 67

Cardiorespiratory arrest, after total lymphoid irradiation in RA, 1205

Cardiovascular involvement, in juvenile progressive systemic sclerosis, 699

Carpal bone, cystic radiolucencies and, in synovial amyloidosis, 1052

Carpal ligament, transverse, amyloid in synovium of, 1052

Carpal tunnel syndrome, synovial amyloidosis in hemodialysis and, 1052

Cartilage

- articular, immune complexes of, in RA and OA, 241
- epiphyseal, response to force in chondrocytes, 419
- human, proteoglycan extraction from, 323
- indomethacin in, 237
- keratan sulfate as marker of, 1367
- lacerated, salicylates, indomethacin and, in OA, 548
- mandibular condylar, in ICR mice, 1027
- in MRL/l mice with arthritis, 529
- murine, salicylates, GAG synthesis and, 922
- OA, proteoglycan depletion, salicylates, indomethacin and, 548
- RA, antirheumatic drugs and, 405
- response of, to force in chondrocytes, 419
- salicylates in, 237
- stress-induced proteins in chondrocytes from, in OA, 1140
- synovial inflammation in, in Pond-Nuki dog model of OA, 554
- in temporal mandibular joint in mice, 1027

- Cartilage damage, triamcinolone hexacetonide and, 1267
- Cartilage degradation
neutral proteoglycanases and, in experimental OA, 1393
in RA and OA, 241
- Cartilage destruction
in MRL/l mice with arthritis, 529
in RA, 1192
- Cartilage nucleoside triphosphate pyrophosphohydrolase, 413
- Cartilage proteoglycan synthesis, murine antigen-induced arthritis and, 813
- Cartilage space narrowing, hindfoot, in RA, 1234
- Cartilage structure, proteoglycan extraction and, 323
- Cartilage surface charge, in aging and OA, 660
- Cartilage thickness, proteoglycan extraction and, 323
- Catechol estrogens, rheumatic diseases and, 121
- Cationized ferritin, cartilage surface charge in aging and OA and, 660
- Cell binding, of rheumatoid synovial fluid fibronectin, 601
- Cell loss, chemically induced articular cartilage damage and, 1267
- Cell proliferation, cartilage response to force in chondrocytes and, 419
- Cell wall polymers, streptococcal cell wall-induced arthritis and, 1402
- Cellular immunity, to collagen and laminin in scleroderma, 775
- Cellular proliferation, substrain heterogeneity in PGE₂ synthesis and, 317
- Central nervous system disease, anticentromere antibodies in in connective tissue disease, 1076
- Central nervous system involvement, in inflammatory vascular disease in Sjögren's syndrome, 1341
- Central nervous system lupus erythematosus, basal ganglia calcifications in, 1412
- Cerebritis, lupus, 1412
- Ceruloplasmin, copper, hydrogen peroxide, penicillamine and, 914
- Cervical spine, apophyseal joint ankylosis of in adult-onset RA, 958
- CH50, in SLE pregnancy, 58
- Chemotaxis, synovial fluid fibronectin in RA and, 601
- Chicken erythrocytes, gold sodium thiomalate and, 1384
- Childhood benign rheumatoid nodules, chronic arthritis after, 1175
- Childhood eosinophilic fasciitis, 948
- Childhood reflex neurovascular dystrophy, 952
- Chlorambucil, in refractory inflammatory myositis, 590
- Chondrocalcinosis
adenosine triphosphate pyrophosphohydrolase in, 1283, 1377
in RA, 717
- Chondrocyte death, murine antigen-induced arthritis and, 813
- Chondrocyte glycosaminoglycan synthesis, murine, salicylates, sulfate and in articular cartilage, 922
- Chondrocyte proteoglycan synthesis, murine antigen-induced arthritis and, 813
- Chondrocytes
articular cartilage and, in aged ICR mice, 1027
cartilage response to mechanical force in, 419
chemically induced articular cartilage damage and, 1267
in chondrocalcinosis, 118
epiphyseal, cartilage response to mechanical force in, 419
murine antigen-induced arthritis and, 813
salicylates, indomethacin and, in OA, 548
stress-induced proteins and, in OA, 1140
- Chondroitin sulfate, phosphorylation of proteoglycans and, 804
- Chromatin, acetylator phenotype in SLE and, 995
- Chronic arthritis, following benign rheumatoid nodules in childhood, 1175
- Chronic atrophic gastritis, in Sjögren's syndrome and other rheumatic diseases, 388
- Chronic cutaneous lupus erythematosus; *see also* Cutaneous lupus erythematosus
- Chronic cutaneous lupus erythematosus, pulmonary hypertension, lupus anticoagulant and, 118
- Chronic inflammatory back pain
clinical criteria for, 41
HLA-B27 positive ankylosing spondylitis and, 40
- Chronic inflammatory joint disease, after benign rheumatoid nodules in childhood, 1175
- Chronic knee effusions, iodide clearance in, in RA and OA, 1096
- Chronic lymphocytic leukemia, T1 + B cells and, in RA, 971
- Chronic polyarthritis, *Escherichia coli*-induced, 522
- Chronic RA-like polyarthritis with immunodeficiency, adenovirus type 1 infection in, 455
- Chronic rheumatoid synovitis, iodide and hypoperfusion in, 1096
- Chronic tophaceous gout
allopurinol hypersensitivity in, 707
endogenous pyrogen (IL-1) and, 1039
- Chronic uveitis, primary, NSAID in, 1317
- Chrysotherapy; *see also* Auranofin; Aurothioglucose; Gold IgM and IgM rheumatoid production during, 356
- ¹⁴C-hydroxyproline production, dermal fibroblasts and in progressive systemic sclerosis, 504
- Chylous joint effusions, post-traumatic, 1303
- Circulating B cells, absence of in SLE and panhypogammaglobulinemia, 100
- Circulating immune complexes
cyclosporine and, in Behçet's disease, 671
in juvenile dermatomyositis, 154
in SLE, 904
- Circulating keratan sulfate, in OA, 1367
- Circulating natural killer cells, in Sjögren's syndrome, 182
- Circulating rheumatoid factor, in MRL/l mice, 529

- Clomiphene stimulation, plasma hormones in gout and, 127
- Collagen
- cellular immunity and, in scleroderma, 775
 - denatured, synovial fluid fibronectin in RA and, 601
 - lymphokine modulation of scleroderma fibroblasts and, 502
 - mandibular condylar cartilage in ICR mice and, 1027
- Collagen antibodies, in OA articular cartilage, 241
- Collagen production, lymphokine modulation of scleroderma fibroblasts and, 502
- Collagen synthesis, aminopropeptide of procollagen I and, in scleroderma, 647
- Collagenase
- cartilage surface charge in aging and OA and, 660
 - IgG and IgM rheumatoid factor in RA and OA cartilage, 244
 - immunoglobulins in, in articular cartilage, 243
- Collagenolytic activity, in OA cartilage and synovia in Ponde Nuki dog, 554
- Colloidal iron, cartilage surface charge in aging and OA and, 660
- Community resources, patient education about, in RA, 300
- Complement
- disease activity in SLE and, 904
 - immune complexes and, 222
 - in Japanese SLE patients, 693
 - PMN intracellular killing, phagocytosis and, in RA, 395
- Complement C1q, serum, in RA, 240
- Complement C1q binding assay
- disease activity in SLE and, 904
 - immune complexes and, 222
- Complement C2, gold sodium thiomalate and, 1384
- Complement C2 deficiency, in pregnancy and SLE, thrombocytopenic purpura in, 341
- Complement C3
- IL-2 and γ -interferon in RA and, 174
 - in SLE pregnancy, 58
- Complement C3 anaphylatoxin, in synovial fluid in RA, 1089
- Complement C3a, in synovial fluid in RA, 1089
- Complement C3 \bar{A} , in synovial fluid in RA, 1089
- Complement C4
- in SLE, 904
 - in SLE pregnancy, 58
- Complement C5b-9, IL-2 and γ -interferon in RA and, 174
- Complement C9, IL-2 and γ -interferon in RA and, 174
- Complement CH50, in SLE, 905
- Complement fixation, anti-Mi-1, anti-Mi-2 and, 796
- Complement-dependent cytotoxic antibody titers, in SLE, 263
- Complete heart block, congenital, Ro (SS-A) antibody and antigen in, 1321
- Computed tomography
- in early ankylosing spondylitis, 930
 - of hindfoot in RA, 1234
- Concanavalin A
- L-canavanine in SLE and, 52
 - Concanavalin A (*cont'd*)
 - mononuclear cells, GAG synthesis and, in PSS, 188
- Concanavalin A-induced suppressor cells, procainamide and, 276
- Concanavalin A-stimulated mononuclear cell proliferation
- hydrogen peroxide, penicillamine and, 914
- Condylar articular surface, cartilage surface charge in aging and OA and, 660
- Condylar cartilage, mandibular, in ICR mice, 1027
- Condyles, human mandibular, articular cartilage in aged ICR mice and, 1027
- Congenital complete heart block, Ro (SS-A) antibody and antigen in, 1321
- Congenital heart block
- in neonatal LE, 271
 - SLE, anti-Ro antibodies and, 1077
- Connective tissue disease
- anticentromere antibodies in, 1076
 - anticytoskeletal autoantibodies in, 889
 - autoantibodies and HLA phenotypes in Japanese with, 579
 - human vasculitis in, MRL/Mp autoimmune mouse model for, 1146
 - inflammatory, calcium and magnesium in, 169
 - Mi-2 antibodies and, 796
 - in mothers in neonatal LE, 271
 - T1+ B cell subsets in, 971
- Connective tissue remodeling, fibronexus and, in RA, 1105
- Continuing medical education, 1163
- Copper and copper sulfate, hydrogen peroxide, penicillamine and, 914
- Cornea, lack of keratan sulfate in macular corneal dystrophy, 1367
- Coronary arteries, epicardial, in primary scleroderma myocardial disease, 637
- Coronary arteritis, in mice, 652
- Coronary reserve, in primary scleroderma myocardial disease, 637
- Coronary sinus blood flow, in primary scleroderma myocardial disease, 637
- Corticosteroid drugs
- in Behçet's disease, 671
 - calcium and, 169
 - chemically induced articular cartilage damage and, 1267
 - hormone modulation in SLE and, 1243
 - magnesium and, 169
 - multicentric reticulohistiocytosis, dysphagia and, 231
 - prescription of after continuing medical education about, 1163
 - suspensions, hyaluronic acid synthesis and, 1275
 - T cells, EBV-induced B cells and, in RA, 961
 - in thrombotic thrombocytopenic purpura in C2-deficient SLE, 341
- Cortisol, in gout, 127
- C-reactive protein
- antibiotics in Whipple's disease and, 352

- C-reactive protein (*cont'd*)
 serum, in polymyalgia rheumatica, 383
- CREST syndrome
 cardiac dysrhythmias in, 1259
 IgG antibodies in, 889
 pulmonary involvement in, 759
 Raynaud's disease and, 87
 restrictive lung disease and anticentromere antibodies in, 759
 in systemic sclerosis, 496
 terminology problems in, 359
- Cricopharyngeal obstruction, in polymyositis/dermatomyositis, 630
- Crithidia luciliae* kinetoplasts, binding of antihistone antibodies to, 163
- Crohn's disease
 erosive granulomatous arthritis in, 958
 in SLE, 466
- Crowned dens syndrome, acute neck pain due to calcifications and, 1417
- Crystal phagocytosis, in OA, 511
- Crystal-induced endogenous pyrogen production, gouty inflammation and, 1039
- Crystals
 CPPD, interleukin-1 and, 1039
 hydroxyapatite, interleukin-1, inflammation and, 1039
 monosodium urate and CPPD in knee synovial fluid, 1319
 silica, endogenous pyrogen (IL-1), gouty inflammation and, 1039
 synovial fluid, apatite and CPPD in OA, 511
 urate, interleukin-1 and, 1039
- Cutaneous lupus erythematosus; *see also* Discoid lupus; Lupus
 chronic, pulmonary hypertension, lupus anticoagulant and, 118
 subacute, 571
- Cycloheximide, rheumatoid factor synthesis in RA synovial membrane and, 742
- Cyclophosphamide, intravenous, D-penicillamine, bronchiolitis obliterans and, 93
- Cyclosporine
 in Behçet's disease, 671
 in giant cell arteritis, 1078
 in intractable polymyositis, 1436
- Cyproterone acetate, hormone modulation in SLE and, 1243
- Cystic radiolucencies of bone, amyloid and, in synovial amyloidosis in hemodialysis, 1052
- Cysts, popliteal
 anterior tibial mass and, 477
 intraarticular volume in RA and OA and, 444
- Cytology, synovial fluid, blastomycotic arthritis and, 516
- Cytoskeletal-extracellular matrix interactions, in RA, 1105
- Cytotoxicity
 autologous mixed leukocyte reaction in RA and, 736
 corticosteroid, in Behçet's disease, 671
 in SLE, 624
- Cytotoxicity (*cont'd*)
 spontaneous, gold sodium thiomalate and, 1384
 for T cells in SLE, 262
- D**
- D-cysteine, hydrogen peroxide, concanavalin-A mononuclear cells and, 914
- Degenerative joint disease
 complement C3 in, 1089
 interleukin-2 and, 1318
 stress-induced protein in chondrocytes in, 1140
- Denatured DNA
 acetylator phenotype in SLE and, 995
 IgM anti-DNA antibodies and, in SLE, 431
- Dendritic cells, HLA-DR-expressing, synovitis and, 977
- Deoxyribonucleic acid (DNA), cartilage degradation by neutral proteoglycanases in experimental OA and, 1393
- Dermal fibroblasts
 human, substrain heterogeneity in PGE₂ synthesis of, 315
 lymphokines, collagen production and, 502
 porcine synoviocytes and, in RA, 1105
- Dermatitis; *see* Arthritis-dermatitis syndrome
- Dermatomyositis; *see also* Polymyositis/dermatomyositis
 antibodies to Mi in, 796
 cricopharyngeal obstruction in, 630
 dysphagia in, 630
 juvenile, immunogenetic study of, 151
- Dermatomyositis/polymyositis, steroid-resistant, immunosuppressive drugs in, 590
- Dexamethasone, fibronectin in human synovium and, 1016
- Diagnosis-related group regulations, 204
- Diagnosis-related group-based reimbursement, in rheumatic diseases, 846
- Dialysis, synovial amyloidosis in, 1052
- Diaphyseal mass, after prednisone, 361
- Diffuse scleroderma
 cardiac dysrhythmias in, 1259
 clinical characteristics of, 639
 lymphocyte-induced angiogenesis and, 1133
 pulmonary involvement in, 759
- Digital angiography, dural sinus thrombosis in Behçet's disease and, 359
- Digital arteries, in mixed connective tissue disease, 768
- Digital photoplethysmography findings, angiographic findings in MCTD and, 768
- Digital tip pitting scars and ulcerations, in Raynaud's phenomenon, 87
- Digital ulcers, DMSO and normal saline in, in systemic sclerosis, 308
- Dihydrotestosterone, in adjuvant arthritis in rats, 959
- Dimethyl sulfoxide (DMSO)
 in systemic sclerosis, 1437
 topical, in hand ulcers in systemic sclerosis, 308
- Dipyridamole, in primary scleroderma myocardial disease, 637

Discoid lupus; *see also* Cutaneous lupus erythematosus; Lupus

immunofluorescence, fibromyalgia and, 836
skin lesions in a fraternal twin with neonatal lupus, 271

Disease activity

complement, immune complexes and, in SLE, 904
inspiratory muscle dysfunction and dyspnea in SLE and, 781

in juvenile dermatomyositis, 151
leukergy test in rheumatic diseases and, 899

methotrexate and, in RA, 721
patient education about, in RA, 300
in polymyalgia rheumatica, 383
in RA, 1205
in SLE, 1123
and T1+ B cells in RA, 971

Disease duration

and elderly-onset RA, 987
and juvenile dermatomyositis, 151
and nailfold capillary abnormalities in systemic sclerosis, 496
and scleroderma, 775
and T cells, EBV-induced B cells in RA and, 961

Disease outcome, in elderly-onset and younger-onset RA, 987

Disease progression, radiologic abnormalities of hands and wrists in RA and, 16

Disease remission, prednisolone and, in polymyalgia rheumatica, 383

Disease severity, T cells, EBV-induced B cells and, in RA, 961

Distal femora, salicylate, indomethacin and, in OA, 548

DNA

antihistone antibodies and, in systemic rheumatic disease, 285

binding activity, L-canavanine in SLE and, 52
double-stranded, high and low avidity antibodies to in SLE, 425

lymphoid tissue, Sm and, 294

Down's syndrome, SLE and, 598

D-penicillamine; *see also* Penicillamine

D-penicillamine-associated bronchiolitis obliterans, intravenous cyclophosphamide and oral prednisone in, 93

DR antibodies, in SLE, 44

Drug abuse, in nongonococcal septic arthritis, 210

Drug-induced fasciitis and polyarthritis, 1179

Drug-induced lupus erythematosus

antihistone antibodies in, 158
clinical and laboratory features of, 160
Crithidia luciliae kinetoplasts and, 163

Drugs; *see also* Auranofin; Gold; Corticosteroid; Steroid Drugs

allopurinol, 707
angiotensin converting enzyme inhibitors, 480
antibiotic, 75, 352
antimalarial, 1243

Drugs (*cont'd*)

antirheumatic, 405
auranofin, 450, 1211
aurothioglucose, 1228
bleomycin sulfate, 459
captopril, 597
charges for and DRG, 204
chlorambucil, 590
corticosteroid, 231, 671, 837, 961, 1243, 1267, 1344
cycloheximide, 742
cyclophosphamide, 93
cyclosporine, 671, 1078, 1436
cyproterone acetate, 1243
dexamethasone, 1016
DMSO, 308, 1437
gastritis and, in Sjögren's syndrome, 389
glucocorticoids, 369
gold sodium aurothiomalate, 1121, 1228
hydrocortisone, 1275
ibuprofen, 104, 1117, 1430
immunosuppressive, 75, 590
indomethacin, 237, 548, 1008
intravenous pulse methylprednisolone, 477
iodine, 198

lidocaine, 198

mefenamic acid, 686

methicillin, 210

methotrexate, 590, 721

methylprednisolone acetate suspension, 1275

Motrin, 238

nifedipine, 490

NSAID; *see* Nonsteroidal antiinflammatory drugs

oxyphenbutazone, 450, 686

penicillamine, 369, 376, 882, 914, 1228

phenylbutazone, 450, 686

prednisolone, 383, 1008

prednisone, 93, 361, 554, 630, 1393

procainamide, 158, 276

salicylates, 237, 548

slow-acting therapeutic agents, 961

steroid, 121, 383, 405, 948, 1267, 1393

T1+ B cells in RA and, 971

thalidomide, 836

thiol-containing, 1228

tiopronin, 595, 1228

triamcinolone hexacetonide, 1267

zomepirac, 686

Dural sinus thrombosis, in Behçet's disease, digital angiography and, 359

Dysphagia

multicentric reticulohistiocytosis, corticosteroids and, 233
in polymyositis/dermatomyositis, 249

Dyspnea

penicillamine and, in scleroderma, 882
restrictive lung disease and, in scleroderma, 759
unexplained, in SLE, 781

E

- Echovirus type 11, in acute monocytic arthritis, 98
- Effusions
 - human synovial, intraarticular volume and clearance in, 441
 - joint, post-traumatic chylous, 1303
 - knee, chronic, iodide clearance and in RA and OA, 1096
 - knee joint, synovial fluid crystals in, in OA, 511
 - in RA and OA, 441
 - in septic arthritis and bursitis, 941
- Elbow joint, periarticular osteoporosis in RA and, 27
- Elderly-onset rheumatoid arthritis, clinical features of, 987
- Endogenous sulfate, salicylates, GAG synthesis and, in murine cartilage, 922
- Endothelial cell protein, in JRA, 256
- Enteropathy, protein-losing, in SLE, 1059
- Enzyme immunoassay, synovial fluid fibronectin in RA and, 601
- Enzyme-linked immunosorbent-inhibition assay, for keratan sulfate, 1367
- Enzymes
 - angiotensin converting enzyme inhibitors and RA, 480
 - antirheumatic drugs and, in RA, 405
 - collagenolytic, Pond-Nuki dog model of OA and, 554
 - interleukin-1 in human synovial tissue in vitro and, 853
- Eosinophilic fasciitis, in a 2-year-old, 948
- Epidemiology
 - juvenile arthritis in Rochester, MN, 239
 - rheumatoid arthritis, 485
- Epiphyseal cartilage, response to force in chondrocyte cultures, 419
- Epstein-Barr virus
 - antibodies, in RA, 339
 - in RA, 961
- Epstein-Barr virus-induced B cells, T cells and, in RA, 961
- Erosions
 - bony, of hindfoot in RA, 1234
 - joint, in RA, 1326
 - in MRL/l arthritis, 529
 - pressure, bone resorption in RA and, 820
- Erosive azotemic osteoarthropathy, amyloidosis and, 1075
- Erosive granulomatous arthritis, in Crohn's disease, 958
- Erosive polyarthritis, adenovirus type 1 infection in, 455
- Erythrocyte immune adherence receptors (CRI), in autoimmune diseases, 349
- Erythrocyte sedimentation rate
 - blood gold concentrations in RA and, 1215
 - in giant cell arteritis and polymyalgia rheumatica, 837
 - methotrexate and, in RA, 721
 - in polymyalgia rheumatica, 383
- Erythrocytes
 - antibodies in SLE and, 44
 - chicken, gold sodium thiomalate and, 1384
 - in inflammatory connective tissue disease, 169
 - in SLE, 262
- Escherichia coli*, induction of polyarthritis in rabbits by, 522

- Esophageal dysfunction, nifedipine and, in progressive systemic sclerosis, 490
- Esophageal dysmotility
 - IgG antibodies in, 889
 - lymphocyte-induced angiogenesis and, 1133
- Esophageal hypomotility, in Raynaud's disease, 87
- Esophageal involvement, in polymyositis/dermatomyositis, 630
- Esterase-positive cells, rheumatoid adherent cells and, 863
- Esterase-positive mononuclear cells, fibronectin in human synovium and, 1016
- Estrogen
 - 16 alpha-hydroxyestrone, 1122
 - catechol, rheumatic diseases and, 121
- Estrogenic suppressive agents, sex steroids and, 121
- Exercise, aerobic, in RA, 32
- Experimental osteoarthritis, cartilage degradation by neutral proteoglycanases in, 1393
- Extensor tendon mechanism, rupture of, in wrist drop in scleroderma, 586
- Extracellular matrix-cytoskeletal interactions, RA, 1105
- Extracellular pyrophosphate generation, cartilage nucleoside triphosphate pyrophosphohydrolase and, 413
- Extractable nuclear antigen autoantibodies, in juvenile dermatomyositis, 151

F

- F(ab')₂ fragments, antibodies, specificity of human IgG to, 562
- F(ab')₂ fragments, antiidiotypic antibody in RA, RF synthesis and, 873
- Factor VIII-related antigen, in JRA, 256
- Familial amyloid polyneuropathy, HLA and, 1188
- Family practice residencies, rheumatology training in, 471
- Family practitioners, referral of patients with musculoskeletal disease by, 1156
- Farr assay, avidity antibodies to dsDNA in SLE and, 425
- Fasciitis
 - eosinophilic, in a 2-year-old, 948
 - polyarthritis and, during anti-tuberculosis therapy, 1179
- Fatigue
 - aerobic exercise in RA and, 32
 - in juvenile primary fibromyalgia syndrome, 138
 - myoadenylate deaminase deficiency and, 1298
- Fc fragments, antibody specificity to F(ab')₂ and, 562
- Fc receptors
 - PMN intracellular killing in RA and Felty's syndrome and, 395
 - synovial fluid fibronectin in RA and, 601
- FDA Arthritis Advisory Committee
 - labeling of arthritis drugs, 450
 - postmarketing surveillance of NSAID, 1168
- Feet
 - abnormalities of, in RA, 1234
 - allopurinol hypersensitivity in tophaceous gout and, 707
 - in childhood reflex neurovascular dystrophy, 952

Feet (cont'd)

- tarsal coalition of, 331
- Felty's syndrome, phagocytosis and intracellular killing by PMN cells in, 395
- Femoral condyle, chemically induced articular cartilage damage and, 1267
- Femoral head
 - cystic radiolucencies of in amyloidosis in hemodialysis, 1052
 - human OA articular cartilage, biomechanics of, 521 (erratum)
- Ferritin, cationized, cartilage surface charge in OA and aging and, 66
- Fetal death, in SLE pregnancies, 58
- Fever
 - endogenous pyrogen (interleukin-1) and, 1039
 - in polymyositis/dermatomyositis, 249
 - in *Salmonella* bacteremia in SLE, 75
- Fibrillar ultrastructure of amyloid depositis, in synovial amyloidosis in hemodialysis, 1052
- Fibrillation
 - chemically induced articular cartilage damage and, 1267
 - salicylates, indomethacin, OA cartilage and, 548
- Fibrin, synovial fluid fibronectin in RA and, 601
- Fibrinopeptide A in plasma, in JRA, 256
- Fibroblast collagen production in scleroderma, lymphocyte modulation of, 502
- Fibroblast-lymphocyte interactions, mononuclear cells, GAG synthesis and in PSS, 188
- Fibroblasts
 - dermal human, PGE₂ synthesis and, 315
 - fibronectin in human synovial, 1016
 - lymphokines, collagen production and, 502
 - mononuclear cells, GAG synthesis and in PSS, 188
 - porcine, synoviocytes and, in RA, 1105
 - synovial, adenovirus type 1 infection in polyarthritis and, 455
 - synovial fluid fibronectin in RA and, 601
- Fibrocartilage in MRL/l mouse arthritis, 529
- Fibromyalgia syndrome
 - juvenile primary, 138
 - primary, immunofluorescence and, 836
- Fibronectin
 - in articular cartilage of ICR mice, 1027
 - in human synovium, 1016
 - synovial fluid, in RA, 601
- Fibronectin-containing extracellular matrix, in RA, 1105
- Fibronexus of type B synoviocytes, in RA, 1105
- Fibrosis
 - penicillamine and, in scleroderma, 882
 - pulmonary, lung cancer and, in systemic sclerosis, 1336
 - in systemic sclerosis, 759
- Fibrositis
 - characteristics of, 132
 - primary, immunofluorescence and, 836
 - psychogenic rheumatism and, 1435
 - tender point count and, 479

- Fibrous histiocytoma, malignant, of heart, polyarthritis as presenting symptom of, 944
- Finger flexor tenosynovitis, synovial amyloidosis in hemodialysis and, 1052
- Fingernail capillary photomicroscopy, angiographic findings in MCTD and, 768
- Fingers
 - involvement of single digit, in Raynaud's phenomenon, 459
 - in mixed connective tissue disease, 768
 - in Raynaud's disease, 87
 - in Raynaud's phenomenon, 1317
- Fisher 344 rats, AMRL in adjuvant arthritis and, 537
- Forced expiratory volume, penicillamine and in scleroderma, 882
- Functional assessment, efficiency of, health status measurements, 542
- Functional impairment, Jaccoud's arthropathy in SLE, 825
- Functional outcome, assessment of, physician continuing medical education and, 1163

G

- Galactosamine-rich proteoglycans, kinetics of, extraction of from cartilage, 323
- Gamma globulin, in SLE and common variable hypogammaglobulinemia, 462
- γ -Interferon, autologous mixed leukocyte reaction in RA and, 731
- γ -Interferon, in RA, 174
- Gangrene, in JRA, 256
- Gastritis, atrophic, in Sjögren's syndrome, 388
- Gastroesophageal reflux, nifedipine and, in progressive systemic sclerosis, 490
- Gastrointestinal complications of NSAID, 1169
- Gaucher's disease, bone ischemia and, 218
- General practitioners, patterns of, referral of patients with musculoskeletal disease by, 1156
- Genetics
 - anti-DNA antibody idiotypes in SLE, 999
 - E coli*-induced chronic polyarthritis in rabbits, 522
 - inflammatory vascular disease in MRL/Mp autoimmune mice, 1146
 - murine lupus and genetic markers, 1082
 - rheumatic fever-associated B cell alloantigens, 1047
- Genital ulcers, in Behçet's disease, 671
- Giant cell arteritis
 - aortic regurgitation in, 582
 - cyclosporine in, 1078
 - polymyalgia rheumatica and, tests for, 837
 - seronegative polyarthritis in, 1356
- Glialoma cells in neuropsychiatric SLE, 789
- Glucocorticoid-induced osteopenia, in rheumatic diseases, 361
- Glucocorticoids, bone mass in RA and, 369
- Glucosamine-rich proteoglycans, extraction of, from cartilage, 323
- Glucose, synovial fluid, iodide clearance and, in RA, 1096

Glucose levels, knee synovitis due to echovirus type 11 and, 98

Glycosaminoglycan binding, synovial fluid fibronectin in RA and, 601

Glycosaminoglycan synthesis

- mononuclear cells and, 188
- in murine articular cartilage, salicylates and, 922
- salicylates, indomethacin and, in OA, 548

Glycosylation, proteoglycan phosphorylation and, 804

Gm allotypes, in SLE, 828

Gold; *see also* Auranofin; Aurothiomalate; Chrysotherapy

- children exposed to, in utero, 235
- concentrations in blood in RA, 1211
- oral, in RA, with preexisting uremia, 710
- Miller-Fisher syndrome during treatment with, 838
- in RA, 1211
- sodium thiomalate, human monocyte maturation in, 1384

Gold therapy, neutral proteoglycan degradation in RA and, 405

Gold toxicity, HLA-Bw35 in RA and, 236

Gout

- adenosine triphosphate pyrophosphohydrolase in, 1283
- coexistent with RA, 238
- cortisol in, 127
- endogenous pyrogen (IL-1) in, 1039
- luteinizing hormone in, 127
- plasma follicle-stimulating hormone in, 127
- progesterone in, 127
- sex hormones in, 127
- testosterone in, 127
- of spine, with no peripheral tophi, 1312
- tophaceous, chronic, allopurinol sensitivity in, 707

Gouty arthritis, complement C3 in, 1089

Gouty inflammation, 1039

Gram-negative bacteremia, in SLE, 78

Granulation tissue myofibroblasts, fibronexus and, 1105

Granulocytes, in inflammatory connective tissue disease, 169

Granulomatous arthritis, erosive, in Crohn's disease, 958

Granulomatous myositis, sporotrichal arthritis presenting as, 1425

Group education, psychosocial concerns in RA and, 300

Group leaders, patient education in RA and, 304

Guillain-Barré syndrome with ophthalmoplegia, after gold in RA, 838

Guinea pig studies, triamcinolone hexacetonide and cartilage damage, 1267

H

³H-glycosamine, mononuclear cells, GAG synthesis and, in PSS, 188

³H-proline, collagen synthesis and procollagen I in scleroderma, 647

³H-thymidine, mononuclear cells, GAG synthesis and, in PSS, 188

Hand

- angiography of, in mixed connective tissue disease, 768

Hand (cont'd)

- Jaccoud's deformities of, 825
- osteopenia of, 1180
- pressure erosions in, in RA, 821
- in psoriatic arthritis, poliomyelitis and, 704
- in RA, 16, 1326
- in seronegative polyarthritis in giant cell arteritis, 1364
- ulcers of, DMSO in, in systemic sclerosis, 308

Haptoglobins

- calcium, magnesium and, 169
- in giant cell arteritis and polymyalgia rheumatica, 837

Headache, in juvenile primary fibromyalgia syndrome, 138

Health assessment and outcome, in elderly-onset RA, 987

Health professionals, self-help patient education and, 680

Health status measurement, efficiency and sensitivity of, 542

Heart

- congenital complete heart block, Ro (SS-A) in, 1321
- congenital heart block in SLE, anti-Ro antibodies and, 1077
- Ig and RF production in rheumatoid pericardium, 1071
- ischemic heart disease in polymyositis/dermatomyositis, 249
- malignant fibrous histiocytoma of, polyarthritis in, 944
- myocarditis in adult Still's disease, 452

Heat shock, proteins in chondrocytes in OA, 1140

Helper T cells, in synovitis, 977

Hemodialysis

- erosive azotemic osteoarthropathy, amyloidosis and, 1075
- maintenance, renal insufficiency, ibuprofen and, 1430
- synovial amyloidosis in, 1052

Hindfoot, computed tomography of, in RA, 1234

Hip

- joint

 - abscesses of, 198
 - periarticular osteoporosis in RA and, 27
 - replacement in synovial amyloidosis in hemodialysis, 1052

Histidyl-tRNA synthetase, myositis-specific Jo-1 antigen and, 839

Histiocytoma, malignant fibrous, of heart, polyarthritis as presenting symptom of, 944

Histocompatibility complex antigen, HLA-DR+ T cells in RA and, 8

Histone antigens, *Crithidia luciliae* kinetoplasts and, 163

Histones, acetylator phenotype in SLE and, 995

Histopathologic inflammatory vascular disease, in MRL/Mp autoimmune mice, 1146

HLA

- antigens in connective tissue diseases in Japanese, 579
- determinants, neonatal LE and, 271
- genotypes, in systemic onset JRA, 146
- phenotype, in Japanese with connective tissue diseases, 579
- system, familial amyloid polyneuropathy and, 1188
- type

 - in juvenile dermatomyositis, 151
 - in systemic onset JRA, 146

HLA-A gene, in systemic onset JRA, 147

- HLA-A2, B44, Cw5 antigen combination, in Kawasaki syndrome, 938
- HLA-B gene, in systemic onset JRA, 148
- HLA-B8 antigen, in juvenile dermatomyositis, 151
- HLA-B27 positive ankylosing spondylitis, spondylitic disease in relatives of patients with, 40
- HLA-Bw35
antigens and gold toxicity in RA, 236
gene in systemic onset JRA, 146
- HLA-C gene, in systemic onset JRA, 148
- HLA-Cw3, immune adherence receptors (CRI) in autoimmune diseases, 349
- HLA-DQ antigens, in connective tissue diseases in Japanese, 579
- HLA-DR
antigens
anticollagen antibodies and, 1316
T cells and, in RA, 8
gene, in systemic onset JRA, 148
- HLA-DR3
in a fraternal twin, in neonatal LE, 271
antigen
in juvenile dermatomyositis, 151
tiopronin-induced nephrotic syndrome and, 595
- HLA-DR4 gene, in systemic onset JRA, 146
- HLA-DR7 gene, in systemic onset JRA, 146
- Hormone modulation, in SLE, 1243
- Hormones
16 alpha-hydroxyestrone in SLE, 1122
luteinizing, in gout, 127
plasma follicle-stimulating, in gout, 127
sex, 121, 127
- Human autoimmunity, murine lupus model for, 1081
- Human blood leukocytes, interleukin-1, inflammation and, 1039
- Human studies
cartilage, proteoglycan extraction from, 323
chondrocytes, stress-induced proteins in, in OA, 1140
dermal fibroblasts, PGE₂ synthesis of, 315
- Human studies
femoral head OA cartilage, biomechanics of, 521 (erratum)
- IgG, antibody specificity of F(ab')₂ fragments to, 562
- immune complexes, IgG anti-F(ab')₂ antibodies and, 562
- leukocytes, thiol-containing drugs in RA and, 1228
- lymphokine modulation of scleroderma fibroblasts, 502
- mandibular joint, spontaneous OA in, mouse model for, 1027
- monocyte maturation, gold sodium thiomalate and, 1384
- synovium
effusions, intraarticular volume and clearance in, 441
fibronectin in, 1016
interleukin-1 and, 853
vasculitis, MRL/Mp mouse model of, 1146
- Human T cell leukemia virus, antibodies to, in SLE, 481
- Human T lymphotropic viruses, antibodies to, in rheumatic diseases, 1170
- Humerus, pressure erosion of, 823
- Humoral immune response, avidity antibodies to dsDNA in SLE and, 425
- Hyaline cartilage, articular, salicylates, GAG synthesis and, 922
- Hyaluronic acid
cartilage response to mechanical force in chondrocytes and, 419
proteoglycan phosphorylation and, 804
- Hyaluronic acid synthesis, corticosteroid suspension and, 1275
- Hyaluronidase, surface charge in aging and OA cartilage and, 660
- Hybridoma clones, murine, rheumatic fever-associated B cell alloantigen marker and, 1048
- Hydrocortisone, hyaluronic acid synthesis and, 1275
- Hydrogen peroxide, penicillamine and, 914
- Hydroxyapatite crystals, in joints, interleukin-1 and, 1039
- Hypergastrinemia, in Sjögren's syndrome, 388
- Hyperglobulinemia, in inflammatory vascular disease in, Sjögren's syndrome and, 1251
- Hyperimmunization, *E coli*-induced chronic polyarthritis in rabbits and, 522
- Hypersensitivity, allopurinol, in severe chronic, tophaceous gout, 707
- Hypertension, pulmonary, chronic cutaneous LE, lupus anticoagulant and, 118
- Hyperthyroidism, erosive azotemic osteoarthropathy, amyloidosis and, 1075
- Hypertrophic pulmonary osteoarthropathy, 571
- Hypochlorite, thiol-containing drugs and, 1228
- Hypocomplementemia
lupus pregnancy and, 58
Salmonella bacteremia in SLE and, 75
- Hypogammaglobulinemia
adenovirus type 1 infection in, in RA-like polyarthritis, 455
common variable, concurrent SLE and, 462
- Hypopepsinogenemia, in Sjögren's syndrome, 388

I

- ¹²³I radioactivity, in human synovial effusions in RA and OA, 441
- Ia antigens
antilymphocyte antibodies in SLE and, 44
IL-2, α -interferon and, in RA, 174
- Ibuprofen
meningitis in (NZB x NZW)F₁ mice and, 104
obese persons and, 1117
renal insufficiency, maintenance hemodialysis and, 1430
- ICR mice
articular cartilage in temporomandibular joints of, 1027
cartilage surface charge and, 660
- Idiopathic thrombocytopenic purpura, speckled ANA, SLE and, 596
- IgA and IgM rheumatoid factor synthesis, 1219

IgG

antibodies

- anti-DNA in SLE, 431
- antinuclear, acetylator phenotype and, in SLE, 995
- to microfilaments in connective tissue disease, 889
- to nDNA in SLE, 431
- in neonatal LE, 271
- in SLE, 285
- in articular cartilage in RA, 241
- ascites, RF synthesis suppression in RA and, 873
- complement activation, immune complexes and, 224
- human, antibody specificity to F(ab')₂ of, 562
- L-canavanine in SLE and, 52
- lupus anticoagulant and, 67
- rheumatoid factor in RA and OA articular cartilage, 241
- synthesis in RA synovial membrane cells, 742

IgM

antibodies

- anti-DNA and anti-RNA, in SLE, 431
- antilymphocyte, in SLE, 44
- antinuclear, acetylator phenotype and, in SLE, 995
- in connective tissue disease, 889
- in RA, 356
- in SLE, 285

articular cartilage in, 241

low molecular weight, 112

rheumatoid factor suppression in, 873

rheumatoid factor

- OA articular cartilage and, 241
- polyclonal, cross-specificity of, in RA, 875
- in RA, 356

synthesis

- gold therapy and, in RA, 1439
- IgA rheumatoid factor synthesis and, 1219
- rheumatoid synovial membrane cells and, 742

IgM staining, antibody specificity in SLE and, 262

ILR-1 antibodies, HLA-DR+ T cells in RA and, 8

Immune aberrations, brain and, 121

Immune adherence receptors, CR1, in autoimmune diseases, 349

Immune complexes

- autoantibody specificities of, in RA and OA cartilage, 241
- Behçet's disease and, 671
- complement activation and, 222
- disease activity in SLE and, 904
- human, IgG anti-F(ab')₂ antibodies and, 562
- in juvenile dermatomyositis, 151

Immune response, HLA-DR+ T cells in RA and, 8

Immune system, sex steroids and, 121

Immune thrombocytopenia, in SLE, 1059

Immunoblastic lymphadenopathy, polyarthritis of, synovial fluid lymphocytes in, 120

Immunodeficiency

- adenovirus type 1 infection in, in RA-like polyarthritis, 455
- Epstein-Barr virus in, in RA, 339

Immunodiffusion, Mi reference serum and, 796

Immunoendocrinology, 121

Immunofluorescence, fibromyalgia and, 836

Immunogenetic studies, juvenile dermatomyositis, 151

Immunoglobulin:albumin ratio, in cartilage extracts and synovial fluid, 243

Immunoglobulin-bearing cells, in synovitis, 977

Immunoglobulins

murine SLE and, 1081

- PMN intracellular killing, phagocytosis and, in RA, 395
- in rheumatoid pericardium, 1071
- in SLE peripheral blood mononuclear cells, 436
- synthesis, procainamide and, 276

Immunohistochemical studies, IL-2 and γ -interferon in RA, 174

Immunohistology, of synovitis, 977

Immunologic disorders, in SLE, 622

Immunoreactivity, of rheumatoid synovial fluid fibronectin, 601

Immunoregulation

defects of, in RA, 961

L-canavanine in SLE and, 52

Immunosuppressive drugs

- in D-penicillamine-associated bronchiolitis obliterans, 93
- Salmonella* bacteremia in SLE and, 75
- in steroid-resistant dermatomyositis/polymyositis, 590

Indomethacin

autologous mixed leukocyte reaction in RA and, 731

in cartilage, 237

prostaglandin E₂ in rheumatoid adherent cells and, 868

proteoglycan depletion in OA and, 548

S aureus-impaired B cell proliferation in SLE and, 1008

Infection

adenovirus type 1, in RA-like polyarthritis, 455

Salmonella bacteremia in SLE, 75

Infectious arthritis, synovial effusions in septic arthritis and bursitis, 941

Inflammation

AMLR in adjuvant arthritis and, 537

calcium and, 169

complement C3 and, 1089

coronary arteritis in mice after *L casei* injection, 652

crystal-induced endogenous pyrogen production and, 1039

gouty, interleukin-1 and, 1039

hypochlorite, myeloperoxidase and, 1228

joint chondrocyte proteoglycan synthesis and, 813

magnesium and, 169

in MRL/l mouse arthritis, 529

synovial fluid fibronectin in RA and, 601

synovial membrane, in Pond-Nuki dog model of OA, 554

in synovitis, 977

synovium, immune complexes in RA cartilage and, 241

Inflammatory cell infiltration, in MRL/l mouse arthritis, 529

Inflammatory connective tissue disease, abnormal calcium and magnesium in, 169

Inflammatory joint disease, chronic, after benign rheumatoid nodules of childhood, 1175

Inflammatory myopathy, cricopharyngeal obstruction in, 630

Inflammatory myositis, refractory, steroids, chlorambucil, and methotrexate in, 590

Inflammatory polyarthritis, in Down's syndrome, 598

Inflammatory vascular disease
in MRL/Mp autoimmune mice, 1146
peripheral, 1341
in Sjögren's syndrome, 1251

Inorganic pyrophosphate
in cartilage, 413
chondrocytes, proteoglycans and, in chondrocalcinosis, 118

Inorganic sulfate, salicylate-induced depletion of, GAG synthesis in mice and, 922

Inspiratory muscle dysfunction and unexplained dyspnea, in SLE, 781

Interferon, in SLE, 624

Interleukin-1
gouty inflammation and, 1039
from human synovial tissue in vitro, 853
mononuclear cells, GAG synthesis and in PSS, 188
in scleroderma, 1316
substrain heterogeneity in PGE₂ synthesis and, 315
synoviocytes and, in RA, 1105

Interleukin-2
autologous mixed leukocyte reaction in RA and, 731
mitogens, interleukin-1 and, 853
in RA, 174, 1318
receptor antibodies in SLE, 44
receptors and HLA-DR+ T cells in RA, 8

Intermediate filaments, antibodies to, in connective tissue disease, 889

Internal medicine residencies, rheumatology training in, 471

Internal organ involvement, collagen and laminin in scleroderma and, 775

Intima collagen, cellular immunity to, in scleroderma, 775

Intraarticular C3, in synovial fluid in RA, 1089

Intraarticular steroid injections, synovial fluid crystals after, in OA, 511

Intraarticular volume, in human synovial effusions, 441

Intracellular killing, polymorphonuclear cells and, in RA and Felty's syndrome, 395

Intradermal bleomycin sulfate injection, local, Raynaud's phenomenon of single digit after, 459

Intravascular coagulation, in systemic onset JRA, 256

Intravascular thrombin generation, fibrinopeptide A in JRA and, 256

Intravenous cyclophosphamide, D-penicillamine-associated bronchiolitis obliterans and, 93

Intravenous pulse methylprednisolone, in Still's disease, 477

Iodide, hypoperfusion in rheumatoid synovitis and, 1096

Iodine, arthrography in septic arthritis and, 198, 835 (erratum)

Iron, surface charge in aging and OA cartilage and, 660

Ischemia, rheumatoid joints and, 1096

Ischemic heart disease, in polymyositis/dermatomyositis, 249

J

J2 antibodies, HLA-DR+ T cells in RA and, 8

Jaccoud's arthropathy of the knee, in SLE, 825

Japanese population, SLE in, 693

Japanese white rabbits, *E coli*-induced chronic polyarthritis in, 522

Jo-1 antigen, myositis-specific, histidyl-tRNA synthetase and, 839

Joints
abnormalities of, cartilage damage and, 1268
acute monocytic arthritis due to echovirus type 11, 98
ankle, 334
ankylosis of, apophyseal, in adult-onset RA, 958
aspiration of, human synovial effusions in RA and OA and, 441
cartilage catabolism and, 1367
complaints about, in blastomycosis, 516
crystals, interleukin-1, inflammation and, 1039
counts of
aerobic exercise in RA and, 35
in RA, 613
destruction of
in murine antigen-induced arthritis, 813
in RA-like disease in MRL/l mice, 529
diseases of, after benign rheumatoid nodules of childhood, 175
effusions
knee, synovial fluid crystals in, in OA, 511
posttraumatic, 1303
erosions of
in polyarthritis in giant cell arteritis, 1362
in RA, 1326
human mandibular, OA in, mouse model for, 1027
inflammation of
chondrocyte proteoglycan synthesis and, 813
synovial fluid fibronectin in RA and, 601
involvement of
penicillamine in juvenile chronic arthritis and, 376
in psoriasis, 959
sporotrichal arthritis, granulomatous myositis and, 1425
in MRL/l murine arthritis, 529
narrowing of, in RA, 1326
pain in
aerobic exercise in RA and, 32
penicillamine and, in juvenile chronic arthritis, 376
sacroiliac, 198, 922
scores in
in assessment of RA, 1326
in elderly-onset and younger-onset RA, 987
space narrowing in, in giant cell arteritis, 1362
subtalar, computed tomography of, in RA, 1234
swelling in
methotrexate and, in RA, 721

Joint, swelling in (*cont'd*)

- in polyarthritis in giant cell arteritis, 1362
- synovial fluid crystals in, in OA, 511
- talocalcaneonavicular, 333
- temporomandibular, mice, articular cartilage in, 1027
- tenderness in
 - methotrexate and, in RA, 721
 - polyarthritis in giant cell arteritis and, 1362
- Juvenile arthritis, epidemiology of, in Rochester, MN, 239
- Juvenile chronic arthritis, penicillamine in, 376
- Juvenile dermatomyositis, immunogenetic study of, 151
- Juvenile primary fibromyalgia syndrome, 138
- Juvenile progressive systemic sclerosis, 699
- Juvenile rheumatoid arthritis; *see also* Adult Still's disease
 - Down's syndrome and, 598
 - sex ratios and sibship size in kindreds, 753
 - systemic onset, HLA type in, 146

K

- K562 target cells, natural killer cells and, in Sjögren's syndrome, 182
- Kawasaki syndrome, HLA-A2, B44, Cw5 antigen combination in, 938
- Keratan sulfate
 - as marker of cartilage catabolism, 1367
 - proteoglycan phosphorylation and, 804
- Kidney failure, cause of death after TLI in RA, 1205
- Kinetics of proteoglycan extraction from human cartilage, 323
- Klinefelter's syndrome, SLE, sex steroids, hormones and, 121
- Km phenotypes, in SLE and, 828
- Knee
 - cartilage
 - canine, salicylates, indomethacin and, in OA, 552
 - degradation by neutral PG in experimental OA and, 1391
 - proteoglycan degradation in RA and, 405
 - chemically induced articular cartilage damage and, 1267
 - E coli*-induced chronic polyarthritis in rabbits and, 525
 - effusions, chronic, in RA and OA, 441, 1096
 - joint
 - effusions, synovial fluid crystals in, in OA, 511
 - in MRL/l mouse arthritis, 530
 - periarticular osteoporosis in RA and, 27
 - in synovitis, 977
 - pain, patterns of referrals of patients with, 1156
 - pressure erosions of, in RA, 821
 - proteoglycan synthesis, chondrocyte death and, 813
 - in seronegative arthritis in giant cell arteritis, 1364
 - synovial fluid, MSU and CPPD crystals in, 1319
 - synovial inflammation in Pond-Nuki dog model of OA, 554
 - synovitis of, due to echovirus type 11, 98
- Koopman, William J., new Editor, *Arthritis and Rheumatism*, 714
- Kunkel Memorial Lecture, 1081

L

- L243 antibodies, in SLE, 44
- Lactate, synovial fluid, iodide clearance and, in RA, 1096
- Lactobacillus casei* cell walls, group B, coronary arteritis in mice after injection of, 652
- Laminin, cellular immunity to, in scleroderma, 775
- L-canavanine
 - autoimmune phenomena and, 1198
 - in SLE, 52
- Leu-1, Leu-8, Leu-10 antibodies, in SLE, 44
- Leu-3a:Leu-2a ratios, pulse therapy and in rheumatic diseases, 477
- Leu-11+ cells, in Sjögren's syndrome, 182
- Leukemia
 - chronic lymphocytic, T1+ B cells in RA and, 971
 - virus, human T cell, absence of antibodies to in SLE, 481
- Leukery test, in rheumatic diseases, 899
- Leukocytes
 - human blood, interleukin-1, inflammation and, 1039
 - human, thiol-containing drugs in RA and, 1228
 - interleukin-1 and, 853
 - killer cells, AMLR and, in RA lymphocytes, 731
 - leukery test in rheumatic diseases and, 899
- Leukocytosis, in polymyositis/dermatomyositis, 249
- Lidocaine, arthrography in septic arthritis and, 198, 835 (erratum)
- Ligaments, transverse carpal, amyloid in synovium of, 1052
- Ligand characteristics, of rheumatoid synovial fluid fibronectin, 601
- Lipopolysaccharides, streptococcal cell wall-induced arthritis and, 1402
- Liver, methotrexate and, in RA, 721
- Low back pain, patterns of referrals of patients with, 1156
- Low molecular weight IgM, in RA, 112
- Low-dose oral pulse methotrexate, in RA, 721
- Lumbar spine, 201
- Lumbar spine radiographs, interpretation of, 1066
- Lung, penicillamine and, in scleroderma, 882
- Lung biopsy, in D-penicillamine-associated bronchiolitis obliterans, 95
- Lung cancer, pulmonary fibrosis and, in systemic sclerosis, 1336
- Lupus; *see also* Cutaneous lupus erythematosus; Discoid lupus; Lupus erythematosus; Neonatal lupus; Systemic lupus erythematosus
 - murine, model for human autoimmunity, 1081
 - pregnancy, 58
- Lupus anticoagulant
 - aortic arch syndrome, anticardiolipin antibodies and, 594
 - in lupus-like syndromes, 67
 - pregnancy and, 58
 - pulmonary hypertension, chronic cutaneous LE and, 118
- Lupus erythematosus
 - CNS, basal ganglia calcifications in, 1412
 - drug-induced, antihistone antibodies in, 158
 - neonatal, in a fraternal twin, 271

Lupus erythematosus (*cont'd*)
 subacute cutaneous, 571
 Lupus-like syndromes, lupus anticoagulant and, 67
 Lupus-prone mice, plasma renin activity and, 599
 Lupus transverse myelitis, vertebral fractures, spinal cord compression and, 1387
 Lupus vasculitis, lupus anticoagulant and, 67
 Luteinizing hormone, in gout, 127
 Lyme arthritis, possibility of, in Rochester, MN, 239
 Lymphadenopathy, immunoblastic, SF lymphocytes in polyarthritis of, 120
 Lymphoblasts, HLA-DR+ T cells in RA and, 8
 Lymphocyte-induced angiogenesis, scleroderma and, 1133
 Lymphocyte staining, antibodies in SLE and, 44
 Lymphocyte transformation, cellular immunity in scleroderma and, 775
 Lymphocyte typing, in Still's disease, 477
 Lymphocytes
 in adjuvant arthritis, 537
 in polyarthritis of immunoblastic lymphadenopathy, 120
 quantitation of Sm nuclear antigen in, 294
 RA, killer cells and AMLR in, 731
 in Reiter's syndrome, 478
 RF synthesis suppression in RA and, 873
 synovial, in RA, 863
 T, in experimental arthritis, 841
 T1+ B cells in RA and, 971
 Lymphocytic infiltration, IL-2, γ -interferon and, in RA, 174
 Lymphocytic leukemia, chronic, T1+ B cells and, in RA, 971
 Lymphocytotoxins, brain cross-reactive, antineuronal antibodies and, in SLE, 789
 Lymphoid cells, Ig, rheumatoid factor and, in rheumatoid pericardium, 1071
 Lymphoid tissue, Sm content, DNA and, 294
 Lymphokine-stimulated cytotoxicity, gold sodium thiomalate and, 1384
 Lymphokines, modulation of scleroderma fibroblasts by, 502
 Lymphotropic viruses, human T, antibodies to, rheumatic diseases and, 1170
 Lysosomes, chondrocytes in articular cartilage of aged ICR mice and, 1027

M

Macrophage-like synovial cells, T lymphocytes, rheumatoid adherent cells and, 863
 Macrophages
 arteritis in mice after *L casei* injection in, 652
 γ -interferon and, in RA, 174
 gold sodium thiomalate and, 1384
 procainamide, immunoglobulin synthesis and, 276
 synovial fluid fibronectin in RA and, 601
 Macroscopic synovitis, 977
 Macular corneal dystrophy, lack of keratan sulfate in, 1367
 Magnesium, in inflammatory connective tissue disease, 169
 Malakoplakia, renal, SLE and, 237

Malignancy
 in polymyositis/dermatomyositis, 249
 reflex sympathetic dystrophy and, 1079
 systemic sclerosis and, 1336
 Mandibular condylar cartilage, in ICR mice, 1027
 Mandibular condyle
 human, articular cartilage in aged ICR mice and, 1027
 of ICR mice, cartilage surface charge and, 660
 Mandibular joint, human, OA in, mouse model for, 1027
 Manometric studies, nifedipine and esophageal dysfunction in PSS, 490
 Mechanical force, cartilage response to, in chondrocytes, 419
 Medical Research Education Subcommittee, ARA, rheumatology training in residency programs, 471
 Medicare, diagnosis-related group-based reimbursement from, 836
 Medication, patient education about, in RA, 300
 Mefenamic acid, utilization of, 686
 Meningitis, in (NZB \times NZW) F_1 mice, ibuprofen and, 104
 Meningococcemia, presenting as septic arthritis and tenosynovitis, 576
 Menopause
 bone fractures, prednisone and, 361
 effect of glucocorticoid on bone mass in RA and, 369
 Mesenchymal cells, synovial cell proliferation in MRL/l arthritis and, 529
 Metabolic abnormalities
 in erosive azotemic osteoarthropathy, 1075
 low plasma renin activity in MRL/Mp-lpr/lpr mice, 599
 Metalloproteoglycan-degrading enzymes, in RA cartilage, 405
 Metaphyseal mass, after prednisone treatment, 361
 Metaphysis, salicylates, indomethacin and, in OA, 548
 Methicillin-resistant *Staphylococcus aureus*, in nongonococcal septic arthritis, 210
 Methotrexate,
 low-dose oral pulse, in RA, 721
 in refractory inflammatory myositis, 590
 Methylprednisolone acetate suspension, hyaluronic acid synthesis and, 1275
 Mi-2, purification of, 798
 Microangiopathic hemolytic anemia, in pregnancy in C2-deficient SLE, 341
 Microfilaments, antibodies to, in connective tissue disease, 889
 Microscopic synovitis, 977
 Midbody of mitotic cells, antibodies to, 889
 Miller-Fisher syndrome, during gold treatment in RA, 838
 Mineralization of articular cartilage in aged ICR mice, 1027
 Mitogen-activated blasts, OKT4+ and OKT8+ cells in SLE and, 262
 Mitogenic response, L-canavanine in SLE and, 52
 Mitogens, interleukin-1 and, 853
 Mitogen-stimulated normal human mononuclear cells, lymphokines, collagen production and, 502
 Mitotic cells, IgG antibodies in CREST syndrome and, 889

- Mixed connective tissue disease
angiographic findings in, 768
antihistone antibodies in, 285
- Mixed lymphocyte reaction
autologous, in adjuvant arthritis, 537
rheumatoid adherent cells and, 863
- Mobility, health status measurement and, 542
- Monarticular arthritis, blastomycosis presenting as, 516
- Monoclonal antibodies
natural killer cells and in Sjögren's syndrome, 182
procainamide and, 276
rheumatic fever-associated B cell alloantigens and, 1047
in SLE, 44
- Monoclonal rheumatoid factor, synthesis of, antiidiotypic antibody in RA and, 873
- Monocytes
fibronectin in human synovium and, 1016
gold sodium thiomalate and, 1384
interleukin-1, inflammation and, 1039
suppressor, impaired B cell proliferation in SLE and, 1008
synovial fluid fibronectin in RA and, 601
- Monocytic arthritis, acute, echovirus type 11 in, 98
- Monocytosis, knee synovitis and, 98
- Mononuclear cell supernates, substrain heterogeneity in PGE₂ synthesis and, 315
- Mononuclear cells
angiogenesis in scleroderma and, 1133
glycosaminoglycan synthesis and, 188
human, lymphokine modulation of PSS fibroblasts and, 502
inflammatory, in MRL/l arthritis, 529
normal, collagen biosynthesis, scleroderma fibroblasts and, 496
peripheral blood, cellular immunity and in scleroderma, 775
NK cell function and, in SLE, 624
RF synthesis, synovial membrane cells and, 742
- Mononuclear inflammatory vascular disease, in Sjögren's syndrome, 1146, 1251, 1341
- Mononuclear pleocytosis, in immunoblastic lymphadenopathy, 120
- Monosodium urate, in synovial fluid of the knee, 1319
- Morbidity
coagulopathy in JRA and, 256
after total lymphoid irradiation in RA, 1205
- Morning stiffness, aerobic exercise in RA and, 36
- Morphea, childhood, eosinophilic fasciitis in a 2-year-old and, 948
- Mortality
in murine SLE, 1082
in polymyositis/dermatomyositis, 249
after total lymphoid irradiation in RA, 1205
- Motrin, coexistent RA and gout and, 238
- Mouse studies; *see also* Balb/c mice; C3Heb/FeJ mice; C3H/HeJ mice; C57BL/6 mice; ICR mice; Lupus-prone mice; MRL/Mp autoimmune mice; MRL/Mp-+/+ mice; MRL/Mp-lpr/lpr mice; Murine; (NZB × NZW)F₁ mice
- Mouse studies (*cont'd*)
anti-Sm antibodies in SLE, 294
articular cartilage in temporomandibular joint of mice, 1027
coronary arteritis, 652
L-canavanine in autoimmune phenomena, 1198
rheumatic fever-associated B cell alloantigens, 1047
- Mouse thymocytes, IL-1, mononuclear cells, GAG synthesis and, in PSS, 188
- Mouth inspiratory pressure, in SLE, 781
- Mouth ulcers, in Behçet's disease, 671
- MRL/l arthritis, inflammation in, 529
- MRL/l mice, RA-like disease in, 1087
- MRL/Mp autoimmune mice, inflammatory vascular disease in, 1146
- MRL/Mp-+/+ mice, inflammatory vascular disease in, 1146
- MRL/Mp-lpr/lpr mice
inflammatory vascular disease in, 1146
low plasma renin activity in, 599
- Multicentric reticulohistiocytosis, cause of dysphagia, treated with corticosteroids, 231
- Murine antigen-induced arthritis, cartilage proteoglycan synthesis, chondrocyte death and, 813
- Murine articular cartilage, salicylates, GAG synthesis and, 922
- Murine hybridoma clones, rheumatic fever B cell alloantigen marker and, 1048
- Murine lupus, model for human autoimmunity, 1081
- Murine patellar cartilage, salicylates, GAG synthesis and, 922
- Murine SLE, human T cell leukemia virus and, 481
- Murine spleen studies, T and B cell mitogens, Sm antigen and, 294
- Muscle, in polymyositis/dermatomyositis, 249, 630
- Muscle biopsy, in sporotrichal arthritis, 1425
- Muscle dysfunction, in SLE, 781
- Musculoskeletal disease, referral of patients with, 1156
- Musculoskeletal involvement, in juvenile primary fibromyalgia syndrome, 138
- Musculoskeletal pain, tender point count and, 479
- Myalgia, myoadenylate deaminase deficiency and, 1298
- Myelitis, lupus transverse, complications mimicking, 1307
- Myeloperoxidase, thiol-containing drugs and, 1228
- Myoadenylate deaminase deficiency, progressive myalgia, polyarthralgia and, 1298
- Myocardial disease, primary scleroderma, decreased coronary reserve in, 637
- Myocardial infarction, in ANA-negative SLE, 1185
- Myocarditis, in adult Still's disease, 452
- Myofibroblasts, granulation tissue, fibronexus and, in RA, 1105
- Myositis
antibodies to Mi and, 796
cricopharyngeal obstruction as cause of dysphagia in, 630
granulomatous, sporotrichal arthritis presenting as, 1425
inflammatory, steroids, chlorambucil, and methotrexate in, 590

Myositis (cont'd)

- total body irradiation in, 831
- Myositis-specific Jo-1 antigen, histidyl-tRNA synthetase and, 839
- Myristyl-gamma-picrolinium chloride, hyaluronic acid synthesis by corticosteroids and, 1275

N

- Nailfold capillary abnormalities, in systemic sclerosis, 496
- Nailfold capillary patterns, in mixed connective tissue disease, 769
- Native DNA
 - acetylator phenotype in SLE and, 995
 - IgG antibodies to, in SLE, 431
- Native DNA antibodies, *Crithidia luciliae* kinetoplasts and, 163
- Natural killer cells
 - circulating, in Sjögren's syndrome, 182
 - impaired, in the AMLR in RA, 731
 - in SLE, 624
- Neck pain, acute, due to calcifications, 1417
- Necrotizing vasculitis, systemic, SLE and, 620
- Neonatal lupus erythematosus; *see also* Cutaneous lupus erythematosus; Discoid lupus; Lupus; Systemic lupus erythematosus
 - in one fraternal twin, 271
- Neoplasms, malignant, systemic sclerosis and, 1336
- Nephropathies, nonamyloid, in synovial amyloidosis, 1052
- Nephrotic syndrome, tiopronin-induced, HLA-DR3 antigen and, 595
- Nervous system involvement, in inflammatory vascular disease in Sjögren's syndrome, 1341
- Neuraminidase, surface charge in aging and OA cartilage and, 660
- Neuroblastoma cell line binding, neuropsychiatric SLE and, 789
- Neurologic involvement, lupus anticoagulant and, 67
- Neurologic/traumatic lesions, sparing of extremities from rheumatic diseases after, 705
- Neuronal cell binding antibodies, in neuropsychiatric SLE, 789
- Neuropsychiatric SLE, antineuronal antibodies in, 789
- Neurovascular dystrophy, reflex, in childhood, 952
- Neutral metalloproteoglycan-degrading enzyme activity, cartilage degradation in experimental OA and, 1393
- Neutral proteoglycan degradation, in human RA cartilage, 405
- Neutral proteoglycan or proteoglycanase, cartilage degradation in experimental OA and, 1393
- Neutrophil aggregation, leukergy test in rheumatic diseases and, 899
- Neutrophilic inflammatory vascular disease, in Sjögren's syndrome, 1146, 1251, 1341
- Neutrophils, synovial fluid, iodide clearance and, in RA, 1096
- New Zealand white rabbits, *Escherichia coli*-induced chronic arthritis in, 522

Nifedipine, esophageal dysfunction in PSS and, 490

Nodules

- benign, rheumatoid, of childhood, chronic arthritis after, 1175
- rheumatoid, methotrexate and, 721
- subcutaneous, in elderly-onset RA, 987
- Nongonococcal septic arthritis, drug abuse and methicillin-resistant *S aureus* in, 210
- Nonsteroidal antiinflammatory drugs (NSAID)
 - coexistent RA and gout and, 238
 - FDA and, 450
 - ineffective therapy, referral of patients after, 1156
 - postmarketing surveillance of, 1168
 - primary chronic uveitis and, 1317
 - T cells, EBV-induced B cells and, in RA, 961
 - utilization of, 686
- 19 Nortestosterone, murine lupus and, 121
- Nuclear antigens
 - in juvenile dermatomyositis, 151
 - Sm, quantitation of, 294
- Nuclear ribonucleoprotein (RNP), Sm antigen and, 294
- Nucleolar localization of PM-Scl antigen, 226
- Nucleoside triphosphate pyrophosphohydrolase, cartilage, inorganic pyrophosphate and, 413
- Nucleotide metabolism, cartilage nucleoside triphosphate pyrophosphohydrolase and, 413
- Nucleotide pyrophosphohydrolase, in synovial fluid, 1377
- Nurses, patient education in RA and, 304
- Nutrition and nutritionists, patient education in RA and, 300
- (NZB × NZW)_F1 mice, ibuprofen and meningitis in, 104

O

- Obesity, ibuprofen and, 1117
- Occlusive vascular phenomena, in ANA-negative SLE, 1185
- Occupational therapists, patient education in RA and, 304
- Occupational therapy, charges for, 204
- Ocular involvement, in Behçet's disease, 671
- Odontoid process, acute neck pain due to calcifications and, 1417
- OKT4, OKT8 cells
 - IL-2 and, in RA, 174
 - in SLE, 262
- OKT4, OKT8 monoclonal antibodies, procainamide and, 276
- OKT4:OKT8 ratios, methylprednisolone pulse therapy in rheumatic disease and, 477
- Oncornaviruses, type C, human T cell leukemia virus in SLE and, 481
- Ophthalmoplegia, in Guillain-Barré syndrome, after gold therapy in RA, 838
- Oral gold, in RA with preexisting uremia, 710
- Oral prednisone and cyclophosphamide, effect of on D-penicillamine-associated bronchiolitis obliterans, 93
- Organ involvement
 - in SLE, 905
 - in systemic sclerosis, 496

Orosomucoid studies, in giant cell arteritis and polymyalgia rheumatica, 837

Orthopedic surgeons, patterns of referral of patients with musculoskeletal disease to, 1156

Osteoarthritic articular cartilage
human femoral head, biomechanics of, 521 (erratum)
in temporomandibular joint in mice, 1027

Osteoarthritic cartilage
intact, with normal proteoglycan extraction, 323
proteoglycan depletion, salicylates, indomethacin and, 548

Osteoarthritis
adenosine triphosphate pyrophosphohydrolase in, 1283
autoantibodies of IC in articular cartilage in, 241
cartilage surface charge in, 660
chronic knee effusions in, 441
clinical characteristics of, 513
clinical features of synovial effusions in, 442
education about, for primary care practitioners, 108
experimental, cartilage degradation by neutral PG in, 1393
interleukin-1 release from synovium and, 855
iodide clearance in knee effusions in, 1096
keratan sulfate as marker of cartilage catabolism and, 1367
patterns of referrals of patients with, 1156
periarticular osteoporosis in RA and, 25
stress-induced proteins in chondrocytes in, 1140
synovial fluid ATPPPH in, 1377
synovial fluid crystals in, 511
synovial inflammation in cartilage of Pond-Nuki dog in, 554

Osteoarthropathy
erosive azotemic, amyloidosis and, 1075
hypertrophic pulmonary, 571

Osteoclasts, periarticular osteoporosis in RA and, 25

Osteopenia
glucocorticoid-induced, in rheumatic diseases, 361
hand, 1180

Osteophytes, chemically induced articular cartilage damage and, 1267

Osteoporosis, periarticular, in RA, 25

Oxygen intermediates, generation of, by thalidomide in RA, 836

Oxygen uptake (aerobic capacity), exercise in RA and, 35

Oxyphenbutazone
FDA and, 450
utilization of, 686

P

Pain

abdominal, in *Salmonella* bacteremia in SLE, 75

aerobic exercises in RA and, 35

back, inflammatory, in HLA-B27 positive AS relatives, 40

health status measurement and, 542

joint, aerobic exercise in RA and, 32

neck, acute, due to calcifications, 1417

self-help patient education and, 680

Pain (cont'd)

thoracic, HLA-B27 positive ankylosing spondylitis and, 40

Pain assessment, by patients, in hand ulcers in systemic sclerosis, 308

Pancytopenia, methotrexate and in RA, 721

Panhypogammaglobulinemia
with recurrent pyogenic infections, SLE and, 462
SLE and, 100

Pannus
cartilage destruction in RA and, 1192
E coli-induced chronic polyarthritis in rabbits and, 524
in RA, 1192, 1193, 1195, 1197

Pannus formation
fibronexus and, in RA, 1105
rheumatoid, chondrocytes and, 1193

Pan-T antibodies, in SLE, 44

Papain, proteoglycan phosphorylation and, 804

Paralysis, psoriatic polyarthritis and, 703

Paresthesias, in primary juvenile fibromyalgia syndrome, 138

Patellar cartilage
murine, salicylates, GAG synthesis and, 922
proteoglycan extraction from, 323

Patient education
assessing physician/patient perceptions in RA, 300
in RA, 1289
self-help education, 680

Patient outcome, physician continuing medical education and, 1163

Patient pain assessment, hand ulcers in systemic sclerosis and, 308

Pauciarticular JRA, sex ratio and sibship size in kindreds, 753

Pelvis, bone crisis in Gaucher's disease and, 218

Penicillamine; *see also* D-penicillamine
bones in RA and, 369
hydrogen peroxide and, 914
in juvenile chronic arthritis, 376
myeloperoxidase and, 1228
pulmonary function in scleroderma and, 882

Pepsin agglutinator, F(ab')₂ fragments and, 562

Pepsinogen, in Sjögren's syndrome, 388

Peptides
chondroitin sulfate, proteoglycan phosphorylation and, 804
synovial fluid fibronectin in RA and, 601

Peptidoglycan-polysaccharide fragments, streptococcal cell wall-induced arthritis and, 1402

Periarticular osteoporosis, in RA, 25

Pericarditis, meningococemia and, 576

Peripheral blood B cells, impaired proliferation of by *Staphylococcus aureus* Cowan 1 in SLE, 1008

Peripheral blood lymphocytes, circulating NK cells in in Sjögren's syndrome, 182

Peripheral blood mononuclear cells
anti-DNA and anti-RNA production in SLE and, 431

- Peripheral blood mononuclear cells (*cont'd*)
 cellular immunity and, in scleroderma, 775
 natural killer cell function and, in SLE, 624
 in Reiter's syndrome, 478
 RF synthesis in RA synovial membrane cells and, 742
- Peripheral inflammatory vascular disease in Sjögren's syndrome, 1341
- Peroxidase activity, gold sodium thiomalate and, 1384
- Phagocytosis
 crystal, in OA, 511
 polymorphonuclear cells and, in RA and Felty's syndrome, 395
- Pharmacists, patient education in RA and, 300
- Phenotypes
 adherent cells in RA and, 863
 Gm and Km, in SLE, 828
 T1+ B cells and in RA, 971
- Phenylbutazone, 450, 686
- Phorbol myristate acetate, substrain heterogeneity in PGE₂ synthesis and, 315
- Phorbol myristate acetate-stimulated superoxide production, gold sodium thiomalate and, 1384
- Phosphatase, articular cartilage in aged ICR mice and, 1027
- Phosphate, chondroitin sulfate, proteoglycan phosphorylation and, 804
- Phospholipase, substrain heterogeneity in PGE₂ synthesis and, 315
- Phospholipids, pulmonary hypertension, cutaneous LE, lupus anticoagulant and, 118
- Phosphopeptides, proteoglycan phosphorylation and, 804
- Photosensitivity, in a fraternal twin with neonatal LE, 271
- Physical therapist, patient education in RA and, 304
- Physical therapy, charges for, 204
- Physician/patient communication, patient education about, in RA, 300
- Physician/patient interaction, after continuing medical education, 1163
- Physician/patient perception assessment in RA, 300
- Physicians
 patient education in RA and, 300
 self-help patient education and, 680
- Phytohemagglutinin
 cellular immunity and, in scleroderma, 775
 L-canavanine in SLE and, 52
- Phytohemagglutinin-activated peripheral T cells, in SLE, 262
- Phytohemagglutinin-stimulated mononuclear cells, collagen production by scleroderma fibroblasts and, 502
- Plasma follicle-stimulating hormone levels, in gout, 127
- Plasma renin activity, in lupus-prone mice, 599
- Platelet counts, in SLE pregnancies, 60
- Platelet factor 4, in JRA, 256
- Platelet-secreted protein, in JRA, 256
- Pleocytosis, mononuclear, in immunoblastic lymphadenopathy, 120
- PM-Scl antigen, nucleolar localization of, 226
- POEMS syndrome, 719
- Pokeweed mitogen-stimulated cells, procainamide and, 276
- Pokeweed mitogens, L-canavanine in SLE and, 52
- Poliomyelitis, psoriatic arthritis and, 703
- Polyarthralgia, myoadenylate deaminase deficiency and, 1298
- Polyarthritis
 chronic, *Escherichia coli*-induced, 522
 fasciitis and, during antituberculosis therapy, 1179
 of immunoblastic lymphadenopathy, SF lymphocytes and, 120
 inflammatory, in Down's syndrome, 598
 in malignant fibrous histiocytoma of the heart, 944
 RA-like, adenovirus type 1 infection in, 455
 seronegative, in giant cell arteritis, 1362
 undiagnosed, referrals of patients with, 1156
- Polyarticular gout, acute, endogenous pyrogen (IL-1) in, 1039
- Polyarticular JRA
 intravascular coagulation and, 256
 sex ratio and sibship size in kindreds, 753
- Polycationic labels, surface charge in aging and OA cartilage and, 660
- Polyclonal IgM rheumatoid factor, cross-specificity of, in RA, 875
- Polyethylene glycol
 avidity antibodies to dsDNA in SLE and, 425
 non-complement-activating immune complexes and, 222
- Polymorphonuclear cells
 inflammatory, in MRL/I arthritis, 529
 in RA and Felty's syndrome, 395
- Polymyalgia rheumatica
 giant cell arteritis and cyclosporine in, 1078
 initial clinical presentation of, elderly-onset RA and, 987
 serum C-reactive protein in, 383
 tests for, 837
- Polymyositis; see also Dermatomyositis
 antibodies to Mi in, 796
 dysphagia in, 630
 intractable, cyclosporine in, 1436
 total body irradiation in, 828
- Polymyositis/dermatomyositis
 antibodies to intermediate filaments in, 889
 prognostic factors in, 249
 rash in, 249
- Polynuropathy, familial, HLA system and, 1188
- Polypeptides, endogenous pyrogen (interleukin-1), 1039
- Polysorbate 80, hyaluronic acid synthesis by corticosteroids and, 1275
- Polysynovitis, immunoblastic lymphadenopathy and, 120
- Pond-Nuki dog model, synovial inflammation in cartilage in OA, 554
- Popliteal cysts
 anterior tibial mass and, 477
 intraarticular volume in, in RA and OA, 444
- Porcine synoviocytes, in RA, 1105

- Postgastrectomy blind loop syndrome, arthritis-dermatitis syndrome and, 214
- Postmarketing surveillance of NSAID
- Post-traumatic chylous joint effusions, 1303
- Post-traumatic knee pain, patterns of referrals of patients with, 1156
- Potassium hydroxide, in blastomycotic arthritis, 516
- Prednisolone
- cartilage degradation in experimental OA and, 1393
 - in cricopharyngeal obstruction in inflammatory myopathy, 630
 - D-penicillamine-associated bronchiolitis obliterans and, 93
 - impaired B cell proliferation in SLE and, 1008
 - osteopenia and, 361
 - in polymyalgia rheumatica, 383
 - in synovial inflammation in Pond-Nuki dog model of OA, 554
- Pregnancy
- onset of adult-onset Still's disease during, 957
 - sex steroid metabolism and, 121
 - in SLE, 58
 - systemic sclerosis and, 237
 - thrombocytopenic purpura in C2-deficient SLE and, 341
- Premature infants, SLE in, 573
- Pressure erosions, bone resorption in RA and, 820
- Primary care practitioners
- continuing medical education in rheumatology for, 1163
 - educational program, management of OA, 108
- Primary chronic uveitis, NSAIDs in, 1317
- Primary fibromyalgia syndrome
- juvenile, 138
 - psychological factors in, 145 (erratum)
- Primary fibrositis syndrome, immunofluorescence and, 836
- Primary Raynaud's phenomenon, connective tissue disease and, 87
- Primary scleroderma myocardial disease, decreased coronary reserve in, 637
- Primary sicca syndrome, antihistone antibodies and, 285
- Procainamide
- antihistone antibodies and, in drug-induced LE, 158
 - effect of, on immunoglobulin synthesis, 276
- Procollagen I, aminopropeptide of, collagen synthesis in scleroderma and, 647
- Progesterone, in gout, 127
- Progressive systemic sclerosis; *see also* Scleroderma; Systemic sclerosis
- cardiac dysrhythmias in, 1259
 - clinical features of, 504, 1260
 - juvenile, 699
 - lymphocyte-induced angiogenesis and, 1133
 - mononuclear cells and glycosaminoglycan synthesis in, 188
 - nifedipine and esophageal dysfunction in, 490
 - wrist drop in, 586
- Pronase, surface charge in aging and OA cartilage and, 660
- Prostaglandin E₂, synoviocytes and, in RA, 1107
- Prostaglandin E₂
- interleukin-1 and, 853
 - rheumatoid adherent cells and, 863
 - synoviocytes and, in RA, 1105
- Prostaglandin E₂ synthesis, substrain heterogeneity in, 315
- Protease
- cartilage degradation in experimental OA and, 1398
 - RA cartilage, PG degradation, antirheumatic drugs and, 405
- Protein
- acute-phase, interleukin-1 and, 853
 - complement, in rheumatic diseases, 1090
 - endothelial cell in JRA, 256
 - noncollagenous, collagen production, lymphokines and, 502
 - phosphorylation of proteoglycans and, 804
 - platelet-secreted, 256
 - small nuclear RNP, 1348
 - SP-70, in chondrocytes in OA, 1140
 - stress-induced, in chondrocytes in OA, 1140
 - synovial fluid fibronectin in RA and, 601
 - type C-related, human T cell leukemia virus in SLE and, 481
- Protein binding, ibuprofen, renal insufficiency, hemodialysis and, 1430
- Proteinaceous matrix, cartilage surface charge and, 660
- Protein-losing enteropathy, in SLE, 1059
- Proteinuria, pregnancy in SLE and, 58
- Proteoglycan degradation, neutral, human RA cartilage and, 405
- Proteoglycan depletion, salicylates, indomethacin, OA cartilage and, 548
- Proteoglycan synthesis
- cartilage, murine antigen-induced arthritis and, 813
 - cartilage response to force in chondrocytes and, 419
- Proteoglycanase, neutral, cartilage degradation in experimental OA and, 1393
- Proteoglycans
- chondrocytes and, in chondrocalcinosis, 118
 - extraction of, from human cartilage, 323
 - keratan sulfate-containing, cartilage and, 1367
 - in mandibular condylar cartilage in ICR mice, 1027
 - phosphorylation of, 804
 - salicylates, indomethacin and, in OA, 548
- Protrusion acetabuli, 820
- Pseudogout, adenosine triphosphate pyrophosphohydrolase in, 1283
- Psoriasis, joint involvement in, 959
- Psoriatic arthritis, protective effect of poliomyelitis on, 703
- Psychogenic rheumatism, fibrositis and, 1435
- Psychological factors
- in fibrositis, 132
 - in juvenile primary fibromyalgia syndrome, 138
 - primary fibromyalgia syndrome and, 145 (erratum)
- Psychological tests, fibrositis and, 132

Psychosocial problems, patient education about, in RA, 300
 PTK2 cells, in connective tissue disease, 889
 Pulmonary fibrosis, lung cancer and, in systemic sclerosis, 1336
 Pulmonary function
 in D-penicillamine-associated bronchiolitis obliterans, 94
 penicillamine and in scleroderma, 882
 in systemic sclerosis, 759
 Pulmonary hypertension, chronic cutaneous LE, lupus anticoagulant and, 118
 Pulmonary involvement
 in progressive systemic sclerosis, 759, 1264
 in Raynaud's disease, 87
 Pulmonary osteoarthropathy, 571
 Pure red cell aplasia, in SLE, 1059
 Purine biosynthesis, 17 beta-estradiol in, 127
 Purpura, thrombotic thrombocytopenic, in pregnancy in SLE, 341
 Purpura fulminans, in JRA, 256
 Pyrophosphatase, inorganic, neutral, in pathologic joint fluids, 1283
 Pyrophosphate
 cartilage nucleoside triphosphate pyrophosphohydrolase and, 413
 chondrocytes, PG and, in chondrocalcinosis, 118
 inorganic, in cartilage, 413
 Pyrophosphohydrolase, cartilage nucleoside triphosphate, 413

Q

Quackery, patient education about, in RA, 300
 Quantitative sacroiliac scintigraphy, computed tomography and, in early ankylosing spondylitis, 930

R

Rabbit studies; *see also* Japanese white rabbits; New Zealand white rabbits
 Escherichia coli-induced chronic polyarthritis, 522
 Radiography
 compared with computed tomography in early AS, 930
 interpretation of lumbar spine radiographs, 1066
 Radio-labeled albumin (RISA) clearance, in synovial effusions in RA and OA, 441
 Radiologic abnormalities
 in hands and wrists in RA, 16
 tarsal coalition, 331
 Rat studies; *see also* Fisher 344 rats
 autologous mixed lymphocyte reaction in adjuvant arthritis, 537
 bacterial cell wall-induced arthritis, 1318
 testosterone in adjuvant arthritis, 959
 Raynaud's phenomenon
 fingers in, 1317
 IgG antibodies in, 889
 lymphocyte-induced angiogenesis and, 1133
 primary, connective tissue disease and, 87

Raynaud's phenomenon (*cont'd*)
 of single digit, after local intradermal bleomycin sulfate, 459
 SLE and, 620
 Red cell aplasia, in SLE, 1059
 Reflex neurovascular dystrophy, childhood, 952
 Reflex sympathetic dystrophy, malignancy and, 1079
 Regurgitation, aortic, in giant cell arteritis, 582
 Reiter's syndrome, peripheral blood mononuclear cells in, 478
 Renal abnormalities, thrombotic thrombocytopenic purpura in SLE and, 341
 Renal biopsy, tiopronin-induced nephrotic syndrome in RA and, 595
 Renal disease, lupus anticoagulant and, 67
 Renal function
 in inflammatory vascular disease in MRL/Mp mice, 1152
 NSAID and, 450
 Renal insufficiency, ibuprofen, maintenance hemodialysis and, 1430
 Renal malakoplakia, SLE and, 237
 Renal toxicity, cyclosporine and, in Behçet's disease, 671
 Reticulohistiocytosis, multicentric, dysphagia treated with corticosteroids and, 231
 Retinal artery occlusion, in ANA-negative SLE, 1185
 Rheumatic diseases
 16 alpha-hydroxyestrone in, 1122
 antibodies to human T lymphotropic viruses and, 1170
 atrophic gastritis and, 388
 diagnosis-related group-based reimbursement for, 846
 glucocorticoid-induced osteopenia in, 361
 leukery test in, 899
 sex steroids and, 121
 steroid pulse, T cells and, 477
 Rheumatic fever-associated B cell alloantigens, identification of by monoclonal antibodies, 1047
 Rheumatism, psychogenic, fibrositis, 1435
 Rheumatoid adherent cells, T lymphocyte proliferation and, 863
 Rheumatoid arthritis
 actin cytoskeleton of porcine synoviocytes in, 1105
 adenosine triphosphate pyrophosphohydrolase in, 1283
 adherent cells in, 863
 adult-onset, apophyseal joint ankylosis in, 958
 anemia and methotrexate in, 721
 angiotensin converting enzyme inhibitors and, 480
 antibodies to intermediate filaments in, 889
 assessing physician/patient perceptions in, 300
 auranofin in, 1211
 autoantibodies of immune complexes in cartilage of, 241
 bone resorption in, 820
 calcium in, 169
 cartilage destruction in, 1192
 cartilage in, human, antirheumatic drugs and, 405
 chondrocalcinosis in, 717
 chronic knee effusions in, 441

Rheumatoid arthritis (*cont'd*)

- clinical characteristics of, 725, 966, 971, 987, 1206
- clinical features of synovial effusions in, 442
- complement C3 anaphylatoxin in synovial fluid in, 1089
- computed tomography of hindfoot in, 1234
- corticosteroids in, 961
- cost of, 204
- CPPD crystal deposition in, 717
- Crithidia luciliae* kinetoplasts in, 163
- diagnosis-related group-based reimbursement for, 846
- disease activity and methotrexate in, 721
- disease duration in, 961
- disease severity in, 961
- E coli*-induced chronic polyarthritis in rabbits and, 522
- effect of glucocorticoids on bone mass and, 369
- elderly-onset, clinical features of, 987
- Epstein-Barr antibodies in, 339
- Epstein-Barr virus in, 961
- erythrocyte sedimentation rate and, in RA, 721
- etiopathogenesis of similar disease in MRL/l mice, 529
- extracellular matrix-cytoskeletal interactions in, 1105
- fibronectin in synovium in, 1016
- fibronectin-containing extracellular matrix in, 1105
- γ -interferon in, 174
- gold concentrations in blood in, 1211
- gold sodium thiomalate in, 1121, 1384
- gold toxicity and HLA-Bw35 in, 236
- gout coexistent with, 238
- hand in, 1326
- HLA-Bw35 and gold toxicity in, 236
- HLA-DR+ T cells in, 8
- human, MRL/l arthritis and, 529
- IgG anti-F(ab')₂ antibodies in, 562
- IgM and IgM-RF production during chrysotherapy in, 356
- immunohistologic patterns of synovitis and, 977
- immunologic assessment after TLI in, 1205
- impaired killer cells and AMLR in, 731
- interleukin-1 and synoviocytes in, 1105
- interleukin-2 in, 174, 1318
- iodide clearance in knee effusions in, 1096
- joint count indices in, 613
- joint erosions in, 1326
- joint narrowing in, 1326
- joints and methotrexate in, 721
- liver enzymes and methotrexate in, 721
- low molecular weight IgM in, 112
- magnesium in, 169
- methotrexate in, 721
- Miller-Fisher syndrome after gold in, 838
- nodules and methotrexate in, 721
- pancytopenia and methotrexate in, 721
- pannus and, 1192, 1193, 1195, 1197
- patient education about, 300, 1289
- pattern of referrals of patients with, 1156
- penicillamine in, 914
- periarticular osteoporosis in, 25

Rheumatoid arthritis (*cont'd*)

- phagocytosis and intracellular killing by PMN cells in, 395
- popliteal cyst presenting as anterior tibial mass, 477
- with preexisting uremia, oral gold in, 707
- pressure erosions in, 820
- prostaglandin E₂ and, 1105
- radiologic abnormalities of hand and wrist in, 16
- refractory, total lymphoid irradiation in, 1205
- rheumatoid factor in development of, 485
- rheumatoid factor and methotrexate in, 721
- rheumatoid factor synthesis in synovial membrane cells in, 742
- rheumatoid pericardium in, Ig and rheumatoid factor in, 1071
- seronegative, RF synthesis in synovial membrane cells and, 742
- seropositive, IgA rheumatoid factor synthesis and, 1219
- serum C1q in, 240
- sex steroids and, 121
- slow-acting therapeutic agents in, 961
- suppression of RF synthesis by antiidiotypic antibody in, 873
- synovial fluid fibronectin in, 601
- synovial lymphocytes in, 863
- synoviocytes in, 1105
- T cells and Epstein-Barr virus-induced B cells in, 961
- T helper lymphocytes in, 863
- T1+ B cell subsets in, 971
- thalidomide in, 836
- thiol-containing drugs in, 1228
- tiopronin-induced nephrotic syndrome, HLA-DR3 antigen and, 595
- tissue hypoperfusion in, 1096
- vasculitis in, antihistone antibodies and, 285
- Rheumatoid arthritis T cells, autologous mixed leukocyte reaction and, 731
- Rheumatoid arthritis-like disease, in MRL/l mice, 529, 1087
- Rheumatoid arthritis-like polyarthritis, chronic with immunodeficiency, adenovirus type 1 infection in, 455
- Rheumatoid disease, rheumatoid factor in development of, 485
- Rheumatoid effusions, intraarticular volume and clearance in, 441
- Rheumatoid factor
 - circulating, in MRL/l mice, 529
 - development of RA and, 485
 - in elderly-onset RA, 987
 - IgA, IgM rheumatoid factor synthesis and, 1219
 - IgG; *see* IgG rheumatoid factor
 - IgM; *see* IgM rheumatoid factor
 - lack of in polyarticular JRA, 256
 - methotrexate and, in RA, 721
 - monoclonal, antiidiotypic antibody in RA and, 873
 - murine SLE and, 1081
 - polyclonal IgM, cross-specificity of, 875
 - in rheumatoid pericardium, 1071

Rheumatoid factor (*cont'd*)
 T1+ B cells in RA and, 971
 Rheumatoid factor synthesis
 antiidiotypic antibody suppression of, in RA, 873
 IgG and IgM, RA synovial membrane cells and, 742
 Rheumatoid nodules
 benign, childhood, chronic arthritis after, 1175
 methotrexate and, 721
 Rheumatoid pannus
 cellular heterogeneity in, 1197
 chondrocytes and formation of, 193
 Rheumatoid pericardium, immunoglobulin and rheumatoid factor in, 1071
 Rheumatoid synovitis, chronic, iodide and hypoperfusion in, 1096
 Rheumatoid synovium, fibronectin in, 1016
 Rheumatology and rheumatologists
 in the American Rheumatism Association, 1, 1201
 assessing physician/patient perceptions in RA and, 300
 diagnosis-related group regulations and, 204
 diagnosis-related group-based reimbursement in, 846
 early citations about, 1320
 internal medicine and family practice residencies and, 471
 referral of patients with musculoskeletal disease to, 1156
 Rheumatology education
 continuing medical education and, 1163
 osteoarthritis, 108
 Rheumatology practice, 1
 Rheumatology residents, training of, 471
 Rheumatology training, in internal medicine and family practice residencies, 471
 Ribonucleic acid (RNA); *see* Histidyl-tRNA synthetase
 Ribonucleoprotein (RNP) antibodies, detection of, 1356
 Ribonucleoprotein (RNP) reactivity, shifts from Sm to in SLE, 1348
 Ribs, pressure erosions of, 822
 RNA hybridization studies, HLA-DR+ T cells in RA and, 8
 Ro (SS-A) antibody and antigen, in congenital complete heart block, 1321
 Rosette inhibition, antibodies in SLE and, 44
 Rupture, extensor tendon in wrist drop in scleroderma, 586

S

Sacroiliac joint, HLA-B27 positive ankylosing spondylitis and, 40
 Sacroiliitis, computed tomography and, in early ankylosing spondylitis, 930
 Salicylates
 in cartilage, 237
 GAG synthesis in murine articular cartilage and, 922
 proteoglycan depletion in OA and, 548
 Saline, normal, in hand ulcers in systemic sclerosis, 308
 Saliva, in Saxon test for xerostomia, 1128
Salmonella bacteremia in SLE, 75
 Saxon test for xerostomia, 1128

Schirmer test for xerostomia, 1128
 Scintigraphy, quantitative sacroiliac, computed tomography and, in ankylosing spondylitis, 930
 Sclerodactyly, IgG antibodies in, 889
 Scleroderma; *see also* Progressive systemic sclerosis; Systemic sclerosis
 autoantibodies in, in Argentina, 715
 calcium in, 169
 cellular immunity to collagen and laminin in, 775
 clinical features of, 639, 776, 778
 diffuse, 639, 759, 1259
 interleukin-1 in, 1316
 lymphocyte-induced angiogenesis and, 1133
 magnesium in, 169
 penicillamine and pulmonary function in, 882
 pulmonary involvement in, 759
 SLE and, 620
 wrist drop in, 586
 Scleroderma fibroblast collagen, lymphokine modulation of, 502
 Scleroderma fibroblasts, collagen synthesis by aminopeptide of procollagen I and, 647
 Scleroderma myocardial disease, primary, decreased coronary reserve in, 637
 Scleromalacia perforans, 570
 Secondary hyperparathyroidism, erosive azotemic osteoarthropathy, amyloidosis and, 1075
 Seizures, thrombotic thrombocytopenic purpura in SLE and, 341
 Self-help education for arthritis patients, 680
 Septic arthritis
 arthrography in, 198, 835 (erratum)
 meningococcemia and, 576
 nongonococcal, 204
 septic shock and, cause of death after TLI in RA, 1205
 sympathetic synovial effusions in, 941
 Septic disc, 570
 Serine, phosphorylation of proteoglycans and, 804
 Serine protease, antirheumatic drugs and, in RA cartilage, 405
 Seronegative polyarthritis, in giant cell arteritis, 1362
 Seronegative rheumatoid arthritis, RF synthesis in synovial membrane cells and, 742
 Seropositive rheumatoid arthritis
 IgA RF, IgM RF synthesis and, 1219
 popliteal cyst presenting as anterior tibial mass, 477
 rheumatoid factor in development of, 485
 rheumatoid factor synthesis in synovial membrane cells and, 742
 Serum amyloid A protein, antibiotics in Whipple's disease and, 352
 Serum anticentromere antibody, in CREST syndrome, 87
 Serum complement C1q, in RA, 248
 Serum C-reactive protein, in polymyalgia rheumatica, 383
 Sex hormones, in gout, 127

- Sex ratios and sibship size, in JRA kindreds, 753
- Sex steroids, rheumatic diseases and, 121
- Sexuality, patient education about in RA, 300
- Shoulder, *E coli*-induced chronic polyarthritis in rabbits and, 524
- Shoulder tendinitis, referral of patients with, 1156
- Sialic acid residue, cartilage surface charge in aging and, 660
- Sicca syndrome
primary, antihistone antibodies and, 285
in Sjögren's syndrome, 389
- Sickness Impact Profile, 1163, 1293
- Silica crystals, endogenous pyrogen (interleukin-1) and, 1039
- Silicon dioxide, endogenous pyrogen (interleukin-1) and, 1039
- Sjögren's syndrome
atrophic gastritis in, 388
circulating natural killer cells in, 182
Crithidia luciliae kinetoplasts and, 163
diagnosis of, 592
inflammatory vascular disease in, 1146, 1251
peripheral inflammatory vascular disease in, 1341
- Skin
blind loop syndrome, arthritis-dermatitis syndrome and, 214
collagen synthesis in scleroderma and, 647
mononuclear cells, GAG synthesis and in PSS, 188
- Skin disease, in systemic sclerosis, 496
- Skin involvement, anticentromere antibodies and, in CREST syndrome, 759
- Skin lesions
in Behçet's disease, 671
in neonatal LE, 271
- Skin reaction, from DMSO in systemic sclerosis, 308
- Skin thickening
collagen and laminin in scleroderma and, 775
penicillamine and, in scleroderma, 882
- Skin toxicity, topical DMSO in systemic sclerosis and, 308
- Sleep patterns, aerobic exercise in RA and, 36
- Sleep quality, in juvenile primary fibromyalgia syndrome, 138
- Slow-acting therapeutic agents, T cells, EBV-induced B cells and, in RA, 961
- Sm to RNP reactivity shifts in SLE, 1348
- Sm antigen, quantitation of, 294
- Small cytoplasmic ribonucleoprotein antibodies (scRNP), 1356
- Small nuclear ribonucleoprotein antibodies (snRNP), detection of, 1356
- Smoking
cigarette, lung cancer in systemic sclerosis and, 1336
pulmonary function in systemic sclerosis and, 759
- Social factors, health status measurement and, 542
- Social workers, patient education in RA and, 304
- Sodium iodoacetate, chemically induced articular cartilage damage and, 1267
- Sodium salicylate
GAG synthesis, articular hyaline cartilage and, 922
proteoglycan depletion, OA cartilage and, 548
- Sodium sulfate, salicylates, GAG synthesis and, 922
- Sodium urate, endogenous pyrogen (interleukin-1) and, 1039
- Soft tissue calcifications, in juvenile dermatomyositis, 151
- Soft tissue sites, in juvenile primary fibromyalgia syndrome, 138
- Soft tissue swelling, computed tomography of hindfoot in RA and, 1234
- Speckled pattern ANA, idiopathic thrombocytopenic purpura, SLE and, 596
- Spinal cord compression, mimicking lupus transverse myelitis, 1307
- Spindle poles, antibodies to in connective tissue disease, 889
- Spine
cervical, apophyseal joint ankylosis of, in RA, 958
HLA-B27 positive ankylosing spondylitis and, 40
interpretation of lumbar spine radiographs, 1066
lumbar
compression fractures, transverse myelitis and, 1307
tophaceous gout of, with no peripheral tophi, 1312
- Spondylitic disease, in relatives of HLA-B27 positive AS patients, 40
- Spontaneous abortions, lupus anticoagulant and, 67
- Spontaneous osteoarthritis, in articular cartilage in ICR mice, 1027
- Sporotrichal arthritis, presenting as granulomatous myositis, 1425
- SS-B antibody, atrophic gastritis in Sjögren's syndrome and, 388
- Staphylococci-induced endogenous pyrogen (interleukin-1) crystals, gouty inflammation and, 1039
- Staphylococcus aureus*
methicillin-resistant, in septic arthritis, 210
PMN intracellular killing, phagocytosis and, in RA, 395
- Staphylococcus aureus* Cowan 1, impaired B cell proliferation by, in SLE, 1008
- Steroid drugs
cartilage degradation in experimental OA and, 1393
chemically induced articular cartilage damage and, 1267
in eosinophilic fasciitis in 2-year-old, 948
immunity and, 121
myocarditis in adult Still's disease and, 452
neutral proteoglycan degradation in RA cartilage and, 405
in polymyalgia rheumatica, 383
sex, rheumatic diseases and, 121
- Steroid injections, intraarticular, synovial fluid crystals in OA and, 511
- Steroid-resistant dermatomyositis/polymyositis, immunosuppressive drugs in, 590
- Stiffness
in juvenile primary fibromyalgia syndrome, 138
thoracic, HLA-B27 positive ankylosing spondylitis and, 40

Still's disease

- adult, HLA type in, 146
- adult-onset, onset of during pregnancy, 957
- lymphocytes, intravenous pulse methylprednisolone and, 477
- myocarditis in, 452
- Streptococcal cell wall-induced arthritis, 1402
- Stress-induced proteins, in chondrocytes in OA, 1140
- Subcutaneous nodules, in elderly-onset RA, 987
- Substrain heterogeneity in PGE₂ synthesis of human dermal fibroblasts, 315
- Subtalar joint, computed tomography of, in RA, 1234
- Sulfated glycosaminoglycan synthesis, salicylates and, in murine articular cartilage, 922
- Superoxide production, phorbol myristate acetate-stimulated, GST and, 1384
- Suppressor cell functions, L-canavanine in SLE and, 52
- Suppressor cells, AMLR in adjuvant arthritis and, 537
- Suppressor monocytes, impaired B cell proliferation in SLE and, 1008
- Suppressor T cells, Epstein-Barr virus-induced B cells in RA and, 961
- Surface antigens, T cells and, in SLE, 262
- Surgery
 - in cricopharyngeal obstruction in inflammatory myopathy, 630
 - health status measurement and, 542
- Survival rates
 - polymyositis/dermatomyositis, 249
 - in systemic sclerosis with pulmonary involvement, 763
- Sustentaculum tali, 331
- Swelling
 - aerobic exercise in RA and, 35
 - knee, pain and, referrals of patients with, 1156
 - soft tissue, of hindfoot in RA, 1234
- Synovial amyloid, in end-stage renal failure, 1052
- Synovial amyloidosis, in hemodialysis, 1052
- Synovial biopsy
 - benign rheumatoid nodules of childhood and, 1175
 - in seronegative polyarthritis in giant cell arteritis, 1362
- Synovial cell function, fibronectin in human synovium and, 1016
- Synovial cell proliferation, in joints in MRL/l arthritis, 529
- Synovial cells
 - IgA rheumatoid factor synthesis by, 1219
 - macrophage-like, T lymphocytes, RA adherent cells and, 863
- Synovial clearance of iodide, hypoperfusion in chronic rheumatoid synovitis and, 1096
- Synovial effusions
 - clinical features of, in RA and OA, 442
 - human, intraarticular volume and clearance in, 441
 - hyaluronic acid synthesis by corticosteroids and, 1275
 - microvascular physiology of, 441
 - in septic arthritis and bursitis, 941

Synovial fibroblasts, adenovirus type 1 infection in RA-like polyarthritis and, 456

Synovial fluid

- ATPPPH and neutral inorganic pyrophosphatase in, 1283
- collagen antibodies in, 243
- complement C3 anaphylatoxin in, in RA, 1089
- cytologic analysis of in blastomycotic arthritis, 516
- echovirus type 11 in, in acute monocytic arthritis, 98
- in human synovial effusions in RA and OA, 441
- iodide clearance and, in RA, 1096
- knee, MSU and CPPD crystals in, 1319
- Synovial fluid crystals, in OA, 511
- Synovial fluid fibronectin, in RA, 601
- Synovial fluid glucose:serum glucose ratio, iodide clearance and, in RA, 1096
- Synovial fluid lactate, iodide clearance and, in RA, 1096
- Synovial fluid leukocytes, synovial fluid crystals in effusions in OA and, 511
- Synovial fluid lipids, 1305
- Synovial fluid lymphocytes, in polyarthritis of immunoblastic lymphadenopathy, 120
- Synovial fluid neutrophils, iodide clearance and, in RA, 1096
- Synovial fluid nucleotide pyrophosphohydrolase, 1377
- Synovial fluid temperature, iodide clearance and, in RA, 1096
- Synovial inflammation, in cartilage in Pond-Nuki dog model of OA, 554
- Synovial lymphocytes, in RA, 863
- Synovial membrane
 - intraarticular variation in synovitis and, 977
 - rheumatoid factor synthesis in, in RA, 742
- Synovial membrane inflammation, in cartilage in Pond-Nuki dog in OA, 554
- Synovial stroma, inflammation and, in MRL/l arthritis, 529
- Synovial tissue
 - adenovirus type 1 infection in, RA-like polyarthritis and, 455
 - adherent cells in RA and, 863
 - human, interleukin-1 in, 853
- Synoviocyte proliferation, fibronex and, in RA, 1105
- Synoviocytes
 - fibronectin in human synovium and, 1016
 - interleukin-1 and, 853
 - porcine, in RA, 1105
 - type B, fibronex of in RA, 1105
- Synovitis
 - due to echovirus type 11, 98
 - human rheumatoid, MRL/l arthritis and, 529
 - intraarticular variation in, 977
 - rheumatoid, chronic, iodide and hypoperfusion in, 1096
 - rheumatoid factor synthesis in RA and, 742
- Synovium
 - collagenolytic cartilage activity in OA in Pond-Nuki dog, 554
 - fibronex and, 1105

Synovium (*cont'd*)

- human, interleukin-1 in, 853
 - hyaluronic acid synthesis by corticosteroids and, 1275
 - inflamed, immune complexes in RA articular cartilage and, 241
 - knee, in polyarthritis in giant cell arteritis, 1364
 - neutral metalloproteoglycan-degrading enzyme activity and, 1393
 - rheumatoid, periarticular osteoporosis in RA and, 25
 - rheumatoid synthesis in RA synovial membrane and, 742
 - synovial amyloidosis in hemodialysis and, 1052
 - wrist, in wrist drop in scleroderma, 586
- Systemic lupus erythematosus; *see also* Cutaneous lupus erythematosus; Discoid lupus; Lupus; Neonatal lupus erythematosus
- AA1 (other activation antigen) antibodies in, 44
 - 16 alpha-hydroxyestrone in, 1122
 - anti- α -interferon antibodies in, 624
 - anti-DNA antibody idiotype in, 999
 - anti-DNA, anti-RNA, peripheral blood mononuclear cells and, 431
 - antihistone antibodies in, 285
 - anti-interferon antibodies in, 624
 - antilymphocyte antibodies in, 262
 - anti-skeletal muscle antibody and, 781
 - anti-Sm antibodies and, 294
 - anti-Tac antibodies in, 44
 - ARA Criteria for Classification of, 620
 - ARA Revised Criteria for applied to Japanese, 693
 - autologous erythrocyte receptor phenotypes in, 262
 - avidity antibodies to dsDNA in, 425
 - B cells in, 44
 - β_2 -microglobulin (β_2m) antibodies in, 44
 - bowel involvement in, 466
 - circulating immune complexes in, 904
 - clinical features of, 782
 - common variable panhypogammaglobulinemia and, 100
 - complement C3 in, 904
 - complement C4 in, 904
 - concurrent with common variable hypogammaglobulinemia, 462
 - congenital heart block, anti-Ro antibodies and, 1077
 - Crithidia luciliae* kinetoplasts and, 163
 - cytotoxicity in, 624
 - detection of snRNP and scRNP antibodies in, 1356
 - diagnosis-related group-based reimbursement for, 846
 - Down's syndrome and, 598
 - DR antibodies in, 44
 - dyspnea, unexplained, in, 781
 - 5E9 antibodies in, 44
 - erythrocytes in, 262
 - 4F2 antibodies in, 44
 - false-positive diagnosis of, 622
 - Gm allotypes in, 828
 - hormone modulation in, 1243

Systemic lupus erythematosus (*cont'd*)

- idiopathic thrombocytopenic purpura, speckled ANA and, 596
 - IgG and IgM ANA and acetylator phenotype in, 995
 - IgG and IgM antibodies in, 285
 - IgM antilymphocyte antibodies in, 44
 - immunologic disorders in, 622
 - impaired B cells, *Staphylococcus* Cowan I and, 1008
 - incidence of, in Baltimore, 80
 - inspiratory muscle dysfunction and unexplained dyspnea in, 781
 - interferon in, 624
 - interleukin-2 receptor antibodies in, 44
 - Jaccoud's arthropathy of knees in, 825
 - Km phenotypes and, 828
 - L243 antibody in, 44
 - L-canavanine and induction of, by alfalfa, 52
 - Leu-1, Leu-8, Leu-10 antibodies in, 44
 - lung volume restriction in, 781
 - measures of disease activity in, 904
 - monoclonal antibodies and, 44
 - mouth inspiratory pressure in, 781
 - murine, 1081
 - myocardial infarction in, 1185
 - natural killer cells in, 624
 - neuropsychiatric, antineuronal antibodies in, 789
 - occlusive vascular phenomena in, 1185
 - OKT4 and OKT8 cells in, 262
 - organ involvement in, 905
 - pan-T antibodies in, 44
 - patterns of referral of patients with, 1156
 - pregnancy in, 58
 - in premature infant, 573
 - pure red cell aplasia and protein-losing enteropathy in, 1059
 - renal malakoplakia and, 237
 - Salmonella* bacteremia in, 75
 - sex steroids and, 121
 - T cells in, 44
 - T1+ B cells in, 971
 - T3, T4, T8, T11 antibodies in, 44
 - T4 cells in, 262
 - temporal shifts from Sm to RNP reactivity in, 1348
 - transferrin receptor antibodies in, 44
- Systemic necrotizing vasculitis, SLE and, 620
- Systemic onset JRA
- HLA type in, 146
 - intravascular coagulation in, 256
 - steroid pulse, T cells and, 477
- Systemic sclerosis
- antibodies to intermediate filaments in, 889
 - autoantibodies in, in Argentina, 715
 - cancer and, 1336
 - clinical findings in, 882
 - with CREST syndrome after Raynaud's disease, 87

Systemic sclerosis (*cont'd*)

- DMSO in, 1437
- normal saline in hand ulcers in, 308
- penicillamine and pulmonary function in, 882
- pregnancy and, 237
- pulmonary involvement in, 759
- topical DMSO in hand ulcers in, 308

T

- T cell leukemia virus, human, absence of antibodies to, in SLE, 481
- T cell mitogens, Sm and, 294
- T cell regulation, Epstein-Barr virus-induced B cells in RA and, 961
- T cells
 - anticollagen antibodies, HLA-DR antigens and, 1316
 - autologous mixed lymphocyte reaction in adjuvant arthritis, 537
 - cyclosporine and, in Behçet's disease, 671
 - γ -interferon and, in RA, 174
 - HLA-DR antigens and, in RA, 8
 - L-canavanine in SLE and, 52
 - procainamide and, 276
 - RA, autologous mixed leukocyte reaction and, 731
 - in Reiter's syndrome, 478
 - in SLE, 44
- T helper cells, in synovitis, 977
- T lymphocyte proliferation, rheumatoid adherent cells and, 863
- T lymphocytes, in experimental arthritis, 841
- T lymphotropic viruses, human, antibodies to, rheumatic diseases and, 1170
- T1 antigen, in B cell subsets in RA, 971
- T1+, Ig+ phenotype, B cells and, in RA and chronic lymphocytic leukemia, 971
- T3 antibodies, in SLE, 44
- T4 cells, in SLE, 262
- T4, T8 antibodies
 - in RA, 8
 - in SLE, 44
- T11 antibodies, in SLE, 44
- Tachycardia, in progressive systemic sclerosis, 1259
- Talocalcaneonavicular joint, 333
- Tarsal coalition, 331
- Telangiectasias, antibodies to IgG in, 889
- Telangiectasias, lymphocyte-induced angiogenesis and, 1133
- Temporal arteritis, 571
- Tender point count, fibrositis and, 479
- Tenderness, in juvenile primary fibromyalgia syndrome, 138
- Tendinitis, shoulder, referrals of patients with, 1156
- Tendons
 - finger flexor, amyloid in synovium of, 1052
 - wrist drop and, in progressive systemic sclerosis, 586
- Tenosynovitis
 - finger flexor, synovial amyloidosis in hemodialysis and, 1052

Tenosynovitis (*cont'd*)

- meningococcemia and, 576
- progressive systemic sclerosis and, 586
- Terminology, CREST syndrome, 359
- Testosterone
 - in adjuvant arthritis in rats, 959
 - in gout, 127
 - murine lupus and, 121
- Tetanus toxoid and antitoxoid, IgG anti-F(ab')₂ antibodies, human IC and, 562
- Thalidomide, in RA, 836
- Thiol-containing drugs, hypochlorite and, 1228
- Thoracic pain and stiffness, HLA-B27 positive ankylosing spondylitis and, 40
- Thrombocytopenia
 - immune, in SLE, 1059
 - lupus pregnancy and, 58
- Thrombocytopenic purpura
 - idiopathic, speckled ANA, SLE and, 596
 - thrombotic, in pregnancy in C2-deficient SLE, 341
- Thrombocytosis, in JRA, 256
- Thrombosis
 - dural sinus, diagnosis of, in Behçet's disease, 359
 - vascular, lupus anticoagulant and, 67
- Thrombotic thrombocytopenic purpura, in pregnancy in C2-deficient SLE, 341
- Thymocytes
 - interleukin-1 and, 853
 - mouse, mononuclear cells, GAG synthesis and, in PSS, 188
- Thyroiditis, autoimmune, in SLE, 1059
- Tibial plateau
 - cystic radiolucencies of, in amyloidosis in hemodialysis, 1052
 - proteoglycan degradation, antirheumatic drugs and, in RA, 405
- Tiopronin
 - myeloperoxidase and, 1228
 - nephrotic syndrome induced by, HLA-DR3 antigen and, 595
- Tissue destruction, MRL/l arthritis and, 529
- Tissue fibroblasts, fibronectin in human synovium and, 1016
- Tissue hypoperfusion, in RA, 1096
- Tissue myofibroblasts, granulation, fibronexus and, 1105
- Tophaceous gout
 - chronic, allopurinol sensitivity in, 707
 - endogenous pyrogen (IL-1) and, 1039
 - spinal, with no peripheral tophi, 1312
- Topical dimethyl sulfoxide (DMSO), in hand ulcers in systemic sclerosis, 308
- Total body irradiation, in polymyositis, 831
- Total joint arthroplasty, health status measurement and, 542
- Total lymphoid irradiation, in refractory RA, 1205
- Toxicity
 - blood gold concentrations in RA and, 1121
 - methotrexate, in RA, 721

Toxicity (*cont'd*)

- penicillamine, in RA, 914
- renal, cyclosporine and, in Behçet's disease, 671
- skin, DMSO in hand ulcers in systemic sclerosis and, 308
- Transferrin receptor antibodies, in SLE, 44
- Transient anisocoria, in SLE, 1059
- Transverse carpal ligament, amyloid in synovium of, 1052
- Transverse myelitis, lupus, vertebral fractures, spinal cord compression and, 431
- Traumatic arthritis, complement C3 in, 1089
- Traumatic joint disease, interleukin-1 in, 1318
- Triamcinolone hexacetonide chemically induced articular cartilage damage and, 1267
- Trypsin
 - mononuclear cells, GAG synthesis and, in PSS, 188
 - proteoglycan phosphorylation and, 804
- Tuberculosis wrist, 570
- Tumors, malignant fibrous histiocytoma of heart, polyarthritides in, 944
- Twins, fraternal, neonatal LE in one, 271
- Type C oncornaviruses, human T cell leukemia virus in SLE and, 481

U

Ulcers

- genital, in Behçet's disease, 671
- hand, DMSO and normal saline in, in systemic sclerosis, 308
- inflamed, in systemic sclerosis, 308
- mouth, in Behçet's disease, 671
- Ulnar arteries, in mixed connective tissue disease, 768
- Ultrasound, endogenous pyrogen (IL-1), gouty inflammation and, 1039

Urate

- monosodium, in knee synovial fluid, 1319
- sodium, endogenous pyrogen (interleukin-1) and, 1039

Urate crystals, interleukin-1 and, 1039

Uremia, preexisting in RA, oral gold in, 710

Uric acid metabolism, 17 beta-estradiol and, 127

Uronic acid

- in human cartilage, 325-327
- neutral proteoglycan degradation in RA and, 407
- salicylates, indomethacin, cartilage and, in OA, 548

Uveitis

- in Behçet's disease, 671
- primary chronic, NSAID in, 1317

V

Valgus deformity, computerized tomography of hindfoot in RA and, 1234

Vascular abnormalities, in mixed connective tissue disease, 768

Vascular disease, inflammatory, in MRL/Mp autoimmune mice, 1146

Vascular involvement, in systemic onset JRA, 256

Vascular thromboses, lupus anticoagulant and, 67

Vasculitis

- human, MRL/Mp autoimmune mouse model for, 1146
- lupus, in SLE, 466
- systemic necrotizing, SLE and, 620

Ventricular function, in primary scleroderma myocardial disease, 637

Ventricular tachycardia, in progressive systemic sclerosis, 1259

Vertebral fractures, mimicking lupus transverse myelitis, 1307

Viruses

- EBV-induced B cells and T cells in RA, 961
- human T cell leukemia, absence of antibodies to, in SLE, 481
- human T lymphotropic, antibodies to, in rheumatic disease, 1170

Vision, in Behçet's disease, 671

Vital capacity, penicillamine and, in scleroderma, 882

W

Walking, patient education about, in RA, 300

Weakness, cricopharyngeal obstruction in inflammatory myopathy and, 630

Wegener's granulomatosis, 569

Whipple's disease, antibiotics in, 352

White blood cell count, adenosine triphosphate pyrophosphohydrolase and, 1283

White blood cells, synovial fluid absolute, crystals and, in OA, 512

Wound healing, delayed, after TLI in RA, 1205

Wrist

- in amyloidosis with hemodialysis, 1052
- drop, in progressive systemic sclerosis, 586
- pressure erosions in, in RA, 821, 823
- in RA, 1326
- radiologic abnormalities of, in RA, 16
- tuberculosis, 570

X

Xerostomia, Saxon test for, 1128

Y

Yersinia enterocolitica antigens, T cells in Reiter's syndrome and, 478

Younger-onset RA, comparison with elderly-onset RA, 987

Z

Zomepirac, utilization of, 686

Zvaifler, Nathan J., Editor, *Arthritis and Rheumatism*, 1980-1985, 713